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‘’Your time is limited, so don’t waste it living someone else’s life. Don’t be trapped by 
dogma — which is living with the results of other people’s thinking. Don’t let the noise of 
others’ opinions drown out your own inner voice. And most importantly, have the 
courage to follow your heart and intuition. They somehow already know what you truly 
want to become. Everything else is secondary’’ 
 
‘’You can’t connect the dots looking forward; you can only connect them looking 
backwards. So you have to trust that the dots will somehow connect in your future. You 
have to trust in something — your gut, destiny, life, karma, whatever. This approach has 
never let me down, and it has made all the difference in my life’’ 
Steve Jobs, 2005  
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Abstract 
Both growth hormone deficient (GHD) and vitamin D deficient adults complain of 
fatigue. Suboptimal skeletal muscle mitochondrial function has been implicated in 
several disorders where fatigue is a prominent feature. I examined in vivo dynamic 
skeletal muscle metabolism in GHD and vitamin D deficient adults using a non-invasive 
tool called phosphorus-31 magnetic resonance spectroscopy (31P MRS). 31P MRS can 
quantify abnormalities in metabolic work-cost relationship during exercise. 
In the first study, skeletal muscle metabolism was assessed in age, gender and physical 
activity matched untreated GHD adults, GH treated GHD adults and healthy volunteers. 
Fatigue perception was compared across the 3 groups using specific domains within a 
validated quality of life questionnaire (QoL-AGHDA). Whilst untreated GHD adults 
experienced more fatigue compared to treated GHD adults and normal volunteers, they 
did not demonstrate any perturbations in peripheral skeletal muscle metabolism as 
determined by 31P MRS: maximal mitochondrial oxidative function, anaerobic glycolysis 
and proton clearance. 
In the second study, the effect of cholecalciferol therapy on skeletal muscle 
mitochondrial function in vitamin D deficient adults who had presented to their local 
primary care team with fatigue was examined. 31P MRS assessments were undertaken in 
12 symptomatic, severely vitamin D deficient subjects before and after treatment with 
cholecalciferol. Cholecalciferol therapy was found to augment skeletal muscle 
mitochondrial oxidative phosphorylation in these individuals. 
To summarise, I have examined dynamic skeletal muscle metabolism in two common 
endocrine disorders with contrasting results. There was no detectable perturbation in 
skeletal muscle metabolism in untreated GHD patients when compared to both matched 
GH replaced GHD patients and healthy controls. On the other hand, I have found that 
maximal mitochondrial function is improved and altered by vitamin D repletion in 
symptomatic vitamin D deficient adults, thereby suggesting a peripheral mechanism for 
fatigue in vitamin D deficiency. This is the first time that a link has been identified 
between vitamin D and the mitochondria in human skeletal muscle using 31P MRS.  
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Chapter 1 Background and Literature review 
1.1 Skeletal muscle Energetics 
The primary evolutionary function of skeletal muscle is to promote locomotion which 
requires considerable energy expenditure. Skeletal muscles possess the unique ability to 
adapt to the increase in energy requirement by increasing ATP production. The increase 
in energy turnover can amount to 300-fold from the resting to the fully activated state 
and this can occur within a few milliseconds (Sahlin et al., 1998). This process of 
metabolic regulation occurs primarily through 3 pathways, namely phosphocreatine 
hydrolysis, anaerobic glycolysis and oxidative phosphorylation. Muscle cells also vary 
according to their relative capacity for oxidative metabolism as opposed to anaerobic 
glycolysis which is determined by the relative proportions of their individual fiber types. 
1.1.1  Physiology of ATP generation in the skeletal muscle (Energetics) 
ATP homeostasis 
A single muscle fiber may contain upto 15 billion thick filaments. When the muscle fiber 
is actively contracting, each thick filament breaks down approximately 2500 ATP 
molecules per second. Because even a small skeletal muscle contains thousands of 
muscle fibers, the ATP demands of a contracting skeletal muscle are enormous. In 
practical terms, the demand for ATP in a contracting muscle fiber is so high that it would 
be impossible to have all the necessary energy locally available as ATP before the 
contraction begins. Instead, a resting muscle fiber contains only enough ATP and other 
high-energy compounds to sustain a contraction until additional ATP can be generated. 
Throughout the rest of the exercise, the muscle fiber will generate ATP at roughly the 
same rate as it is used. This ability to sustain steady supplies of ATP in order to fuel the 
contracting muscles is called ATP homeostasis. 
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Sources of ATP generation 
Since the contracting muscle needs a constant supply of energy in the form of ATP to 
provide its energy demands, the body relies on 3 sources of ATP generation. Energy from 
phosphocreatine hydrolysis is immediately available, and the maximal power of this 
mechanism is reached in a fraction of a second, but the mechanism rapidly fatigues and 
reaches a value close to zero in 10–20 s. At the other end of the spectrum, oxidative 
phosphorylation has a relatively lower maximal power but can be sustained for relatively 
longer periods of time. This mechanism is significantly slower in getting into action; 
about 2 min are needed before its asymptotic value is reached. The characteristics of the 
third mechanism, anaerobic glycolysis, are intermediate between those of the other two 
mechanisms (Figure 1). 
 
Figure 1 Schematic representation of the three mechanisms responsible for ATP 
resynthesis as a function of the time of exercise   
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I. Phosphocreatine hydrolysis 
The primary function of ATP is the transfer of energy from one location to the other 
rather than the long-term storage of energy. During rest, a state of homeostasis exists 
where ATP production matches ATP consumption. During exercise, the demand for 
energy increases markedly and phosphocreatine (PCr), a high energy molecule, serves as 
a source of immediate energy. It releases energy-rich phosphate species which combine 
with ADP (released by the skeletal muscle) to form ATP and creatine. 
ADP + PCr→ ATP + Cr 
Therefore, in order to supply immediate energy for exercise, the skeletal muscle always 
has a richer content of PCr compared to ATP, reflected in a higher PCr peak compared to 
ATP when displayed in the 31P MR spectra (Figure 14) (discussed in chapter 1.5). The high 
energy requirements of the contracting muscle during vigorous physical activity leads to 
the depletion of PCr stores in approximately 12 seconds. 
Following exercise, the skeletal muscle replenishes the energy deficit incurred during 
exercise by transferring surplus energy produced to creatine leading to the 
replenishment of PCr stores in the skeletal muscle.  The PCr consumed during the 
exercise is thereby replaced for future use. 
ATP + Cr→ ADP+ PCr 
II. Glycolysis 
 This is an anaerobic process and occurs within the cytoplasm of the cell. It involves the 
breakdown of glucose to pyruvic acid and generates a net gain of 2 ATP whilst 
generating 2 pyruvic acid molecules from each glucose molecule. It is an inefficient 
process compared to aerobic metabolism. However, its advantage lies in that it does not 
require oxygen and therefore it can produce energy when the availability of oxygen 
limits ATP production aerobically. 
III. Aerobic oxidative phosphorylation 
This process occurs in the mitochondria of the cells in mammals. It normally provides 
95% of the demands of the resting cells (Poehlman et al., 1989).  During this process, 
mitochondria absorb ADP, phosphate ions, oxygen and pyruvic acid from the 
surrounding cytoplasm. The substrates enter the Krebs cycle/citric acid cycle, a process 
that breaks down pyruvate and generates ATP in the process. Specifically, the oxidative 
phosphorylation and electron transport processes occur on the inner mitochondrial 
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membrane. The electron transport chain transports the electrons through its complexes, 
eventually reducing oxygen to water. The free energy generated pumps protons across 
the mitochondrial inner membrane. As the concentration of protons in the intra-
membrane space increases, this gradient is relieved by the passage of protons through 
the complex V. This process is coupled to ATP synthase on the matrix side leading to ATP 
synthesis (Figure 2). Overall it is a very efficient process compared to glycolysis since it 
produces 30 ATP molecules per glucose molecule as opposed to 2 ATP molecules per 
glucose molecule (Frayn, 2009). This is due to the complete oxidation of substrates 
giving a much higher energy yield than the partial breakdown that occurs during 
glycolysis. 
 
Figure 2 Diagram showing the steps of oxidative phosphorylation within the 
mitochondria  
The key pathways are shown with food molecules entering the Krebs /citric acid cycle 
followed by the release of electrons which are transferred across the electron 
transport chain. The electron transport chain pumps protons across the inner 
mitochondrial membrane creating a gradient. Excess protons subsequently return 
across this gradient through complex V. This process is coupled to ATP synthase on the 
matrix side leading to ATP synthesis. 
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1.1.2 Skeletal fiber types 
Since skeletal muscle have to cope with divergent activities ranging from long periods of 
standing to performing explosive movements, our muscles are composed of muscle cells 
with large differences in metabolic profile, contractile speed and cellular Ca2+ handling 
(Borina et al., 2010). The mitochondrial densities of the skeletal muscle vary according to 
the energetic demands of the particular tissue. Muscle fibres can be classified, based on 
myosin heavy chain (MHC) isoforms, as type I (slow oxidative) or type II fibers. Type II 
fibers are further classified into subtypes IIa, IIx and IIb. Type IIb fibers (fast glycolytic) lie 
at the opposite end of the spectrum from type I fibers with the remaining type IIa (fast 
oxidative) and IIx fibers lying somewhere in between (Booth and Thomason, 1991). Type 
I and IIa muscle fibers tend to have a richer mitochondrial enzyme content and are, 
therefore, relatively fatigue resistant (Fitts, 1994). They are red in colour because of their 
rich myoglobin and mitochondrial content and rely primarily on mitochondrial oxidative 
phosphorylation as a means of energy production (Figure 3). Aerobic training can be 
expected to induce a greater increase in the oxidative capacity of the type I muscle 
fibers. On the other hand Type IIb fibers, also known as fast glycolytic fibers, are white 
which reflects a lower myoglobin content and mitochondrial density. They rely more 
substantially on anaerobic glycolysis as a means of fuelling energy demands. Intrinsic 
muscle strength is higher when there are a higher proportion of type II fibers. Thus 
resistance training and anabolic steroids would be expected to induce a greater increase 
in type II fibers than type I fibers. Hence, there are marked differences in contraction 
speed, metabolism and susceptibility to fatigue between the two fiber types. 
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Figure 3 Fiber-type composition of leg muscles in athletes. 
Different types of muscle fibers are shown in a cross-section of muscle, by staining for 
the enzyme myosin-ATPase (which reflects fast-twitch muscles): dark stained fibers are 
type II and lighter stained fibers are type I. Left (a) quadriceps muscle from a high 
jumper and on the right (b) from a marathon runner (Frayn, 2009). 
1.1.3 Muscle activity and energy expenditure 
The source of ATP generation to preserve ATP homeostasis in anaerobic exercise differs 
from those used in aerobic exercise. The fuel selection during these different forms of 
exercise illustrates many important facets of energy transduction and metabolic 
integration. Depending upon the level of muscle exertion, the body responds to ensure a 
constant supply of energy for the contracting muscle. The salient features of different 
levels of activities are described below: 
Resting muscle: In the resting skeletal muscle, ATP production matches consumption 
and a steady state is maintained. The majority of energy is provided by aerobic 
metabolism. 
Moderate levels of activity: As the demand for ATP increases, the mitochondrial ATP 
production rises. This leads to an increase in mitochondrial oxygen consumption. Oxygen 
availability is not a limiting factor, because oxygen can diffuse into the muscle fiber fast 
enough to meet mitochondrial needs but all the ATP produced is needed by the muscle 
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fiber, and no surplus is available. The skeletal muscle now relies primarily on the aerobic 
metabolism of pyruvic acid to generate ATP. The pyruvic acid is provided by glycolysis, 
which breaks down glucose molecules obtained from glycogen in the muscle fiber. If 
glycogen reserves are low, the muscle fiber can also break down other substrates, such 
as lipids or amino acids. As long as the demand for ATP can be met by mitochondrial 
activity, the ATP provided by glycolysis makes a relatively minor contribution to the total 
energy budget of the muscle fiber. 
Peak levels of activity:  The ATP demands are huge and mitochondrial ATP production 
rises to a maximum. This maximum rate is determined by the availability of oxygen, and 
oxygen cannot diffuse into the muscle fiber fast enough to enable the mitochondria to 
produce the required ATP. At peak levels of exertion, mitochondrial activity can provide 
only about one-third of the ATP needed (Conley et al., 2001). The remainder is produced 
through glycolysis. When glycolysis produces pyruvic acid faster than it can be utilized by 
the mitochondria, pyruvic acid levels rise in the sarcoplasm. Under these conditions, 
pyruvic acid is converted to lactic acid thereby, lowering the intracellular pH. This change 
in pH can eventually alter the functional characteristics of key enzymes which can 
culminate in an inability to contract (Mainwood and Renaud, 1985). 
Recovery period: In the recovery period, the conditions in muscle fibers are returned to 
their normal, pre-exertion levels. PCr reserves are replenished and pH is normalised. 
Immediately following exercise, ATP production exceeds its consumption. It is utilised to 
replenish energy stores by converting creatine to phosphocreatine (PCr) and glucose to 
glycogen. Since there is an abundant supply of oxygen to the mitochondria, efficient 
aerobic metabolism is the source of ATP generation. This is, therefore, an important 
stage for exercise physiologists since maximal mitochondrial oxidative phosphorylation is 
stimulated by by-products of ATP turnover such as ADP and inorganic phosphate (Pi). 
Based on this phenomenon, dynamic 31P MRS studies serve to measure mitochondrial 
function during this critical window. 
1.1.4 Muscle fatigue (Peripheral fatigue) 
Skeletal muscle fatigue sets in when it can no longer contract despite continued neural 
stimulation. The cause of fatigue depends on the level of physical activity. 
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After short peak levels of activity such as a 100m sprint, fatigue develops because of the 
exhaustion of the PCr reserves and the accumulation of lactic acid or inorganic 
phosphate (Westerblad et al., 2002). However, if the muscle fiber is contracting at 
moderate levels and ATP demands can be met through aerobic metabolism, fatigue will 
not occur until glycogen, lipid, and amino acid reserves are depleted. This type of fatigue 
affects the muscles of long-distance athletes, such as marathon runners, after hours of 
exertion. 
1.1.5 Summary 
The components of ATP homeostasis ensure that levels of ATP are maintained in the 
exercising muscle. The high ATP turnover rates yield by-products such as ADP and Pi 
which stimulate an increase in the oxidative phosphorylation rate which during recovery 
ensures that PCr concentrations return to quiescent levels. Muscle cells with high 
potential for ATP consumption, although powerful, are susceptible to rapid fatigue 
because of accumulation of by-products. On the other hand, cells with high capacity to 
restore ATP following exercise possess excellent endurance because ATP use and 
restoration are balanced. 
Approximately 50% of the potential chemical energy released from foodstuffs is 
captured in the common chemical intermediate, ATP. ATP, together with its storage 
form, phosphocreatine (PCr), then serves as the immediate cellular energy source on 
which endergonic processes depend. ATP and PCr not only supply immediate cellular 
energy sources, but their relative levels also stimulate or inhibit processes of energy 
metabolism. At rest, normally high levels of ATP and PCr maintain the rate of oxidative 
phosphorylation and anaerobic metabolism at an appropriate level. When exercise 
starts, however, the utilization and decreased levels of ATP and PCr, and the increased 
levels of ADP and Pi stimulate processes of energy metabolism. Enzymes interact with 
products of energy metabolism to regulate the rate at which specific processes proceed. 
Muscles utilize three different systems of energy release during exercise, each of which 
differs in mechanism, capacity and endurance. Consequently, the rate and capacity for 
muscular power output is determined by the ability of these three systems to maintain 
cellular ATP homeostasis. 
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1.2 Fatigue 
1.2.1 Overview 
During voluntary contractions, muscles are activated by complex pathways originating in 
the α-motor neurons within the cortex leading to excitation of lower motor neurons in 
the spinal cord. The lower motor neuron axon carries the action potentials to the 
neuromuscular junction of the muscle. Interruptions in the pathway at the spinal cord 
and above are referred to as central fatigue whereas those occurring in the peripheral 
nerve, neuromuscular junction or muscle are referred to as peripheral fatigue. The brain 
accounts for 20% of the body’s energy consumption at rest (Frayn, 2009). This is because 
the adult human brain is estimated to consist of around 100 billion nerve cells and 900 
billion glial cells which have a high rate of metabolism. This high metabolic requirement 
requires a high rate of blood supply (50ml blood per minute per 100gm of brain tissue) 
(Frayn, 2009). However, during strenuous exercise, the high energy demands of the 
exercising skeletal muscle impose an approximate 18 fold increase in whole-body energy 
requirement over the resting level (Frayn, 2009). This involves major changes in 
substrate supply through the blood (50ml blood per minute per 100gm of muscle tissue 
during vigorous exercise). Hence reduced energy production or supply within the brain 
or muscle can lead to fatigue. Since mitochondrial oxidative phosphorylation is the 
principal source of energy supply in humans, it is not surprising that impairments in 
mitochondrial function often result in neuromuscular signs and symptoms, thereby 
reflecting the high energy ‘footprint’ of the brain and skeletal muscle. 
Fatigue can encompass diverse phenomena that are the consequence of different 
physiological processes.  Therefore, when discussing fatigue, all the dimensions of the 
problem must be examined. Firstly, subjective dimensions or the patients’ perception of 
fatigue must be addressed. Generally, this dimension has three aspects: physical, 
emotional and cognitive. Secondly, objective dimensions namely the functional 
parameters of the skeletal muscle system must be examined. 
1.2.2 Why does fatigue occur? 
In simple terms fatigue occurs because of impairments in one or several of the processes 
that enable contractile proteins to generate a force. However, a more holistic view 
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acknowledges that the site of impairment depends on the task being performed. This 
has been described as the task dependency of fatigue (Bigland-Ritchie et al., 1995). Since 
fatigue is task dependent, it is impossible to identify a single causal mechanism for 
fatigue. However, one approach to this problem is to consider central and peripheral 
fatigue separately. 
1.2.3 Peripheral fatigue 
Metabolic changes in the muscle may occur during fatigue, thereby affecting muscle 
contraction. Generally, peripheral fatigue is more objectively defined and evaluated 
since its pathophysiology is better understood (Cantor, 2010). The key target organ 
implicated in peripheral fatigue is the skeletal muscle which harbours the mitochondria. 
Perturbations in skeletal muscle metabolism such as delayed mitochondrial 
phosphocreatine resynthesis, delayed proton clearance or the accumulation of 
metabolic by-products are the cellular mechanisms responsible for the symptoms of 
peripheral fatigue (Allen et al., 2008). One approach to studying peripheral fatigue is to 
examine muscle energetics, the metabolic pathways by which skeletal muscle generates 
ATP. Abnormal muscle energetics has been implicated in diverse conditions in which 
fatigue is a prominent feature (Wong et al., 1992; Kuhl et al., 1994; Pfeifer et al., 1999; 
Hollingsworth et al., 2008). Muscle energetics can be examined using phosphorus-31 
magnetic resonance spectroscopy (31P MRS) which is described in detail in chapter 1.5. 
1.2.4 Central Fatigue 
Central fatigue is a complex pathophysiological entity and is not well defined (Chaudhuri 
and Behan, 2004). Generally, the assessment of primary central fatigue is based upon 
self-reporting questionnaires (Lee et al., 1991). Central fatigue may occur as a 
consequence of impaired α-motor neuron activation. The complex interplay between 
the nervous system and skeletal muscle during most strenuous exercise makes it difficult 
to design experiments to unequivocally assess the extent of central fatigue. Although 
various researchers have attempted to delineate the precise pathophysiological 
processes responsible, this has proved to be difficult. Since elements of central fatigue 
are often observed independent of muscle fatigue, both the cortex and the spinal cord at 
the level of motoneurons are implicated (Gandevia, 2001). Recently, Cotel et al. 
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provided a cellular mechanism for central fatigue. They demonstrated that during 
prolonged activity, serotonin spillover reaches the axon initial segment where it 
activates serotonin receptors, which inhibit the generation of action potentials in 
motoneurons and in turn, muscle contraction, thereby, providing a possible cellular 
mechanism for central fatigue (Florence Cotel, 2013). Further insight may also be gained 
by studying various biological models of central fatigue. 
Chronic Fatigue Syndrome (CFS) Prototype 
Chronic Fatigue Syndrome is a heterogeneous disorder characterised by debilitating 
fatigue which is severe enough to cause a significant loss of physical and social function 
for a minimum of 6 months. Four of the following symptoms must also be present if 
diagnostic criteria are to be met: sleep disturbance (usually unrefreshing sleep or 
hypersomnia), concentration impairment, muscle pain, multi-joint pains, headaches, 
post-exertional exacerbation of fatigue, sore throat, and tender lymph nodes (Fukuda et 
al., 1994). Although CFS is often multifactorial in origin, neuroendocrine disturbances 
have been implicated in its aetiology. The hypo-thalamo-pituitary (HPA) axis has been a 
particular area of interest and it is quite likely that abnormalities of the HPA axis exist in 
at least some patients. Furthermore, given the many factors that may impinge on the 
HPA axis in CFS, such as inactivity, sleep disturbance, psychiatric comorbidity, 
medication, and on-going stress, it seems likely that HPA axis disturbance is 
heterogeneous and of multifactorial aetiology in CFS (Cleare, 2003). The growth 
hormone-insulin-like growth factor (GH-IGF-1) axis has also been investigated in CFS but 
there is no compelling evidence to suggest that GH dysfunction plays a significant role in 
CFS symptomatology (Moorkens et al., 1998). 
Cancer related fatigue prototype 
Cancer related fatigue has been described as a “persistent, subjective sense of tiredness 
related to cancer and cancer treatment that interferes with usual functioning” (Hofman 
et al., 2007). Fatigue occurs in a variety of cancers with patients reporting fatigue before 
diagnosis to beyond treatment completion (Jacobsen, 2004). In fact survivors of cancer 
may report persistent fatigue for several years (Figure 4). Several hypotheses have been 
proposed for the mechanisms underpinning cancer related fatigue including disruptions 
in the HPA axis, proinflammatory cytokines, circadian rhythm modulation, anaemia and 
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serotonin dysregulation (Wang, 2008). This again probably reflects the multidimensional 
nature of the problem. Treatment modality could also contribute to fatigue since >80% 
of outpatients receiving chemotherapy or radiotherapy reported some degree of fatigue 
as assessed using the Fatigue Symptom Inventory (Hickok et al., 2005; Hofman et al., 
2007). A population-based, cross-sectional postal survey of hormone-naïve survivors 
with the diagnosis of prostate cancer who were treated with radical prostatectomy or 
radiotherapy revealed a higher prevalence of cancer related fatigue in the radiotherapy 
group (26.1%) as opposed to the surgically treated group (13.4%) (Kyrdalen et al., 2010). 
 
Figure 4 Likelihood of reporting chronic fatigue (A) and chronic fatigue with 
impairment (B) among patients with cancer listed in a national registry, compared with 
individuals without cancer 
(Forlenza et al., 2005) 
 
 
1.2.5 Summary 
Exercise begins in the brain and ends in the muscle. Hence any impairment in the entire 
pathway may contribute to fatigue. Whereas peripheral skeletal muscle fatigue is better 
understood, the mechanisms of chronic fatigue have not been fully resolved. The 
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prototypes discussed above provide independent and overlapping potential mechanisms 
for the pathophysiology of this complex phenomenon. Nevertheless, the general picture 
is that central fatigue could be of greater importance during prolonged low-intensity 
activities, where metabolic changes with muscle cells are likely to be limited, whereas 
intramuscular factors appear to dominate during activities of higher intensity (Place et 
al., 2009). However, independent of the source, the impact of fatigue on the ability to 
undertake activities of daily living are both profound and pervasive. This has a knock-on 
effect on social and psychological domains leading to a lower perceived quality of life.   
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1.3 Growth hormone Deficiency 
1.3.1 GHD Adults 
Growth hormone (GH) promotes somatic growth and also regulates several other 
metabolic actions. The metabolic actions of GH were reported in the late fifties following 
the advent of pituitary derived GH preparations (Raben, 1962). Later on retrospective 
epidemiological studies revealed that patients with Multiple pituitary hormone 
deficiency (MPHD), when compared to age and sex matched controls, presented with 
fatigue, low mood, obesity and abnormal metabolic parameters despite being 
adequately supplemented with corticosteroid, thyroxine and sex hormones (Abs et al., 
1999). The development of recombinant growth hormone preparations in the 1980s led 
to investigations into the metabolic effects of GH replacement in GH deficient (GHD) 
adults. 
The syndrome of GH deficiency is characterised by the variable presence of fatigue, 
decreased mood and well-being, reduced bone remodelling, altered body composition 
with centripetal obesity and hyperlipidaemia. However, it is important to appreciate that 
adults with GHD may also have potential confounding factors such as co-existing 
structural pituitary disease or cranial irradiation. The direct or indirect effects of 
suboptimal pituitary hormone replacement and other confounders may also contribute 
to some of the symptoms of GHD. Nonetheless, GH replacement leads to an 
improvement in certain signs and symptoms suggesting that GH deficiency may be 
responsible for some of these symptoms. 
The National Institute of Clinical Excellence (NICE), UK has recommended that GH be 
used in severe GHD adults up to the age of 25 years in order to optimise bone mass 
accrual (NICE, 2003). GH is also recommended for use in older growth hormone deficient 
adults if there is a documented improvement in quality of life (QoL) on GH 
administration using a standardised and validated questionnaire developed specifically 
for GHD adults called the Adults with growth hormone deficiency assessment (AGHDA) 
questionnaire (McKenna et al., 1999). 
One of the striking symptoms of GHD is fatigue and a resulting struggle to perform daily 
chores and tasks. Patients with GHD often have other co-morbidities which can also 
influence their outlook to life and mood but it is well documented  that GH replacement 
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can lead to improvement in energy levels and QoL based on self-reporting assessments 
(Murray et al., 1999; Mukherjee et al., 2005; Koltowska-Haggstrom et al., 2006; 
Jorgensen et al., 2011b). 
I shall be discussing the pertinent features related to GHD in adulthood in this chapter 
with a particular emphasis on the effects of GH on fatigue, skeletal muscle function, QoL 
and the brain.  
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1.3.2 Diagnosis of Growth Hormone deficiency 
Since growth hormone secretion is pulsatile and circadian, random GH levels cannot be 
used to diagnose GHD. Moreover, isolated IGF-1 measurements, a downstream 
regulator of growth hormone action, do not serve as an accurate or reliable index of 
growth hormone status in adulthood (Hilding et al., 1999; Biller et al., 2002). 
Definition 
Severe GHD in adults is defined biochemically but within an appropriate clinical context. 
The syndrome of GHD in adults is characterized by alterations in body composition (such 
as increased abdominal obesity, decreased lean body mass, reduced muscle strength 
and exercise capacity), abnormal metabolic profiles (such as increased serum low density 
lipoprotein cholesterol and reduced insulin sensitivity) and impaired psychological well-
being (Cuneo et al., 1990; Rosen et al., 1995; Carroll et al., 1998; Sesmilo et al., 2001; 
Koltowska-Haggstrom et al., 2006). 
Biochemical diagnosis 
The diagnosis of GHD is established by provocative testing of GH secretion. The insulin 
tolerance test (ITT) is widely regarded as the gold standard (Molitch et al., 2011). This 
test distinguishes GHD from the relatively low GH levels observed in the obese and the 
elderly, provided an adequate hypoglycaemic stimulus has been achieved (Kopelman et 
al., 1979; Hoffman et al., 1994). Because of the potential risks of hypoglycaemia, this test 
should be conducted in specialised endocrine units where it is undertaken frequently by 
staff that are adequately trained. Whereas most healthy subjects respond to insulin-
induced hypoglycaemia with a peak GH production >5.1mcg/L, GHD patients produce a 
peak GH response of <5.1mcg/L (Biller et al., 2002). However, GH response is a spectrum 
and it is important to be aware of the sensitivity and specificity issues surrounding a 
particular cut-off. Hypopituitary patients should also be on adequate hormone 
replacement during testing so as to ensure their other endocrine axes are intact and 
stable. 
The combination of growth hormone releasing hormone (GHRH) with arginine also 
demonstrates considerable utility in separating hypopituitary patients from controls. In 
fact, diagnostic practices have shown a trend toward the GHRH-arginine testing regimen 
(Webb et al., 2009). This is probably because it is better tolerated and does not cause 
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hypoglycaemia. Caution must be applied in GHD patients of hypothalamic origin since a 
false positive result might be obtained because of the direct stimulation of the pituitary 
gland by GHRH. 
Other tests available are the glucagon, arginine and clonidine provocation test but they 
are not well validated in the adult population (Darzy et al., 2003). 
Guidelines published by the GH research society (GRS) recommend that adults with 
known hypothalamic pituitary abnormalities and at least one known deficit of another 
pituitary hormone (excluding prolactin) should undergo a single diagnostic test to 
diagnose the presence of GH deficiency. However, those with childhood onset isolated 
GH deficiency (no evidence of hypothalamic pituitary abnormality or cranial irradiation), 
should be recommended two diagnostic tests once final adult height is achieved, except 
for those having low IGF-1 concentrations (SDS ≤2) where one test may be considered 
sufficient ('Consensus guidelines for the diagnosis and treatment of adults with growth 
hormone deficiency: summary statement of the Growth Hormone Research Society 
Workshop on Adult Growth Hormone Deficiency,' 1998). 
Biochemical surrogate markers 
Of the several biochemical markers of GH action available, only serum IGF-1 
concentrations are useful in titrating GH dosage therapy to age adjusted normal ranges. 
In adults, a normal serum IGF-1 does not exclude the diagnosis of GH deficiency because 
the sensitivity of serum IGF-1 as a marker of GHD declines with age, despite age-specific 
reference ranges. Whereas low IGF-1 concentrations correlate well with GHD in 
childhood and young men (mean age 26.5 years)(de Boer et al., 1994), Toogood et al. 
found that only 21% of elderly GHD patients (aged 61-85 years) had a serum IGF1 lower 
than age matched controls (1996). Therefore, whereas serum IGF-1 concentrations may 
be a helpful adjunct in aiding diagnosis in younger patients, its diagnostic utility declines 
with increasing age. 
To date, measurements of IGF-binding protein-3 (IGF-BP3) or acid-labile subunit (ALS) 
have not provided any advantage over the measurement of serum IGF-1. 
Assay standardization 
The above recommendations for cut-off values for the ITT are based on results obtained 
with polyclonal competitive radioimmunoassay calibrated against the pituitary-derived 
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preparation International Reference Preparation (IRP) 80/505. The GRS advocates future 
use of the recombinant hGH preparation IRP88/64. Further comparative studies are 
required to achieve standardization of GH assays ('Consensus guidelines for the 
diagnosis and treatment of adults with growth hormone deficiency: summary statement 
of the Growth Hormone Research Society Workshop on Adult Growth Hormone 
Deficiency,' 1998).  
19 
 
1.3.3 Causes of growth hormone deficiency in adults 
 
Figure 5 Causes of GHD in adults 
 
Broadly speaking, GHD in adults is classified etiologically as congenital, acquired or 
idiopathic (Figure 5) (Molitch, 2011). Since the development of the pituitary gland 
depends on the sequential temporal and spatial expression of transcription factors and 
signaling molecules, mutations of these critical transcription factors can lead to 
congenital hypopituitarism. Whereas mutations in early transcription factors lead to 
multiple pituitary hormone deficiencies, others can cause isolated deficiencies 
(Alatzoglou and Dattani, 2009). GHD has also been reported due to mutations of other 
critical signaling molecules in the downstream pathway such as the genes encoding the 
GHRH receptor and the GSα gene leading to GHRH resistance (Mantovani et al., 2003; 
Alatzoglou et al., 2009). Congenital GHD is often associated with other congenital 
anatomical changes in the hypothalamic-stalk-pituitary region. The abnormalities range 
from pituitary hypoplasia and stalk agenesis to an ectopic posterior pituitary. These 
abnormalities are often associated with multiple pituitary hormone deficiencies 
(Maghnie et al., 2001). 
Pituitary and hypothalamic tumours may cause hypopituitarism primarily or following 
treatment with surgery or irradiation. Commonly occurring tumours are pituitary 
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adenomas and craniopharyngiomas. GHD risk is temporally linked and dose dependent 
on cranial irradiation. A younger age, a longer duration following radiotherapy and a 
higher dosage increase the probability of developing GHD (Mulder et al., 2009). A dosage 
of ˃40Gy cranial radiotherapy is associated with ˃ 50% likelihood of developing GHD 
(Gleeson et al., 2004). Infiltrative diseases of the hypothalamus and stalk may also cause 
hypopituitarism and diabetes insipidus. 
Finally, idiopathic GHD is very commonly observed in childhood GHD. These patients 
tend to present with biochemically defined GHD in childhood, often with normal 
neuroimaging. However, they are often found to have normal GH responses during 
reassessment at adulthood (Tauber et al., 1997). This discrepancy can be ascribed to 
arbitrarily defined GHD diagnostic thresholds and poor reproducibility of the GH 
response to provocative testing within individuals. Moreover, children with 
constitutional delay in growth and puberty may also have a suboptimal GH response if 
they were not adequately primed with sex steroids at the time of testing. However, it is 
also possible that transient GHD is a true phenomenon in a fraction of these patients 
(Molitch, 2011). It is, therefore, an umbrella term used to describe a heterogeneous 
collection of patients with GHD of unknown cause, transient GHD and occasionally 
incorrectly diagnosed GHD. Idiopathic adult onset GH deficiency has also been described 
where its accurate diagnosis is challenged by the pulsatility of GH secretion, provocative 
test result variability, and suboptimal GH assay standardization. The spectrum between 
attenuated GH secretion associated with the normal aging process and with obesity, and 
truly well-defined Idiopathic adult onset GH deficiency is not distinct and may mislead 
the diagnosis. The reported prevalence of idiopathic adult onset GHD lies between 10-
15% (Katznelson et al., 2011). 
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Table 1 Congenital causes of GHD in adulthood 
Congenital 
Genetic 
Transcription factor defects (PIT-1, PROP-1, LHX3/4, HESX-1, PITX-2) 
GHRH receptor gene defects 
GH secretagogue receptor gene defects 
GH gene defects 
GH receptor/post receptor defects 
Associated with brain structural defects 
Agenesis of corpus callosum 
Septo-optic dysplasia 
Empty sella syndrome 
Holoprosencephaly 
Encephalocele 
Hydrocephalus 
Arachnoid cyst 
Associated with midline facial defects 
Single central incisor 
Cleft lip/palate 
Idiopathic 
 
(Molitch et al., 2011) 
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Table 2 Acquired causes of GHD in adulthood 
Acquired 
Trauma 
Perinatal 
Postnatal 
Central nervous system infection 
Tumours of hypothalamus or pituitary 
Pituitary adenoma 
Craniopharyngioma 
Rathke’s cleft cyst 
Glioma/astrocytoma 
Germinoma 
Metastatic 
Other 
Infiltrative/granulomatous disease 
Langerhans cell histiocytosis 
Sarcoidosis 
Tuberculosis 
Hypophysitis 
Other 
Cranial irradiation 
Surgery of the pituitary or hypothalamus 
Infarction 
Spontaneous 
Sheehan’s syndrome 
 
(Molitch et al., 2011) 
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1.3.4 Treatment of GHD in Adults 
Patient selection 
In the United Kingdom, recombinant human growth hormone replacement is 
recommended by the National Institute for Clinical Excellence (NICE) for the treatment of 
adults with GHD if they fulfil all three of the following criteria (NICE, 2003): 
I. Severe GH deficiency (defined as a peak GH response of <3 mcg/L [9mU/L] during 
an insulin tolerance test or a cross-validated GH threshold in an equivalent test). 
II. A perceived impaired QoL, as demonstrated by a reported score of at least 11 in the 
disease-specific QoL-AGHDA questionnaire. 
III. Already receiving appropriate pituitary hormone replacement. 
It is important to note that the peak GH response of <3mcg/L stipulated by NICE above 
differs slightly from the Endocrine society which recommends a peak GH response of 
<5.1 mcg/L for the diagnosis of adult GHD to be made (Molitch et al., 2011). 
Dose selection 
The objective of treatment is to maximise health benefits and minimise side-effects. 
However, there is considerable inter-individual sensitivity to treatment, particularly in 
the elderly. It is generally recommended that the initial dose should be started low 
(0.15-0.30 mg/day) and be gradually increased on the basis of clinical and biochemical 
responses. There is considerable variation in maintenance doses between individuals but 
the required dose rarely exceeds 1mg/day. 
Clinical experience has demonstrated that the variability in subcutaneous absorption and 
individual responsiveness to GH makes dose determination based on body weight or 
body surface area less helpful than first anticipated. Therefore, GH replacement should 
be titrated to ensure optimum IGF-1 levels ('Consensus guidelines for the diagnosis and 
treatment of adults with growth hormone deficiency: summary statement of the Growth 
Hormone Research Society Workshop on Adult Growth Hormone Deficiency,' 1998). 
GH is generally continued until adult peak bone mass has been achieved (~25 years of 
age)(NICE, 2003). After adult peak bone mass has been attained, the decision to 
continue treatment primarily depends on the impact of GH withdrawal on the patient’s 
Quality of Life. 
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Monitoring treatment efficacy 
Treatment efficacy is evaluated using quality of life questionnaires and by titrating GH 
dosage according to IGF-1 levels. The best available bio-marker of GH action is serum 
IGF-1, which can be used to titrate the GH dosage and avoid over replacement. The 
objective is to maintain IGF-1 levels within an age-related normal range. During the 
initial stages of GH treatment, more frequent measurements are required but this 
eventually settles to once or twice yearly ('Consensus guidelines for the diagnosis and 
treatment of adults with growth hormone deficiency: summary statement of the Growth 
Hormone Research Society Workshop on Adult Growth Hormone Deficiency,' 1998). 
Safety issues and Contraindications 
Fluid retention is sometimes observed with GH therapy. Hence, oedema and carpal 
tunnel syndrome can be experienced. However, these symptoms are often self-limiting 
and respond to a dose reduction. Markers of glycaemia should be monitored because 
GH can be associated with reduced insulin sensitivity. 
Absolute contraindications include active malignancy, idiopathic intracranial 
hypertension and diabetic retinopathy. Although GH can safely be given in pregnancy, it 
should be stopped in the 2nd trimester since GH is endogenously produced by the 
placenta ('Consensus guidelines for the diagnosis and treatment of adults with growth 
hormone deficiency: summary statement of the Growth Hormone Research Society 
Workshop on Adult Growth Hormone Deficiency,' 1998). 
Long term care 
GH replacement, like other pituitary hormones, can potentially be administered for life. 
The dose is usually reduced over time, in keeping with normal physiology. 
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1.3.5 The interplay between growth hormone and other pituitary hormones 
The majority of adults with growth hormone deficiency have concurrent multiple 
pituitary hormone disease secondary to structural aplasia/damage of the pituitary gland. 
This may be congenitally acquired or secondary to the effects of surgery, radiotherapy or 
trauma. The effects of radiotherapy and surgery have potentially deleterious effects on 
long term health outcomes. Adults with GHD could also experience fatigue if there is 
suboptimal replacement of other hormones like thyroxine, cortisol or testosterone. 
Consequently, it is important to be aware of the implications and interactions of the 
thyroidal, adrenal and gonadal axes with the GH-IGF-1 axis since some of the features 
associated with GHD could also reflect the suboptimal replacement of other pituitary 
hormones. 
GH axis and the thyroid axis 
The relationship between the GH-IGF-1 axis and the hypothalamo-pituitary-thyroid (HPT) 
axis is complex and interdependent. Untreated primary hypothyroidism is associated 
with reduced IGF-1 and IGF binding protein-3 that increases with thyroxine replacement 
(Akin et al., 2009). Similarly several studies have demonstrated a variety of alterations in 
the HPT axis following GH administration in both normal and GHD adults and children. 
Whereas conflicting data have been reported in healthy individuals, studies by Porretti 
et al. and Losa et al. demonstrated that GH replacement at a dose that achieves a serum 
IGF-1 in the upper reference range unmasks hypothyroidism in patients with organic 
pituitary disease (Porretti et al., 2002; Losa et al., 2008). It has also been demonstrated 
that apparently euthyroid patients who developed de novo biochemical hypothyroidism 
following GH replacement had reduced QoL compared to those patients who remained 
euthyroid on GH, despite similar QoL scores at the beginning and the attainment of 
similar serum IGF-1 concentrations in both groups (Agha et al., 2007). 
Therefore, it is essential to monitor thyroid function diligently following GH 
commencement particularly in the first 6 months to identify those patients who have 
underlying secondary hypothyroidism. 
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GH axis and cortisol metabolism 
Cortisol metabolism is dependent on the interconversion of cortisol and cortisone which 
is modulated by the isoforms of 11β-hydroxysteroid dehydrogenase (11β-HSD). 11β-
HSD-1 functions as a net reductase converting cortisone to cortisol. GH inhibits 11β-HSD-
1 resulting in a shift from active cortisol to inactive cortisone with increased cortisol 
clearance. This phenomenon may be responsible for precipitating secondary adrenal 
failure after GH commencement (Moore et al., 1999). Tschop et al. studied the 
pharmacokinetics of hydrocortisone substitution in hypopituitary patients following GH 
replacement (Tschop et al., 2000). Using serum and salivary cortisol profiles after 
hydrocortisone administration at baseline and 6 and 12 months following initiation of 
GH replacement, they found no clinically relevant alterations in the pharmacokinetics of 
cortisol following initiation of GH replacement in hypopituitary adults. However, because 
of the variation in cortisol-cortisone conversion within a particular organ or tissue, one 
cannot rule out tissue specific effects. 
GH axis and oestrogen metabolism 
The close interplay between GH and oestrogen leads to the attainment of gender 
specific body composition during puberty. Furthermore, oral oestrogen (due to its first 
pass metabolism in the liver) but not transdermal oestrogen impairs the metabolic 
action of GH on the liver, causing a fall in IGF-I production and fat oxidation. This may 
contribute to a loss of lean tissue and a gain in body fat in postmenopausal women and 
could contribute to an impairment of GH effect in hypopituitary women on GH 
replacement (Leung et al., 2004). 
GH axis and testosterone 
There is evidence to suggest that a synergistic relationship exists between GH and 
testosterone. IGF-1 mRNA (messenger ribonucleic acid) increases when testosterone is 
administered to healthy elderly men and decreases in healthy young men when they are 
rendered hypogonadal (Ferrando et al., 2002). Several studies have demonstrated a 
more pronounced improvement in body composition, muscle strength, endurance and 
QoL with the simultaneous administration of GH and testosterone than with either alone 
(Brill et al., 2002; Gibney et al., 2005; Giannoulis et al., 2006). This suggests that GH and 
testosterone may exert independent and additive effects on protein metabolism, lipid 
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oxidation and resting energy expenditure. This again highlights the importance of 
ensuring adequate testosterone replacement in hypopituitary patients on GH 
replacement. 
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1.3.6 Metabolic abnormalities in GHD adults 
Body composition 
GH and IGF-1 manipulate, and are in turn influenced by, body composition with lean 
healthy individuals demonstrating higher GH but lower IGF-1 levels than their obese 
counterparts. GHD is associated with a typical phenotype characterised by centripetal 
obesity and a reduction in Lean Body Mass (LBM). Some of the deleterious metabolic 
effects of GHD may actually be caused by this centripetal fat distribution (Carroll et al., 
1998). 
Irrespective of the underlying aetiology of GHD, the disorder is consistently associated 
with body composition changes. However, GHD secondary to craniopharyngioma is 
associated with a higher degree of obesity than non-functioning pituitary adenomas. 
This is due to the hyperphagia which develops secondary to the hypothalamic damage 
which may be sustained during tumour growth and subsequent management (Verhelst 
et al., 2005). A KIMS (Pfizer International Metabolic Database) study reported that 
patients undergoing pituitary radiotherapy had a higher mean body fat mass than 
patients with non-radiated tumours. It was suggested that this may be due to the direct 
detrimental effects of radiotherapy on the brain. However, the observed differences in 
these two groups could also be ascribed to the longer duration of untreated GHD in the 
irradiation group. Both of the groups benefitted from GH replacement (Maiter et al., 
2006). 
Although the consequences of GHD continue into later life, its effects in the elderly are a 
less important cause of centripetal weight gain than in younger patients. 
Lipids 
Patients with GHD often have adverse cardiovascular profiles and this may be partially 
responsible for the increased mortality observed in hypopituitary patients. An analysis of 
2589 patients from the KIMS database revealed that 40% of GHD patients aged <20 
years had total serum cholesterol (TC) above 5.3mmol/L. Mean TC increased linearly 
across age groups until it plateaued at 49 years so that in those aged 40 years, 75% of 
patients had a TC above 5.3mmol/L. Similar findings were seen in LDL-cholesterol (LDL-C) 
and to a lesser extent in triglycerides with reciprocal changes in HDL-cholesterol (HDL-C) 
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too. GH replacement was associated with significant improvements in TC, LDL-C and 
HDL-C but no changes in TG (Abs et al., 2006). Older patients also demonstrated an 
improved lipid profile with GH replacement. In fact Attanasio et al. reviewed results from 
242 HypoCCS (The Hypopituitary Control and Complications Study) patients and 
reported the greatest improvement in LDL/HDL ratio in patients aged 40-60 years when 
compared with both younger and older patients (2002a). 
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1.3.7 Growth hormone and skeletal muscle function 
The anabolic effects of GH are apparent in patients with acromegaly and can be 
contrasted with the phenotype of GHD patients. Fatigue (26%) and weakness are 
commonly described by patients with acromegaly and may be prominent symptoms. 
These symptoms may reflect the associated medical consequences of acromegaly, 
including sleep apnea syndrome, cardiomyopathy with reduced function, 
hypopituitarism, hyperthyroidism, depressed mood, and diabetes mellitus (Katznelson et 
al., 2011). In vitro and animal studies have demonstrated the stimulating effect of GH on 
skeletal muscle growth. Several methods have also been used to measure the in vivo 
effects of GH on muscle metabolism in humans including whole body nitrogen retention 
and total and regional muscle protein metabolism using labelled amino acids. 
Adults with chronic, untreated GHD may have multiple somatic impairments including 
compromised muscle performance. They may experience functional limitations, 
diminished productivity, social isolation and excessive fatigue leading to an impaired 
QoL. 
GH purportedly alleviates some of these impairments by increasing circulating levels of 
IGF-1, skin thickness, bone mineral content, lean body mass and reducing fat mass. 
However, whether alleviation of the impairments translates into meaningful 
improvements in physical function remains more controversial. 
In vitro effects of GH/IGF-1 on differentiated skeletal muscle 
Both GH and IGF-1 exert an anabolic effect on skeletal muscle tissue which includes 
myogenic differentiation (Florini et al., 1991). The precise mechanism by which the 
GH/IGF-1 axis influences differentiated skeletal muscle tissue remains unclear. While it is 
clear that IGF-1 is an important myogenic signal that mediates the effects of GH on the 
skeletal muscle (Quinn et al., 1994), the direct role of GH on skeletal muscle tissue using 
cell culture studies is less convincing (Florini et al., 1977; Merrill et al., 1977). A study 
where foetal sheep myoblasts were grown in vitro to examine protein turnover when 
exposed to growth hormone, showed no stimulation of protein synthesis. However, an 
inhibition of protein breakdown was found at high GH concentrations. In contrast, 
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exposure to IGF-1 resulted in a stimulation of protein synthesis at low levels.(Harper et 
al., 1987). 
In vivo effects of GH on skeletal muscle-Human studies 
Woodhouse and co-workers demonstrated an increase in type I fiber size in adults with 
untreated GHD before and after 6 months of GH treatment (Woodhouse et al., 1999). 
These findings are in contrast to healthy control subjects who typically have larger type II 
muscle fibers that are recruited during brief high intensity exercise and smaller type I 
fibers that are recruited during more prolonged lower intensity activity. Because the 
proportion of fiber types are a major influence on contractile properties of skeletal 
muscle, altered fiber composition may be partly responsible for the impaired strength in 
adults with untreated GHD. However, the finding of larger type I fibers is 
counterintuitive and does not explain the increased perception of fatigue experienced by 
adults with GHD, since type I fibers are typically more fatigue resistant (Woodhouse et 
al., 2006). However, this finding is not consistent. Previous studies which compared 
muscle biopsies from adults with untreated GHD revealed qualitatively normal muscle, 
with no obvious features of myopathy and no significant difference in mean fiber size or 
proportion (type I vs. type II fibers) compared with age- and gender-matched healthy 
adult controls (Whitehead et al., 1989; Cuneo et al., 1992). 
There is also discrepancy when interpreting the true impact of GH replacement on 
skeletal muscle. Whereas early muscle biopsy findings demonstrate minimal changes in 
muscle fiber size (Cuneo et al., 1992), subsequent imaging studies (both MRI and CT) 
reveal a significant increase in thigh muscle mass (Cuneo et al., 1992; Janssen et al., 
1999). However, since GH replacement is associated with increased water retention, the 
measurement of cross-sectional areas of the muscle may simply reflect a rise in water 
content. Whether muscle fiber size is truly increased following GH replacement remains 
unclear. 
Effects of GH/IGF-1 on protein metabolism 
Adults with GHD have reduced lean body mass (LBM) and skeletal muscle mass when 
compared with healthy control subjects, suggesting possible impairment in protein 
anabolism. However, because the loss in LBM and muscle mass cannot persist 
indefinitely, metabolic adaptations must occur so that LBM and muscle mass stabilize, 
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albeit at reduced levels, in adults with GHD. Hoffman et al. demonstrated that a decline 
in the rate of protein breakdown occurs to offset the initial fall in protein synthesis so 
that net protein loss is minimized. They hypothesized that normalization of protein 
oxidation may be a homeostatic mechanism that helps to partially reduce protein loss in 
adults with GHD (1998). 
The majority of studies to date suggest that IGF-1 mediates a reduction in protein 
degradation whilst administration of GH results in enhanced protein synthesis. 
Similar to untreated GHD, there must be a homeostatic adaptation to protein anabolism 
in patients with GH replacement, since LBM cannot accrue indefinitely. The time-course 
of this metabolic adjustment remains controversial. However, the majority of placebo-
controlled studies report that the positive effects of GH administration on protein 
synthesis and body composition usually occur within the first few months of treatment 
(Jorgensen et al., 1989; Salomon et al., 1989). In fact a 20 day in-patient study in 4 
patients commencing GH therapy revealed that the initial response of acute nitrogen 
retention, and thus protein accretion, occurred within 2-5 days and subsided after 1-2 
weeks of GH administration. Therefore, protein kinetics during the initial few months of 
GH administration in adults with GHD, as their LBM is increasing, appears to be different 
from that during chronic GH treatment when gains in LBM have stabilised and steady 
state has been achieved (Valk et al., 1994). The duration of enhanced nitrogen retention 
after GH treatment remains controversial and warrants further investigation. 
An interesting discovery has been that infusion of GH and IGF-I into the brachial artery 
increases forearm blood flow several fold (Fryburg et al., 1991; Turkalj et al., 1992). This 
effect appears to be mediated through stimulation of endothelial nitric oxide release 
leading to local vasodilatation. Moreover, co-infusion of a nitric oxide inhibitor with IGF-I 
appeared to blunt the stimulatory effect of IGF-I on forearm protein synthesis (Boger et 
al., 1996). Hence an IGF-I mediated increase in muscle nitric oxide release could account 
for some of the effects of GH on skeletal muscle protein synthesis. 
It, therefore, appears that the acute effects of GH infusion result from increased protein 
anabolism. Conversely, the anabolic effects associated with the long term use of GH on 
skeletal muscle appear to be the result of inhibition of proteolysis, most likely mediated 
through IGF-1, resulting in reduced protein catabolism. 
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Effects of GH/IGF-1 on Lean body mass 
Extensive cross-sectional studies suggest that adults with GHD have increased 
subcutaneous and visceral fat mass with reduced LBM when compared with matched 
healthy control subjects (De Boer et al., 1992; Amato et al., 1993; Beshyah et al., 1995b; 
Hoffman et al., 1995). However, a key shortcoming in all these cross-sectional 
comparisons is the failure to compare with GHD adults on GH replacement. It is possible 
that the increased fat mass observed is due to the morbidity of hypopituitarism rather 
than the effects of GH per se. The reduction in LBM is greater in untreated childhood 
onset GHD (CO-GHD) adults compared with adult onset GHD (AO-GHD) (Attanasio et al., 
2002b) suggesting that GH may play a role in somatic development. 
Although there is general consensus that fat mass is higher and LBM slightly lower in 
adults with GHD (Carroll et al., 1998), it has yet to be conclusively proven that the 
reduced LBM associated with GHD reflects a reduction in metabolically active muscle as 
opposed to reduced water content. However, abnormalities in body composition maybe 
normalised with GH therapy over time (Carroll et al., 1998). 
Hazem et al. undertook a meta-analysis to investigate the effects of GH therapy on body 
composition. Only randomised placebo-controlled trials of GH therapy in adults (>18 
years) were included in the analysis with a minimum treatment period of 3 months. GH 
administration significantly and consistently reduced weight and body fat content while 
increasing lean body mass. However, BMI was not significantly affected. Since the 
majority of included studies had a follow up of 6 months (range 3-24 months), the 
clinical implications of the above findings remain uncertain since no study has shown 
that these changes are maintained on a long term basis (Hazem et al., 2012). 
Effects of GH/IGF-1 on skeletal muscle strength 
Adults with GHD have reduced absolute maximal isometric (where the muscle does not 
shorten i.e. remains the same length) and possibly isokinetic (where the muscle shortens 
at a consistent rate i.e. maintains the same motion) muscle strength that is at least 
partly due to reduced muscle mass. Although findings from earlier studies suggested 
that intrinsic muscle strength might be reduced in these patients, more recent data 
refute this notion (Woodhouse et al., 2006). There are discordant findings between the 
substantial increase in muscle fiber size that occurs in adults treated with GH and the 
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lack of improvement in muscle strength. Interpretation of these findings is complicated 
by differences in severity of GHD, dose of administered GH and considerable individual 
variations in muscle strength. In addition the majority of placebo-controlled trials (4-6 
months) used a shorter time period than the open-labelled studies (1-3 years). 
Johannsson et al. observed an increase in isometric and isokinetic muscle strength in 
proximal muscle groups following 2 years of GH administration in GH deficient adults but 
this was accompanied by reduced local muscle endurance. They postulated that an 
inability of the skeletal muscle to metabolically adapt in terms of muscle glucose storage 
and utilization, oxidative enzyme activity and capillarization could explain this deficit 
(Johannsson et al., 1997). A 10 year, single-centre open-label study investigated the long 
term effects of GH replacement on muscle strength. While there was a sustained 
increase in lean muscle mass and isometric knee flexor strength, other measures of 
upper leg and grip strength showed a transient increase in the 1st five years (0-5 years) of 
the study followed by a decrease in strength to baseline values or below during the 2nd 
five years of the study (5-10 years) (Gotherstrom et al., 2009). When the investigators 
made corrections for age and gender using observed/predicted value ratios, GH partly 
protected against the normal age-related decrease in muscle strength. It is not clear, 
however, how the age and sex adjustments were made. 
Widdowson et al. undertook a meta-analysis to determine the effect of GH replacement 
on muscle strength. Eight randomised, double-blinded, placebo-controlled studies were 
included involving 239 patients. The average duration of GH replacement was 6.7 
months. Analysis revealed no significant improvement when all studies were combined 
nor when measured individually (isometric and isokinetic). Thus, in contrast to open-
labelled longer term studies, short term controlled studies fail to demonstrate a benefit 
on muscle strength with GH therapy (Widdowson and Gibney, 2010). 
Effects of GH/IGF-1 on aerobic performance 
Studies evaluating maximal aerobic capacity (VO2max) have consistently demonstrated 
markedly reduced VO2max in GHD adults when compared with age, weight and height 
matched predictive values (Cuneo et al., 1991; Whitehead et al., 1992; Nass et al., 1995). 
The postulated mechanisms for this are reduced skeletal muscle mass or altered 
metabolism (Cuneo et al., 1991), diminished cardiac capacity (Colao et al., 2001) and 
35 
 
reduced red blood cell volume due to impaired IGF-1 mediated erythropoiesis (Christ et 
al., 1997). Another cardiopulmonary test called the ventilation threshold (VeT) or lactate 
threshold is used as an objective measure of the ability to perform submaximal, 
prolonged work (Woodhouse et al., 2006). The effect of GH replacement on VeT remains 
controversial. Two studies (Cuneo et al., 1991; Woodhouse et al., 1999) reported a 
significant increase (16-18%) in VeT whilst another showed no change when compared 
to a placebo group (Nass et al., 1995). The precise mechanism behind the possible 
increase in Vet remains unclear. Reduced glycolytic anaerobic metabolism (Jones and 
Ehrsam, 1982), improved proton clearance (Jones and Ehrsam, 1982) and delayed 
recruitment of type II fibers (Mateika and Duffin, 1994) are some of the proposed 
mechanisms. 
Widdowson et al. undertook a meta-analysis to examine the effects of GH replacement 
on exercise performance. They included 11 randomised, double blinded placebo 
controlled studies involving 268 patients. GH replacement was associated with a 
significant improvement in maximal power output and maximal oxygen uptake 
(Widdowson and Gibney, 2008). The results of this study must be interpreted cautiously 
because the magnitude of benefit is difficult to ascertain. 
Functional Limitations 
Adults with GHD may suffer functional limitations because muscle power is known to be 
important for performance of daily activities such as rising from a chair, climbing stairs 
and for walking. However, the majority of activities of daily living are performed using 
aerobic metabolism. Thus, perhaps more importantly, it is the aerobic effects of GH that 
are likely to be more relevant in abating fatigue. 
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Figure 6 Growth hormone and its putative physical and functional effects on skeletal 
muscle tissue 
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1.3.8 Quality of Life impairment in GHD 
Definition 
Quality of life (QoL) is a ubiquitous concept that has different philosophical, political and 
health-related definitions. Health related QOL (HRQoL) includes the physical, function, 
emotional and social well-being of an individual. It is a patient-reported outcome usually 
measured with carefully designed and validated tools such as questionnaires. Often 
these instruments measure multidimensional domains of an individual’s functional 
health and well-being. 
QoL in GHD 
Impairment of QoL in hypopituitary adults not receiving GH replacement therapy has 
been evident for a long time (Carroll et al., 1998). Untreated adults patients with GHD 
most often complain of reduced energy levels, vitality, mental fatigue, emotional 
reactions, social isolation and anxiety (Bjork et al., 1989; McGauley et al., 1990). 
Additionally, some of these patients may also complain of a reduced sex drive, poor 
body image, reduced motor mobility, lack of self-confidence, a poor memory, reduced 
cognitive function, decreased mood and attention deficits (Deijen et al., 1996; van Dam 
et al., 2005). 
The majority of these findings originate from small patient cohorts followed for a limited 
time period. The benefits of GH therapy in improving QoL as assessed by the ‘gold 
standard’ of clinical studies, randomised controlled trials (RCT), remains controversial. 
Table 3 illustrates the results of the RCT’s that have examined whether GH therapy leads 
to an improved QoL. In the studies that demonstrated improvements in QoL there was 
inconsistency in terms of the instrument used and the effects measured. The variability 
in the assessment of QoL by different studies may reflect the different tests used in 
measuring QoL. There are both generic and disease specific tests available and therefore 
one would expect the generic tests to have a lower sensitivity to GH-dependent QoL 
indices. This also highlights the multifactorial nature of QoL. There may also be a 
temporal influence of GHD on well-being as Burman et al. demonstrated that there was 
an inverse correlation between duration of GHD and QoL (1995). On the contrary, the 
severity of GHD has not been shown to impact on QoL (Zenker et al., 2002). A meta-
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analysis by Ahmad et al. was unable to pool the findings of the trials assessed because of 
the heterogeneity in outcome measures and the lack of quantitative data to perform the 
meta-analysis. Nonetheless, 11/16 of the trials reported a statistically significant 
improvement in at least one construct of the QoL tool in patients who received active 
treatment (2001). 
 
Table 3 Summary of Studies reporting QoL changes with GH therapy 
Improvement in QoL indices reported No benefit in QoL indices reported  
(n=233) (Ma°rdh G and investigators, 1994) (n=166) (Cuneo et al., 1998) 
(n=173) (Attanasio et al., 1997) (n=40) (Beshyah et al., 1995a) 
(n=148) (Verhelst et al., 1997) (n=40) (Baum et al., 1998) 
(n=73) (Chihara et al., 2006) (n=34) (Sathiavageeswaran et al., 2007) 
(n=48) (Deijen et al., 1998)  
(n=42) (Carroll et al., 1997)  
(n=36) (Burman et al., 1995)  
(n=32) (Wallymahmed et al., 1997)  
 
Qol-AGHDA: A Disease specific questionnaire 
There are several generic and disease specific test available to quantify QoL. Researchers 
have quantified QoL in hormone deficient patients in order to define the importance of 
the deficient hormone in determining QoL. However, patients with a chronic illness 
often adapt, matching their activities to their ability. Since adaption is not detected using 
conventional QoL instruments (Jorgensen, 1999), the relevance of the deficient hormone 
to QoL is often underestimated by the generic investigative approach. Older studies have 
usually relied on well-validated, generic tests of overall health and psychiatric well-being, 
such as the Nottingham Health Profile (NHP). These questionnaires have been criticized, 
however, for their lack of sensitivity to subtle changes in QoL (McKenna et al., 1999). In 
addition, generic tools do not address symptoms that are important to adult patients 
with GHD and concentrate on areas that are of little relevance (McKenna et al., 1999). 
Therefore, for the purpose of the studies described in this thesis, I shall be utilising a 
specific test developed particularly to assess GHD adults, namely QoL-AGHDA (Adults 
with growth hormone deficiency assessment). 
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QoL-AGHDA is a disease-specific, need-based measure which was developed based on 
in-depth qualitative interviews with adult patients with GHD (n=35; 14 men; age range 
20–59 years) attending the Christie Hospital in Manchester, UK (Holmes SJ, 1995). 
Almost all patients were dissatisfied with their body image and complained of lack of 
energy (94% and 91% respectively), 83% had problems with memory and concentration, 
71% described themselves as being short-tempered and easily irritated, 66% suffered 
from lack of strength and stamina, 63% experienced reduced physical and mental drive 
and 57% had difficulties coping with stressful situations and avoided external stimulation 
(Wiren et al., 1998). 
The measure is constructed of 25 items that evoke yes/no answers, acknowledging or 
denying certain problems. The total score is computed by quantifying a range of 
problems so that each ‘yes’ is given a score of 1 and each ‘no’ is attributed a score of 0. 
Therefore, a higher numerical score depicts a poor QoL. It has been shown to have good 
reliability, reproducibility, internal consistency and construct validity across a range of 
languages (McKenna et al., 1999). 
Possible mechanisms for GH-induced impaired QoL 
A cross-sectional case-control study identified abnormalities in the sleep architecture of 
GHD adults. They postulated that increased hypothalamic GH releasing hormone (GHRH) 
activity produced through the loss of negative feedback in GHD could contribute to the 
daytime somnolence and fatigue in GHD (Copinschi et al., 2010). Hence, the fatigue 
perceived by these patients could partly be central in origin. 
Chrisoulidou et al. explored the possible mechanisms of action of GH in improving QoL. 
They discussed the possible mechanisms by which GH modulates QoL including its action 
at various neural sites, modifying mood, memory and cognition. It may also influence 
subjective well-being via somatic changes in body composition, cardiovascular health, 
reproductive function and skin (1998). 
Limitations 
One of the limitations of longitudinal self-reported outcome assessments is the response 
shift phenomenon. Response shift is a change in one’s internal perception or 
understanding of a construct and is thought to be made up of three components: 
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reconceptualisation, reprioritization and recalibration (Schwartz and Sprangers, 1999; 
Sprangers and Schwartz, 1999; Rapkin and Schwartz, 2004).  
 Reconceptualisation is the change in the understanding of which elements or 
components are included in a target construct. 
 Reprioritisation is the change in the preference regarding the relative 
importance of certain components within the construct. 
 Recalibration is the change in the value of scaling of certain health states in 
relation to others. 
In summary, response shift may cause paradoxical or incorrect findings during 
longitudinal questionnaire trials. It is a naturally occurring process believed to be part of 
natural coping and adaptive mechanisms. However, it has the potential to invalidate 
study findings. Although no solution has been found to this problem, research is on-
going to minimise this phenomenon. 
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1.3.9 GHD and the brain 
The reported poor memory and reduced cognitive function observed in GHD patients 
has led to considerable interest in the effects of GH on the central nervous system (CNS). 
I shall briefly summarise an overview of the work undertaken in this particular field. 
Evidence for the presence of GH in the brain 
There are three possible mechanisms by which GH may exert its effect on brain function 
(Figure 7). Firstly, GH may release secondary mediators such as IGF-1 from peripheral 
tissues which may cross the blood brain barrier (BBB) (Coculescu, 1999). Secondly, GH 
may be degraded enzymatically into bioactive fragments which reach the brain and act 
on peptidergic receptors (Stanley et al., 2011). Thirdly, GH may enter the brain itself and 
directly influence the nervous system. This notion is supported by the fact that GH has 
been detected in the brain and CSF (Nyberg and Burman, 1996). 
 
 
Figure 7 Putative mechanisms of action of GH on brain 
 
Growth hormone receptors in the brain 
Specific binding sites for GH in the human brain have been identified and characterised. 
The highest density of GH binding, using iodine-labelled GH was found in the choroid 
plexus followed by the hippocampus, the hypothalamus and the pituitary (Lai et al., 
1991). 
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Evidence of cognitive impairment in GH deficient adults and the effects of GH 
replacement 
Several neuropsychological studies suggest that patients with GHD experience significant 
cognitive impairment (Deijen et al., 1996; Lijffijt et al., 2003; van Dam et al., 2005) and 
that this can be ameliorated by GH replacement (Sartorio et al., 1995; Deijen et al., 
1998; Arwert et al., 2005a). 
However, most of these conclusions have been drawn from cross-sectional comparisons 
between GHD patients and matched healthy controls. Hence the reliability of inferences 
regarding the presence of cognitive impairment in GHD is limited. GHD patients can have 
low mood and low motivation which may impair their performance on cognitive testing. 
The use of heterogeneous GHD patient groups may complicate interpretation due to the 
variability in degree and duration of GHD. Although the various cognitive tests measure 
similar cognitive domains, different tests have been used in different studies, thus, 
limiting their generalisability. Since multiple comparisons were undertaken, lack of the 
adjustment of error rates (such as Bonferroni correction) for multiple post hoc analyses 
could also lead to Type 1 errors. 
Falleti et al. undertook a meta-analysis of all of the neuropsychological literature to date 
to examine the nature and magnitude of cognitive impairment in GHD patients and the 
extent to which GH replacement improves cognitive function (2006).  They concluded 
that patients with GH deficiency have neuropsychological impairments in the domains of 
attention, memory and executive functions when compared to matched controls. When 
comparisons were made in cross-sectional studies between GH treated patients and 
matched healthy controls, the cognitive impairments persisted. However, this method 
did not include comparisons with GHD patients before GH replacement and so we 
cannot determine whether or not the impairments detected actually represented an 
improvement from prior cognitive dysfunction or whether there was no benefit at all. 
Prospective data showed that, compared to a non-treatment baseline, all aspects of 
cognitive function improved following 3-6 months of GH treatment. This improvement 
continued for up to 12 months across the domains of attention, spatial ability, memory 
and executive functions (Deijen et al., 1998) and for as long as 10 years in the memory 
domain (Arwert et al., 2005a). In contrast, Arwert et al. concluded from their meta-
analysis that there was no evidence that GH substitution improved patient reported 
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outcomes in GHD adults. They observed a progressive decrease in effect sizes when 
treatment duration increased, thereby, pointing to the presence of a placebo effect, 
which was most prominent in the start of the treatment period. More importantly they 
found that GH treatment was no more effective than placebo in terms of improving 
patient-reported outcomes (Arwert et al., 2005b). 
Functional MR (fMRI) studies in GHD adults 
Functional MRI is a neuroimaging technique for measuring brain activity. It works by 
detecting the changes in blood oxygenation and flow that occur in response to neural 
activity. When a brain area is more active it consumes more oxygen and to meet this 
increased demand, blood flow increases to the active area. fMRI can be used to produce 
activation maps showing which parts of the brain are involved in a particular mental 
task. 
Arwert et al. compared cognitive function in GHD adults with matched controls using 
both neuropsychological tests and fMRI. They concluded that GH-deficient patients have 
a subnormal memory speed, but no impaired quality of memory performance, which 
may be due to compensatory recruitment of dorsal prefrontal brain regions (Arwert et 
al., 2005c). They then investigated the effects of GH substitution on cognitive 
functioning in GHD adults using neuropsychological tests and fMRI. They concluded that 
6 months of GH treatment improved the long-term as well as working memory in 
patients with GHD, and this was associated with decreased brain activation in the 
ventrolateral prefrontal cortex (Arwert et al., 2006). 
Effect of GH on developing brain structure and function in GHD children 
Webb et al. investigated the effects of GH on developing brain structure and function. 
Reductions in white matter integrity in the corticospinal tract and corpus callosum and 
selective reductions in neural volume in isolated GHD children were identified. The 
abnormalities in white matter fiber density and neural volumes correlated significantly 
with cognitive function and motor skill abilities, which were also significantly impaired in 
isolated GHD children (Webb et al., 2012). 
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1.3.10 Growth Hormone and the mitochondria 
It is well recognized that the actions of GH include protein anabolism, promotion of 
lipolysis and reduced sensitivity to insulin-induced glucose metabolism in liver and 
peripheral tissues (Davidson, 1987; Moller and Norrelund, 2003; Jessen et al., 2005). 
Since GH is an anabolic hormone, GH administration could increase the energetic 
demands on the mitochondria. Skeletal muscle mitochondrial activity maybe a 
particularly relevant and interesting candidate to interrogate since skeletal muscle tissue 
is not only the richest source of ATP generation in the body but is also one of the key 
target sites of growth hormone action along with its downstream regulator IGF-1. 
However, the effects of GH on mitochondrial function are not well established. In this 
section, I shall be discussing the work undertaken (in vitro, in vivo and 31P MRS) so far to 
elucidate the role of GH on mitochondrial function. 
In Vitro and in vivo Studies 
Leung et al. developed an in vitro bio-assay to investigate the role of GH in the 
stimulation of mitochondrial fatty acid oxidation in human fibroblasts. They 
demonstrated that GH directly stimulated fatty acid oxidation in vitro (1997). However, 
IGF-1 had no detectable effect on fatty acid oxidation. In contrast, an in vivo study 
undertaken by Hussain et al. demonstrated that IGF-1 infusion enhances lipid oxidation 
in humans (1994). Therefore in order to explain this dichotomy, Leung et al. postulated 
that the in vivo stimulation of lipid oxidation by IGF-1 occurs indirectly through the 
suppression of insulin secretion and by reducing the inhibitory effect of insulin on whole-
body lipid oxidation. However, the precise mechanism by which GH stimulates fatty 
oxidation still remains unclear. Unterluggauer et al. also demonstrated that IGF-1 
dependent signaling stimulates mitochondrial respiration in prostate cancer cell lines 
(2008). Short et al. attempted to determine whether GH had an impact on mitochondrial 
regulation. They investigated the acute effects of GH by infusing GH or saline in 9 young 
healthy volunteers in a randomised crossover study design. Muscle biopsies were used 
to measure the mitochondrial ATP production rate, mitochondrial protein synthesis rate 
and the abundance of several gene transcripts that regulate muscle oxidative 
phenotype. They demonstrated that a 14 hour infusion of GH with an associated 
physiological elevation of GH in healthy people resulted in an increase in skeletal muscle 
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mitochondrial oxidative capacity, as shown by increased mitochondrial ATP production 
rates and increased citrate synthase activity. It also led to a higher muscle content of 
mRNA transcripts encoding oxidative proteins in mitochondria (COX3 and COX4), a 
nuclear transcription factor that regulates mitochondrial biogenesis (TFAM) and the 
glucose transport protein (GLUT4). However, they observed no effect on muscle protein 
synthesis, including mitochondrial proteins (2008). 
31P MRS and growth hormone production in healthy adults 
Makimura et al. investigated the association between parameters of the GH axis and 
mitochondrial function non-invasively using 31P MRS in healthy adults. At a single centre, 
they investigated 37 healthy adults between the ages of 18-55years. All subjects 
underwent GHRH-arginine testing after an overnight fast. Parameters of the GH axis 
measured included serum IGF-1, peak stimulated GH and GH area under the curve 
(AUC). Mitochondrial function was determined using 31P MRS to assess PCr re-synthesis 
after sub maximal exercise (3 min X 40% maximal voluntary contraction of bilateral 
quadriceps contractions followed by a 5 min recovery). Mitochondrial function was 
measured using τPCr (mitochondrial phosphorylation potential) and Vi (initial rate of PCr 
recovery post-exercise). Both τPCr and Vi were studied as end points. They found a 
gender specific association between PCr recovery and parameters of the GH axis in 
otherwise healthy adult males but not in women (Makimura et al., 2011). Moreover, 
obesity is associated with GH insufficiency (Murray et al., 2007) and they demonstrated 
that 4 of the 26 obese subjects had peak stimulated GH ≤ 4.2 mcg/L. Since obese 
subjects are more likely to have been physically inactive than their slimmer 
counterparts, it could be that an association exists between physical fitness and 
mitochondrial oxidative function (Johansen and Quistorff, 2003) rather than parameters 
of the GH axis. Besides, no explanations were provided for the gender dimorphic effect 
(Figure 8). 
In contrast, Janssen et al. investigated the influence of GH on muscle phosphate 
metabolites at rest in GHD adults using 31P MRS and found no evidence of an effect 
(Janssen et al., 1999). Importantly, however, this method was not undertaken during 
exercise and hence dynamic markers of oxidative phosphorylation were not measured. 
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Figure 8 Growth hormone and phosphocreatine recovery in healthy adults  
Bivariate analyses demonstrating association of (A) IGF-1 and (B) peak stimulated GH 
with Vi (phosphocreatine recovery) in men and (C) IGF-1 and (D) peak stimulated GH 
with Vi in women (Makimura et al., 2011) 
 
1.3.11 Summary 
GHD adults present with a characteristic phenotype with fatigue being a predominant 
symptom. The fatigue also contributes to the impaired QoL often reported by these 
patients. There are multiple lines of evidence pointing towards the effects of GH on 
skeletal muscle metabolism although this does not necessarily translate into 
enhancements in functional outcomes following GH replacement in GH deficient 
subjects. Nonetheless, GH is a regulator of muscle function that potentially enhances 
muscle mass and improves exercise capacity. Skeletal muscle is thus a candidate for a 
common effector tissue responsible for mediating the symptoms and metabolic 
characteristics of GHD. Furthermore, because of the central role of mitochondria in 
energy generation and reports linking an association between GH and mitochondrial 
function, skeletal muscle mitochondrial function is a logical candidate to investigate 
when studying the pathophysiology of fatigue in GH deficiency. 
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1.4 Vitamin D deficiency 
1.4.1 Vitamin D deficiency  
Vitamin D is a prohomone essential for regulating calcium absorption in the gut. Vitamin 
D deficiency is associated with rickets in children and osteomalacia and myopathy in 
adults. Despite being freely available through UVB sunlight exposure of exposed skin, 
and to a lesser degree through eating oily fish, vitamin D deficiency is widespread in 
many developed and developing countries.  This topic consequently figures prominently 
in a rapidly growing scientific literature, as well as in the popular press. This focus is 
appropriate and reflects the many uncertainties about vitamin D status, particularly its 
emerging role in extra-skeletal health, as well as its relationship to musculoskeletal 
disease. This section reviews the assessment of vitamin D status and the risk factors for 
vitamin D deficiency. It also examines the relationship between vitamin D and skeletal 
muscle.  
1.4.2 Sources of vitamin D and metabolism 
Most circulating vitamin D is synthesised from cutaneous exposure to solar rays with diet 
generally being a poorer source of vitamin D (Sinha et al., 2012). Vitamin D exists as 
either ergocalciferol (Vitamin D2) or colecalciferol (Vitamin D3). Whereas ergocalciferol 
is derived from UV irradiated ergosterol of fungus or yeast origin, colecalciferol is animal 
derived. It is formed endogenously in the skin of mammals from its prohormone, 7-
dehydrocholesterol, following solar ultraviolet B (UVB) radiation. It is then metabolised 
in the liver to 25-hydroxyvitamin D (25OHD) and then in the kidneys to either a 
metabolically active form (1, 25-dihydroxyvitamin D [1,25OHD]) or an inactive form (24, 
25-dihydroxyvitamin D) (Figure 9). The activation of vitamin D in the liver and kidney 
occurs by hydroxylation which is catalysed by the mitochondrial cytochrome P450 
system. 1, 25-dihydroxyvitamin D synthesis is stimulated by hypocalcemia, PTH and 
hypophosphataemia. 
48 
 
 
Figure 9 Summary of vitamin D metabolism 
(Girgis et al., 2012) 
 
Biologically active 1,25OHD exerts its effect on target organs by binding to an 
intracellular vitamin D receptor (VDR). This binding leads to conformational changes with 
the receptor that allows it to interact with its heterodimer partner, retinoid X receptor 
(RXR). This liganded complex binds to vitamin D response elements in the DNA to 
regulate gene transcription (Figure 10). VDRs are steroid hormone receptors that are 
proteins with a binding site for a particular steroid molecule. Their discovery on several 
tissues in the body along with several epidemiological studies have raised interest in the 
potential role of vitamin D in several extra-skeletal diseases such as immune disorders, 
cancer and diabetes (Misra et al., 2008). However, the possibility of confounding 
variables in those studies needs to be considered. Long term prospective studies 
examining the effects of vitamin D in preventing these conditions that may be related to 
vitamin D are awaited. 
1.4.3 Vitamin D status assessment 
Serum 25OHD concentration is the best marker of bodily vitamin D status, with a 
circulating half-life of around 3 weeks. Serum 1,25OHD, the active vitamin D hormone, 
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should not be measured as it has a short circulating half-life and does not reflect body 
vitamin D status (DeLuca, 2004; Holick, 2007; Holick, 2009; Bischoff-Ferrari et al., 2010; 
Greene-Finestone et al., 2011). Both adults and children with symptomatic vitamin D 
deficiency (rickets, myopathy and musculoskeletal pain) generally have serum 25OHD 
levels that are less than 30nmol/l. 
What constitutes an optimum level of serum 25OHD remains uncertain, and is different 
depending on whether skeletal or non-skeletal outcomes are being considered, and may 
also be different at different stages of life. Many authorities are now recommending a 
serum 25OHD concentration of 75nmol/L or more (Vieth et al., 2007; Holick et al., 2011), 
largely based on evidence from physiological analysis of peak intestinal calcium 
absorption (Heaney et al., 2003), and an association with better health outcomes in large 
epidemiological studies. Histomorphometric analysis of iliac crest biopsies from 675 
individuals demonstrated that pathological mineralization defects only occurred in the 
context of serum 25OHD <75nmol/L (Priemel et al., 2010). Furthermore, studies using 
serum PTH response as an index of serum 25OHD have recommended wide ranges 
varying from 30-100nmol/L (Sahota et al., 2004; Dawson-Hughes et al., 2005). 
Nevertheless, a serum 25OHD level of 50nmol/l or more can also be viewed as adequate 
for skeletal health (Mithal et al., 2009; Aloia, 2011; Medicine, 2011; Ross et al., 2011), as 
there is currently no level 1 (RCT) evidence that supports an improvement in health from 
elevating 25OHD levels from 50 to 75nmol/l. 
There are several different assays available for measuring 25OHD concentrations but it is 
now accepted that liquid chromatography tandem mass spectroscopy is the ‘gold 
standard’. The National Institute of Standards and Technology (NIST), in collaboration 
with the National Institutes of Health's Office of Dietary Supplements (NIH-ODS) has 
developed a Standard Reference Material for the determination of 25-hydroxyvitamin D 
[25(OH)D] in serum (Carter et al., 2004a; Carter et al., 2004b; Phinney, 2008; Phinney et 
al., 2012). Rigorous use of this standard should improve the assessment, interpretation 
and generalisability of serum 25OHD levels. 
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1.4.4 Risk factors for vitamin D deficiency 
Those individuals with pigmented skin living in northern latitudes are at major risk of 
developing vitamin D deficiency. This is also the key risk factor in sunnier climates such 
as Australia, India and the Middle East where vitamin D deficiency has also been widely 
reported (Sedrani et al., 1983; Sachan et al., 2005; Robinson et al., 2006). With global 
migration and changes in diet towards processed food over the past century, millions of 
other people are now at risk of vitamin D deficiency as well (Lips, 2010). Elderly and 
institutionalised individuals are also at risk because of the relatively large amount of 
time spent indoors. 
A prospective study conducted in Manchester, UK (53oN) examined whether personal 
sunlight exposure levels could provide sufficient vitamin D (25OHD ≥50nmol/L) in white 
adults. This not only confirmed that vitamin D synthesis was negligible during the winter 
months in the UK, but also determined that attaining a ‘peak’ late summer 25OHD level 
of approximately 80nmol/L was required to ensure a ‘trough’ winter level of at least 
50nmol/L [17]. 72% of the population did not attain the ‘peak’ level of 80nmol/L (Webb 
et al., 2010). The same group also examined similar UVB -25OHD dose-responses in 
South Asians, and found that all participants had a vitamin D level <50nmol/L during the 
winter ‘trough’ (Farrar et al., 2011). This indicates that South Asians cannot rely on solar 
vitamin D production to maintain an optimal Vitamin D status in northern latitudes. 
There were similar findings in African-American children living in Texas, North America 
(32 oN) (Shah et al., 2000). It, therefore, seems unlikely that dark skinned people, or that 
the majority of fair skinned people, living in Northern latitudes, will be able to maintain 
adequate vitamin D levels throughout the year if current population habits with relation 
to sun exposure go unchanged. 
Individuals with malabsorption, short bowel, renal and liver disease, survivors of cancer 
and those taking anticonvulsants, rifampicin or highly active antiretroviral drugs are also 
at higher risk. Vegetarians, people with photosensitive skin disorders and those with 
agoraphobia are at also at high risk of vitamin D deficiency. Obesity is a risk factor for 
low serum 25OHD, although total body fat vitamin D stores may be higher, so the clinical 
significance of the biochemical finding is currently uncertain (Drincic et al., 2012). 
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1.4.5 Vitamin D and skeletal muscle function 
Adults with vitamin D deficiency commonly present with myalgia and myopathy (Glerup 
et al., 2000; Plotnikoff and Quigley, 2003; Mouyis et al., 2008; Badsha et al., 2009). The 
role of vitamin D on bone health and calcium metabolism is well established. Over the 
past decade, both clinical and laboratory studies have attempted to understand the 
precise link between vitamin D and muscle strength. Vitamin D may influence muscle 
function through the binding of 1,25 OHD to vitamin D receptors (VDR) in skeletal 
muscle (Meyer and Jones, 1957). 
Lessons from VDR knockout (KO) mouse models 
The VDR knockout mouse model has provided novel insights into the direct effect of 
vitamin D on skeletal muscle tissue. VDR mutant mice are characterised by alopecia, 
reduced body size and weight and impaired motor coordination (Park et al., 1994). The 
VDR KO mouse model has also helped to clarify whether VDR or metabolic abnormalities 
are primarily responsible for the symptoms and clinical findings in this condition. VDR 
mutant mice were found to have muscle fiber diameters that were approximately 20% 
smaller than those of the wild type mice at 3 weeks of age. By 8 weeks of age, these 
muscle fiber changes were more prominent in the VDR KO mutant mice compared to the 
wild type suggesting that either these abnormalities progress over time or that as these 
mice age the metabolic alterations that occur contribute to the morphological changes. 
These morphological changes occur independent of any metabolic abnormalities such as 
hypocalcaemia and hypophosphatemia. The muscle fiber abnormalities were noted 
diffusely without any preference for type I or type II fibers (Endo et al., 2003). This differs 
from the histological changes seen in vitamin D deficient myopathy in humans. 
Muscle morphology 
Muscle biopsies in adults with vitamin D deficiency show type IIa muscle fiber atrophy 
(Sorensen et al., 1979). Type IIa or fast oxidative fibers are rich in myoglobin, 
mitochondria and vascular capillaries. These fibers have a high capacity for generating 
ATP by the mitochondrial oxidative process. Type IIb or fast glycolytic fibers contain less 
myoglobin, mitochondria and blood capillaries. These fibers are rich in glycogen and are 
susceptible to fatigue. A RCT found that treating elderly stroke survivors with 
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ergocalciferol resulted in an increase in muscle strength by reducing atrophy of type IIa 
muscle fibers, which may lead to decreased falls and hip fractures (Sato et al., 2005). 
Molecular mechanisms- Vitamin D receptors (VDR) in muscle tissue 
1,25dihydroxyvitamin D (1,25OHD), the biologically active form of vitamin D, mediates 
its action by binding to the vitamin D receptor (VDR). VDRs are expressed in muscle 
tissue in rodents, chick and cloned human cell lines (Wong et al., 1992; Thambyrajah et 
al., 2000; Ryan and Jones, 2004; Ceglia et al., 2010). However, this was not corroborated 
recently by Wang et al. when they used highly specific antibodies to identify VDRs in the 
skeletal muscle of humans (Wang and DeLuca, 2011). VDRs may act as either nuclear 
receptors (genomic action) or cell membrane receptors (non-genomic action). 
 Genomic effects of 1,25OHD 
The nuclear VDR is a ligand dependent nuclear transcription factor. Intranuclear staining 
detecting its existence was first demonstrated in situ in human skeletal muscle tissue by 
Costa et al. (1986). Following transportation to the nucleus by an intracellular binding 
protein, 1,25OHD binds to the nuclear receptor thereby resulting in mRNA gene 
transcription and de novo protein synthesis. The activation of the nuclear VDR results in 
heterodimerization between the VDR and a steroid receptor called retinoic receptor 
(RXR) (Figure 10). This genomic pathway is involved in muscle calcium uptake, 
transmembrane phosphate transport, phospholipid metabolism and muscle cell 
proliferation and differentiation. Both in vitro and in vivo experiments in chick skeletal 
muscle have demonstrated that 1,25OHD regulates muscle calcium uptake by 
modulating the activity of calcium pumps in the sarcoplasmic reticulum. The calcium 
influx is also regulated by voltage-sensitive calcium channels which thereby regulate 
intracellular calcium (Jones et al., 1948). Modifications in intracellular calcium levels 
control contraction and relaxation of muscle, thus impacting muscle function (Boland et 
al., 1995). 
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Figure 10 Genomic (Classic) vitamin D signaling pathway 
(Girgis et al., 2012) 
 
 Non-genomic effects of 1,25OHD 
Apart from its genomic effects, 1,25OHD induces a rapid, non-transcriptional response 
through a cell surface receptor. This mechanism may also be responsible for 1,25OHD 
mediated muscle contractility. In vitro studies on vitamin D deficient chicks showed that 
when 1,25OHD was added to skeletal muscle cells, it had a rapid effect (1-15min) on 
calcium uptake (Tarnopolsky and Parise, 1999). Inhibitors of RNA and protein synthesis 
did not inhibit these rapid effects suggesting no involvement of the nuclear VDR. Calcium 
channel blockers did suppress these effects indicating that 1,25OHD was acting at the 
membrane and influencing calcium influx into the cell (Tarnopolsky and Parise, 1999) 
(Figure 11). 
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Figure 11 Genomic and non-genomic effects of vitamin D on muscle 
Data on direct effects come predominantly from in vitro studies and are yet to be 
confirmed in vivo, where the presence of the VDR is currently under debate (Girgis et 
al., 2012). 
 
Clinical evidence 
Several large cross-sectional studies have investigated the relationship between vitamin 
D status and muscle strength. Generally, muscle strength is evaluated by handgrip 
strength and/or thigh strength measured by a dynamometer. 
Several cross-sectional studies have shown that lower serum 25OHD levels correlate 
with reduced muscle strength in the elderly (Gerdhem et al., 2005; Houston et al., 2007). 
However, other association studies in a more diverse age range, including healthy 
individuals, have not replicated these findings (Ceglia et al., 2011). A systematic review 
conducted to examine the effects of low vitamin D concentrations and vitamin D 
supplementation on muscle, balance and gait performance in the elderly (≥65 years) was 
also inconclusive (Annweiler et al., 2009). A cross sectional study conducted by Ward et 
al. in post-menarchal adolescent girls in Manchester, UK determined that vitamin D was 
positively associated with muscle power and force (2009). In summary, the cross-
sectional designs of the studies described make it difficult to establish a causal 
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relationship. The elderly age range of the patients studied also makes it difficult to 
differentiate between weakness secondary to aging or vitamin D deficiency. 
Randomised controlled trials to study the effects of vitamin D supplementation on 
muscle strength have been conflicting too. Improvements in quadriceps strength and 
body sway were noted in a RCT where community-dwelling ambulant older women were 
supplemented with ergocalciferol and calcium (Prince et al., 2008). Six months of 
cholecalciferol and calcium supplementation improved muscle strength and physical 
performance in vitamin D deficient (mean serum 25OHD-25nmol/L) healthy adults in 
India (age 31.5 ± 5.0 years) (Gupta et al., 2010). On the contrary, when Ward et al. 
conducted a RCT where post-menarchal adolescent females were supplemented with 
ergocalciferol over one year, there were no improvements in muscle force or power 
despite improvements in serum 25OHD levels (2010). A recent double blinded RCT from 
the same centre in India studied 173 young Indian women (mean age-22 years) with 
vitamin D deficiency who were randomised to one of four groups: calcium 500 mg twice 
daily, vitamin D, calcium + vitamin D, and placebo. Vitamin D was given at 60,000 
IU/week for 8 weeks, and then every 2 weeks for 6 months. Mean serum 25OHD was 
23nmol/L at baseline and increased to approximately 70nmol/L in the two vitamin D-
treated groups and was unchanged in the calcium or placebo groups. At 6 months, there 
were no significant differences in handgrip strength between the four groups, no 
difference in the 6-min walking test, and no difference in the quality of life assessment 
(Goswami et al., 2012). 
The demonstration of unequivocal improvements in muscle strength in vitamin D 
deficiency remains elusive. Possible reasons for this include heterogeneity in patient 
demographics and outcome measured (grip strength, knee strength, hip strength, 6-min 
walk test, sway test) The fact that muscle strength is a function of several variables such 
as age, genetics, body size and physical fitness also needs to be considered. 
1.4.6 Summary 
Vitamin D insufficiency and deficiency remains a major health issue affecting, to differing 
degrees, a large proportion of the population of many countries, both affluent and 
developing. This indicates a widespread failure of public health policy in many societies. 
One can conclude that sunlight in isolation is insufficient to generate sufficient vitamin D 
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production in most people living in northern latitudes, including the UK. Diet is a poor 
source of vitamin D for most of the population. There has been considerable interest in 
the relationship between vitamin D and muscle strength. The present body of evidence 
suggests that treatment with vitamin D does not equivocally lead to improvements in 
muscle strength in otherwise healthy vitamin D deficient adults. However, the study of 
muscle function entails not only the assessment of strength but also of endurance. 
However, rather than focussing on muscle strength which has already been examined by 
several investigators, a novel approach would be to examine skeletal muscle oxidative 
metabolism in symptomatic, vitamin D deficient adults and observe the impact of 
vitamin D therapy on skeletal muscle metabolism post therapy. This technique measures 
the energy cost of an activity and therefore provides insights into the energy efficiency 
of the vitamin D deficient skeletal muscle.  
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1.5 Phosphorus-31 Magnetic Resonance Spectroscopy 
1.5.1  Overview 
Almost three decades ago, Chance et al. reported for the first time that phosphorus 
metabolites could be observed in vivo using Phosphorus-31 Magnetic Resonance 
Spectroscopy (31P MRS) (Chance et al., 1980), thus, offering the  prospect of examining 
muscle energetics in vivo under strictly non-invasive conditions. From that time onwards, 
MRS technology has rapidly evolved with the availability of high field and wide bore 
superconducting magnets and methodological developments (such as dedicated pulse 
sequences, and the spatial localization of the NMR signal). 
Before 31P MRS, the measurement of phosphorylated compound concentrations in living 
cells was non-trivial. Traditional methods such as percutaneous needle biopsy and freeze 
clamping are limited by the possible partial degradation of phosphorylated metabolites 
during extraction. Furthermore, consecutive measurements cannot be made during 
exercise, thereby, making it impossible to obtain high time-resolution kinetics. 
Compared to analytical methods, 31P MRS offers the opportunity of measuring non-
invasively and continuously with a high time-resolution, the concentration of 
phosphorylated compounds involved in muscle energetics using radiofrequency pulses 
and strong magnetic fields. It generates a spectrum which is a plot of signal intensity 
versus frequency that shows the chemical shift. The chemical shift is the resonant 
frequency of a nucleus relative to a standard with the position and number of the 
chemical shift being diagnostic of the molecule. Interestingly, direct biopsy derived 
biochemical and 31P MRS measurements give comparable results when measured during 
exercise (Bangsbo et al., 1993; Tarnopolsky and Parise, 1999). 
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Figure 12 31P spectrum from gastrocnemius and soleus of a healthy volunteer at rest at 
3T and the derived phosphorus spectrum showing relative concentrations of inorganic 
phosphate (Pi), phosphodiesters (PDE), phosphocreatine (PCr) and adenosine 
triphosphate (ATP). 
Please note that due to the bandwidth performance of the adiabatic excitation pulse 
centred on PCr, the beta-ATP moiety is excited to a lesser degree than the alpha and 
gamma moieties. Although ADP is at too low a concentration to be visible in the 
spectrum, the β-ADP resonance would have a chemical shift of -3.09ppm, the α-ADP 
resonance at -7.05ppm (Graaf, 2007). ATP concentrations are buffered by transfer of a 
phosphate group from PCr to ADP as indicated. 
1.5.2 Principles 
Magnetic Resonance Spectroscopy (MRS) gathers information using technology similar 
to Magnetic Resonance Imaging (MRI). However, rather than providing a spatial image, 
MRS offers a frequency spectrum containing discrete signals from compounds of a 
selected resonating nucleus (Figure 12). Commonly studied nuclei using in vivo MRS 
include biologically active metabolites such as 31P, 1H and 13C. The magnitude of a 
metabolite peak in the frequency spectrum is proportional to its concentration in the 
volume of tissue being examined, provided the spectrum is corrected for T1 weighting 
(Figure 12). Measuring changes in these peak areas, which result from either normal 
function, disease processes or from the effects of drugs, enables monitoring of 
intracellular changes which are not necessarily accompanied by structural changes. 
31P Magnetic Resonance Spectroscopy (31P MRS) offers an opportunity to probe 
oxidative mitochondrial function non-invasively by measuring the kinetics of high energy 
phosphate species involved in muscle energy metabolism during and after perturbation 
by exercise, thereby providing a dynamic window into the ‘mitochondrial fitness’ of 
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contracting skeletal muscle. Moreover, it can also be used to measure intracellular pH in 
‘real time’ and quantify the rate of pH recovery (proton efflux) which is a function of the 
vascular supply to the muscle. 
Skeletal muscle is an ideal tissue to interrogate using 31P MRS. It is not only abundant in 
energy rich phosphate metabolite stores but it can be examined within an exercise 
protocol, thus, offering the opportunity to measure fluctuations of phosphate rich 
metabolites continuously in a high time resolution. Moreover, 31P MRS can be utilised to 
study different muscle groups whose phosphorus spectrum may differ because of the 
inherent variations in their fiber compositions. Commonly investigated muscle groups 
are the gastro-soleus complex, vastus lateralis, forearm flexor and thenar muscles 
(Nishida et al., 1992; Pfeifer et al., 1999; De Feyter et al., 2008; Jones et al., 2010). The 
gastro-soleus complex serves as a particularly useful muscle group to investigate 
mitochondrial oxidative potential. Not only is it rich in mitochondrial content but it can 
also be effectively isolated during plantar flexion exercise, thereby, preventing the 
recruitment of other muscles during the examination. 
During the procedure, the candidate muscle group is placed within a magnetic field 
inside the bore of the MR scanner. This creates two distinct energy levels for the angular 
momentum of the phosphorus nuclei. The strength of the magnetic field, measured in 
Tesla, generally vary between 1.5-3.0 Tesla. A higher magnetic field strength gives 
enhanced spectral definition, and a higher signal to noise ratio. Low-energy 
radiofrequency pulses are then applied which cause the phosphorus nuclei to move 
between energy states and allow us to detect their presence. 
31P-MR spectra from skeletal muscle display 7 peaks: 3 from the three phosphate 
moieties of ATP (α,β and γ), 1 from inorganic phosphate(Pi), 1 from phosphocreatine 
(PCr) and 2 from the two smaller resonances of phosphomonoesters (PME) and 
phosphodiesters (PDE), which both contain several distinct chemical species (Figure 12). 
The PME and PDE peaks are only visible when present in sufficiently high concentrations 
or with sufficiently long acquisition times. The area under the curve of each resonance is 
proportional to the concentration of the corresponding metabolite in vivo. Intracellular 
pH can be calculated by measuring the distance between the Pi and PCr peaks, since the 
frequency of the Pi resonance is pH dependent (Moon and Richards, 1973). In order to 
be detectable on the spectra, the corresponding metabolite should be present in 
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concentrations of 1mM or greater to generate a sufficient signal to noise ratio in a 
reasonable acquisition time. The α, β and γ moieties of ATP have a multiplet structure 
owing to J-couplings between the phosphorus nuclei of medium strength (Schroder et 
al., 2005). However, one of the key active metabolites involved in the regulation of ATP 
synthesis, adenosine diphosphate (ADP), does not produce a measurable signal since its 
resting concentration is approximately 10 µM. Nevertheless, this can be calculated 
indirectly using the creatine kinase equilibrium reaction: 
[ADP] = [ATP][Cr]/([PCr][H+] Keq) 
where Keq is the creatine kinase equilibrium constant (1.66 x 109 M-1) (Veech et al., 
1979), [ATP] is assumed to be 8.2 mM throughout. [Cr] is estimated from [PCr], assuming 
that the total creatine pool ([PCr]+[Cr]) is constant and that at rest [Cr]/[PCr] = 0.15/0.85. 
[H+] can be obtained from the measured pH, where pH = -log10 [H+]. The calculations 
are derived from the γ-ATP moiety of the ATP (Jeneson et al., 1997; Cea et al., 2002). 
Skeletal muscle bioenergetics in several conditions such as McArdle’s disease (Ross et 
al., 1981), glycogen storage disease type XIII (Vorgerd and Zange, 2002), 
dermatomyositis (Cea et al., 2002), chronic fatigue syndrome (Wong et al., 1992; Jones 
et al., 2010), muscular dystrophy (Lodi et al., 1999b), Friedrich’s ataxia (Lodi et al., 
1999a), mitochondrial diseases (Kuhl et al., 1994; Taivassalo et al., 1998; Lodi et al., 
2004), type 2 diabetes (Scheuermann-Freestone et al., 2003; De Feyter et al., 2008) and 
aging (McCully et al., 1991; Taylor et al., 1997) have been investigated using this 
technique. 
1.5.3 Key bioenergetic pathways investigated 
31P MRS can be used to investigate different energetic pathways in skeletal muscle. 
Skeletal muscle tissues have the unique ability to sustain very large-scale changes in ATP 
turnover to meet the increased tissue demands when work is initiated. Importantly, the 
ATP concentration is maintained in near steady state despite a several fold increase in 
ATP turnover, often referred to as ATP homeostasis (Hochachka and McClelland, 1997) 
(Figure 13). This ensures that energy is always available to the contracting muscle cells to 
fuel its activity through either oxidative phosphorylation or anaerobic glycolysis. 
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Figure 13 Scheme of the variations of PCr, pH and ATP during a rest-exercise-recovery 
protocol quantified using 31P MRS. 
Note that ATP remains constant (ATP homeostasis) during exercise in a normal subject 
due to its continuous resynthesis by three different metabolic pathways (Park et al., 
2000) 
1.5.4 Mitochondrial oxidative phosphorylation during exercise and recovery 
Skeletal muscle is rich in phosphocreatine reserves which serve as an immediate source 
of energy for muscular activity. The consumption of energy-rich phosphocreatine 
reserves to fuel muscle contraction is referred to as phosphocreatine hydrolysis. Using 
predetermined parameters, for example 25% maximal voluntary contraction (MVC), the 
skeletal muscle can be exercised so as to deplete the PCr reserves, whilst ensuring 
intracellular pH is stable. Avoiding lowering pH too much during this exercise avoids 
lengthening the half-time of PCr recovery and avoids stimulation of the alternative 
anaerobic glycolysis (S Iotti, 1993). 
This can be observed in the MR spectra with the progressive depletion of the PCr peak 
and the corresponding increase in the Pi peak (Figure 14). After the exercise ceases, 
oxidative phosphorylation is maximally stimulated by high concentrations of ADP and 
the mitochondria synthesise ATP which is then converted through the reverse creatine 
kinase reaction to replenish the phosphocreatine (PCr) stores. Since exercise has 
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stopped at this juncture, the rate of increase in PCr is proportional to the rate of 
generation of ATP in the mitochondria which cannot be directly measured. During 
recovery, ATP synthesis relies exclusively on oxidative metabolism because glycolysis is 
inactive. Hence surrogates of maximum mitochondrial oxidative phosphorylation can 
subsequently be computed by measuring the recovery constant for PCr replenishment 
such as the half-time of PCr recovery (1/2 PCr) (Taylor et al., 1983). This statement holds 
true only if the muscles are adequately perfused since optimal substrate delivery to the 
mitochondria is essential in order to measure maximal mitochondrial oxidative 
phosphorylation. Furthermore, the assumption that PCr resynthesis is a function of 
mitochondrial ATP synthesis is supported by observations that PCr resynthesis is absent 
when the muscle is kept ischemic following muscle contraction, and PCr recovery occurs 
only upon reperfusion of the limb(Quistorff et al., 1993). Therefore, the recovery period 
is an important phase of the experiment during which mitochondrial oxidative 
phosphorylation ‘capacity’ is measured (Figure 15). 
Endurance training has been shown to increase mitochondrial content and its associated 
oxidative enzymes and capillary density of the skeletal muscle which link to an 
improvement in metabolic capacity and exercise performance. However, determination 
of local metabolic capacity and profile changes that occur as a response to training 
usually requires an invasive method such as muscle biopsy. Aerobically trained 
individuals such as rowers and long distance runners demonstrate faster PCr recovery 
after exercise (1/2 PCr) suggesting improved muscle oxidative capacity when compared 
to untrained adults or sprint trained runners (McCully et al., 1989; Johansen and 
Quistorff, 2003). 
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Figure 14 31P MRS: After exercise and during recovery 
A selection of phosphorus spectra acquired from the gastrocnemius and soleus of a 
volunteer at 3.0T during recovery from a plantar flexion exercise. A decreasing 
concentration of inorganic phosphate (A) and the replenishment of phosphocreatine 
(B) can be measured. The rate of recovery of phosphocreatine acts as a surrogate 
measure for maximal mitochondrial function.  
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Figure 15 Mitochondrial oxidative potential  
This approach measures the kinetics of PCr recovery using progressive low-level 
exercise that produces relatively small changes in metabolites and therefore, a rapid 
re-attainment of the steady-state condition. The rate of increase in PCr is proportional 
to the maximal mitochondrial oxidative phosphorylation rate. Patients with 
mitochondrial dysfunction typically have delayed rates of phosphocreatine 
resynthesis. 
 
1.5.5 pH handling during exercise and recovery 
Anaerobic glycolysis is activated during moderate to high intensity activities when the 
cellular energy demand outstrips the supply of oxygen to the mitochondria. Although not as 
efficient as oxidative phosphorylation (in terms of ATP production/mole of glucose), it 
serves as a critical source of energy during more intense activities. It produces lactic acid as 
a by-product resulting in intracellular acidification. Again using predetermined parameters 
(such as 35% MVC), the skeletal muscle can be stressed to stimulate the glycolytic pathway. 
Cellular pH increases initially during exercise secondary to H+/proton consumption during 
PCr hydrolysis. Subsequently, pH decreases following anaerobic metabolism due to lactate 
production and then PCr resynthesis. The cell consequently excretes the excess proton load 
through the Na+/H+ antiporter, lactate-H+ cotransporter (membrane transporter systems) 
and others; this is critical for acid resolution (Kemp et al., 1994). Intracellular acidosis may 
be deleterious to the contractile functioning of the myocytes, hence contributing to fatigue 
(Bangsbo et al., 1996). Active proton excretion following fatigue-inducing exercise is 
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associated with the resolution of that fatigue and perception of the ability to return to 
exercise (Mainwood and Alward, 1982). Since the pH can be measured and the rate of 
recovery of phosphocreatine is known at each time point post exercise, and no further 
protons are produced during the recovery phase, the rate of proton efflux can be calculated. 
The pH recovery time which is the time taken to excrete the excess lactic acid from the cell 
can also be measured (Figure 16). Other indices such as nadir pH and maximum rate of 
proton efflux can be measured or derived. If acid transporter function is normal then proton 
efflux rate becomes a surrogate for peripheral vascular supply. The pH recovery time is 
delayed in conditions such as dermatomyositis and polymyositis, thereby implicating 
impaired peripheral vascular supply as a contributor to fatigue (Cea et al., 2002). Apart from 
intracellular acidosis as a cause of fatigue, there is evidence to suggest that fatigue from 
high intensity exercise may actually arise secondary to accumulation of inorganic phosphate 
(Pi) (Fryer et al., 1995; Dahlstedt et al., 2001; Hoybye et al., 2007). Pi is a by-product of 
anaerobic metabolism in skeletal muscle involving hydrolysis of phosphocreatine to creatine 
and Pi. 
 
Figure 16 pH recovery time 
In contrast to low intensity exercise, this involves the study of muscle energetics 
during high-intensity exercise. Anaerobic metabolism contributes significantly to 
energy production resulting in decreased intracellular pH. Active proton excretion 
following exercise is associated with the perception of the ability to return to exercise. 
Diseases with impaired peripheral vascular supply may present with fatigue because of 
delayed proton excretion. 
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1.5.6 Applications in Endocrine diseases 
Hormones initiate biological responses by binding to target cell receptors with high 
affinity and specificity. Target cell receptors, both cell surface and nuclear, initiate a 
signalling cascade which result in physiological changes within the cellular milieu. 
Hormone levels are tightly regulated through a feedback mechanism to ensure 
homeostasis. This physiological equilibrium is disrupted in endocrine disorders resulting 
in metabolic alterations within the cellular milieu which in turn manifest as clinical signs 
and symptoms. 31P MRS has been used to examine mitochondrial function in several 
endocrine diseases. It can provide information regarding either the cause or 
consequence of disease by examining specific components of cellular metabolic 
function. 
Type 2 Diabetes: 
 Insulin has a critical role in the energy transduction pathway. Insulin enhances 
mitochondrial function by stimulating mitochondrial enzymes, increasing protein 
synthesis and suppressing protein degradation (Gelfand and Barrett, 1987; Stump et al., 
2003). Mitochondrial dysfunction has been implicated in the pathogenesis of insulin 
resistance and type 2 diabetes (Patti and Corvera, 2010). Mitochondrial oxidative 
potential in type 2 diabetes has been investigated in vivo using 31P MRS. Delayed post 
exercise recovery kinetics suggested that mitochondrial dysregulation may be implicated 
in the pathogenesis of insulin resistance and type 2 diabetes (Sirikul et al., 2006; 
Schrauwen-Hinderling et al., 2007). However, when healthy controls were carefully 
matched mitochondrial dysfunction was not associated with either insulin resistance or 
type 2 diabetes (De Feyter et al., 2008; Trenell et al., 2008). This has been supported by 
recent work confirming that mitochondrial function and insulin resistance did not 
depend on each other. Prolonged exercise training could, at least partly, reverse the 
mitochondrial impairments associated with the longstanding diabetic state (Figure 17) 
(van Tienen et al., 2012). 
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Figure 17 Mitochondrial oxidative capacity (kPCr-PCr recovery rate constant) and insulin 
sensitivity  
 The kPCr activity in controls, prediabetics, and T2DM before (t=0) and after 52 wk 
exercise training (t=52). kPCr* significantly changed in T2DM group at 52 wk compared 
with T2DM at time zero, analysed with paired t test, P < 0.05 (van Tienen et al., 2012). 
Thyroid disease:  
Thyroid hormone is the major endocrine regulator of energy expenditure. Thyroid status 
in mammals is intricately linked with their basal metabolic rate (BMR). Mitochondrial 
function is, therefore, a logical candidate to investigate when determining the metabolic 
effects of thyroxine. In vitro experiments, primarily on rat liver preparations, have 
revealed that both genomic and non-genomic mechanisms exist by which the 
mitochondrial function may be modulated (Harper and Seifert, 2008). The genomic 
pathway involves the induction of mitochondriogenesis (i.e. synthesis of new 
mitochondria) in order to meet the increased demand for energy by the thyroid 
hormone. This process is mediated by complex interactions between nuclear and 
mitochondrial genomes leading to increased expression of mitochondrial transcription 
factors, nuclear respiratory factor-1(NRF-1), and peroxisome-proliferator-activated 
receptor gamma coactivator-1α (PGC-1α) (Wu et al., 1999; Weitzel et al., 2003; Lee and 
Wei, 2005). Some of these genes are also responsible for the increased expression of 
mitochondrial proteins (Short et al., 2007). Thyroid hormone effects on the expression of 
oxidative phosphorylation genes can occur through the interaction of the thyroid 
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hormone receptor complex with hormone response elements (HRE) in nuclear and 
mitochondrial genes (Scheller and Sekeris, 2003). Thyroid hormones also induce 
substantial modifications in mitochondrial inner membrane protein and lipids. Although 
the precise mechanisms still remain unclear, modifications in the inner mitochondrial 
membrane are responsible for the uncoupling of oxidative phosphorylation which 
subsequently leads to the hypermetabolic effects of thyroxine (Brasitus and Dudeja, 
1988). Both Kaminsky and Argov et al., demonstrated bioenergetic impairments in PCr 
resynthesis in the hypothyroid skeletal muscle using 31P MRS, thereby, implicating 
reduced mitochondrial oxidative capacity (Argov et al., 1988; Kaminsky et al., 1992) . 
Moreover, this was reversible with thyroxine therapy (Argov et al., 1988). Taylor et al., 
however, concluded that proton handling was abnormal too as evident by a slow pH 
recovery (Taylor et al., 1992). Therefore, it seems that a combination of both of these 
factors could be responsible for the debilitating fatigue in hypothyroidism. 
1.5.7 Advantages 
The most obvious advantage of 31P MRS lies in its ability to non-invasively determine 
muscle biochemistry, thereby obviating the need for invasive muscle biopsies. 
Moreover, it is undertaken in ‘real time’ thus, reflecting serial changes in the muscle 
biochemical milieu. Therefore, it is ideal for monitoring dynamic metabolic processes 
and providing measurements of important metabolite concentrations. Reliable and 
reproducible parameters can be calculated and compared. Larson-Meyer et al. 
confirmed that 31P MRS measurements of mitochondrial function such as 1/2 PCr, 
yielded reproducible results that correlated well with whole-body maximal oxygen 
uptake (VO2max) (CV of 4.6-7.1%) (Larson-Meyer et al., 2000). The results are sensitive 
and correlate well with in vitro measurements of oxidative capacity in mitochondria 
isolated from muscle biopsies too (Lanza et al., 2011). Moreover, it is safe and does not 
involve exposure to ionising radiation. 
A cross-sectional design can be employed to investigate abnormal bioenergetic 
footprints in chronic conditions such as Type 2 diabetes and chronic fatigue syndrome. 
It, however, precludes us from concluding whether the underlying defect is secondary to 
the cause of the disease or consequent to the inactivity and reduced well-being as a 
result of it. This can be overcome by designing a longitudinal study. In fact longitudinal 
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studies have been implemented to investigate the effects of drugs/hormones such as 
statins and thyroxine respectively (Sesmilo et al., 2000; Wu et al., 2011). 
1.5.8 Limitations 
31P MRS does have limitations. Considerable inter-individual variations in metabolic 
transactions may occur. For example, the rates of PCr consumption and re-synthesis may 
differ by a factor of 2 among healthy individuals (Kushmerick et al., 1992). While the 
recovery of PCr after exercise is independent of the exercise undertaken, it is not 
independent of the reperfusion of the limb leading to variations between oxidative 
capacity and PCr recovery (Kemp et al., 2002). In other words, abnormal mitochondrial 
respiration could be a primary event due to inherent mitochondrial abnormalities or 
secondary to abnormal substrate delivery. Primary mitochondrial disorders arising from 
mitochondrial DNA defects have a reduced rate of mitochondrial ATP production which 
is typically associated with reduced intracellular acidosis during exercise and an 
increased or normal rate of H+ extrusion from the cell during the initial recovery. On the 
other hand, conditions with abnormal substrate supply will have a reduced rate of 
mitochondrial ATP production but with an increased rate of acidification during exercise 
and a reduced rate of H+ efflux during recovery (Cea et al., 2002).In vivo MRS is a 
relatively insensitive technique compared to in vitro mass spectrometry since 
concentrations in the millimolar range are required for detection with MRS. It is also 
expensive and requires dedicated hardware and software packages. Moreover, 
compared to muscle biopsy, analytical information regarding the oxidative 
phosphorylation pathway is not available. 
1.5.9 Summary 
Since the phosphorus species present in sufficient concentration for in vivo MRS are 
mostly high-energy compounds, 31P MRS can be used to investigate bioenergetics in the 
human skeletal muscle. It not only provides a window into the in vivo energy 
transactions occurring within the contracting skeletal tissue but also permits quantitative 
measurements of energy rich phosphorus species within the muscle, therefore, 
providing a robust and reliable method to interrogate and measure skeletal tissue 
behaviour. 
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Over the past decade, there has been emerging evidence to suggest that crosstalk 
between endocrine hormones and the skeletal muscle tissues exist which is essential to 
maintain optimum muscle function (Pedersen and Febbraio, 2008). Moreover, the 
mitochondrion is a critical regulator of muscle energy and the discovery of hormone 
responsive elements (HRE) on the mitochondria confirms the role of hormones in 
ensuring optimal function. Thus, 31P MRS forms a useful adjunct to investigate novel 
parameters in endocrine disease and may provide insight into the various 
pathophysiologies involved in endocrine myopathies. 
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Chapter 2 Growth hormone and skeletal muscle energetics 
2.1 Introduction 
2.1.1 Background 
Adults with growth hormone deficiency (GHD) experience fatigue, reduced vitality and 
reduced energy levels (Bjork et al., 1989; McGauley et al., 1990). These symptoms 
improve with growth hormone (GH) replacement (Gilchrist et al., 2002; Jorgensen et al., 
2011a), although the precise basis for both the symptoms and their response to 
treatment remain unclear. 
Fatigue may be classified as either central or peripheral. Generally if fatigue occurs at 
rest it suggests a central/psychological origin. Central fatigue is a well-recognised 
symptom and a feature of many conditions. It is a complex pathophysiological entity and 
may well reflect contributions from multiple factors (Chaudhuri and Behan, 2004). The 
objective assessment of central fatigue is primarily based upon validated self-reporting 
questionnaires (Lee et al., 1991). The diagnosis of central fatigue is usually made when 
there is a significant perception of fatigue in the absence of specific skeletal tissue 
(peripheral) abnormalities. 
Commonly patients, who relate their fatigue to physical exercise, tend to experience 
peripheral fatigue. Abnormal skeletal muscle metabolism has been implicated in the 
pathophysiology of peripheral fatigue. Delayed mitochondrial phosphocreatine re-
synthesis, delayed proton clearance and aberrant accumulation of metabolic by-
products have all been described across a range of conditions in which fatigue is a 
prominent feature(Wong et al., 1992; Kuhl et al., 1994; Pfeifer et al., 1999; Allen et al., 
2008; Hollingsworth et al., 2008). The role of mitochondria in cellular energy metabolism 
raises the possibility that impairments in skeletal muscle energy metabolism underlie the 
fatigue in GHD patients. GH has been reported to promote mitochondrial oxidative 
capacity (Short et al., 2008). Recently Makimura et al. demonstrated an association 
between phosphocreatine recovery (a measure of mitochondrial function) and 
parameters of the GH axis in healthy males (Makimura et al., 2011). In contrast, Janssen 
et al. investigated the influence of GH on muscle phosphate metabolites at rest in GHD 
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adults and found no evidence of an effect(Janssen et al., 1999). The latter study was not 
undertaken during exercise, thereby not measuring sensitive markers of dynamic 
oxidative phosphorylation. The skeletal muscle is a logical tissue to study peripheral 
fatigue in GHD adults since both GH receptors and IGF-1 receptors are purportedly 
expressed in skeletal muscle (Beguinot et al., 1985; Frick et al., 1998). 
Phosphorus-31 Magnetic Resonance Spectroscopy (31P MRS) is a non-invasive tool that 
has been used by muscle physiologists to examine for abnormalities in metabolic work-
cost relationships during exercise. Specifically it assesses the oxidative capacity of 
skeletal muscle in vivo by measuring the kinetics of energy rich phosphate species 
involved in muscle energy metabolism (such as those involved in the creatine kinase 
reaction) during and after exercise. It provides temporal information regarding the 
metabolic changes occurring within the skeletal muscle, thereby providing a dynamic 
window into the ‘mitochondrial fitness’ of skeletal muscle. It can also be used to 
measure intracellular pH in ‘real time’ and quantify the rate of pH recovery (proton 
efflux) which is a measure of the cell’s ability to eliminate acid i.e. proton load. The 
technique can also measure concentrations of key cellular metabolites implicated in 
fatigue, such as inorganic phosphate (Hoybye et al., 2007). 
In this study, I used quantitative 31P MRS to establish whether in vivo deficits of skeletal 
muscle mitochondrial function or other bioenergetic abnormalities occur in untreated 
GHD adults and their role in the pathogenesis and clinical expression of fatigue in GHD. 
2.1.2 Aims  
The aim of the present study was to investigate the role of skeletal muscle mitochondrial 
function in the pathophysiology of fatigue in GHD by: 
a. Characterising and comparing in vivo oxidative (τ1/2PCr) and anaerobic (pH recovery 
time) skeletal muscle metabolism in adults with untreated GHD, treated GHD and 
healthy volunteers. 
b. Correlating these data with parallel comparisons of the perception of fatigue across 
the same 3 groups using specific domains within a validated quality of life (AGHDA-
QoL) questionnaire. 
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My hypothesis was that the fatigue experienced by untreated GHD adults is due to 
perturbations in their skeletal muscle metabolism. 
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2.1.3 Study subjects 
This cross-sectional study investigated skeletal muscle metabolism in 3 groups: 
untreated GHD adults, treated GHD adults and healthy controls using 31P MRS. Twenty 
two untreated GHD adults and twenty three treated GHD adults were identified and 
recruited from the KIGS and KIMS database (a pharmaco-epidemiological database of all 
GHD patients maintained by Pfizer Inc.) across Northern England. Twenty healthy 
controls were also recruited through local advertisements. All subjects underwent 31P 
MRS, anthropometry and body composition assessment. They also completed AGHDA 
and physical activity assessment (IPAQ) questionnaires. The study design is summarised 
in Figure 18. 
 
Figure 18 Growth Hormone Cross-sectional study design 
 
Inclusion criteria: 
Patients between 16-50 years of age were eligible for the trial. Although still a matter of 
debate, this age group was chosen in order to eliminate the age associated changes in 
skeletal muscle metabolism (Kent-Braun and Ng, 2000; Kutsuzawa et al., 2001). 
Following the identification of 119 GHD patients using the KIGS/KIMS database, potential 
eligible candidates were screened with their clinicians namely Dr Steve Ball, Dr Tim 
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Cheetham, Prof Simon Bailey and Sr Margaret Miller to ensure appropriate selection of 
volunteers i.e. those who were mentally and physically able to understand the 
consenting process and undergo the exercise MR scan. Prospective subjects were 
subsequently sent Patient Information Sheets (Appendix) and recruited at the Endocrine 
clinics at Newcastle University Hospitals NHS trust (Figure 19). All three groups were 
matched based on age, gender and physical activity levels (Table 4). Subjects were 
diagnosed with Adult GHD if their peak GH on GHRH-arginine testing was less than 
4.1µg/liter (Molitch et al., 2011). Subjects were deemed to be untreated if they had not 
received GH in the past one year. The other abnormal endocrine axes were being 
replaced in hypopituitary subjects. Fasting bloods were obtained in all subjects to ensure 
subjects were receiving adequate therapy. 
Exclusion criteria: 
 Exclusion criteria included those with: 
I. MR incompatible implants since they would be unsuitable for MR imaging,  
II. Learning difficulty due to concerns regarding obtaining consent and 
comprehending instructions 
III. Profound physical impairments which would preclude them from undertaking 
the exercise under the MR scanner 
 
Figure 19 Flowchart of recruitment 
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2.1.4 Approval for study 
The study titled ‘The role of skeletal muscle function and energetics in the symptoms 
and metabolic characteristics of Growth Hormone deficiency: a functional NMR 
approach; REC Reference no: 10/H0907/71’ was granted a favourable opinion by the 
Newcastle and North Tyneside 2 Research Ethics Committee on 21st December 2010. The 
Newcastle upon Tyne Hospitals NHS foundation Trust granted NHS R&D approval for the 
conduct of this project (Trust R&D project-5519) on 26th January 2011.  
Written informed consent was obtained from all participants (see Appendix for details 
regarding PIS and consent form). The investigation was conducted according to the 
principles of the Declaration of Helsinki. 
2.1.5 Phosphorus-31 Magnetic Resonance Spectroscopy protocol 
Magnetic resonance spectroscopy data were acquired using a 3T Achieva scanner 
(Philips, Best, NL) with a 14cm diameter phosphorus surface coil for 
transmission/reception of signal and the in-built body coil for anatomical imaging (Boska, 
1994). Imaging to localise to gastrocnemius and soleus muscles is performed by axial T1 
turbo spin-echo imaging around the fattest part of the calf (TR = 671ms, TE = 10ms, 
256x153 matrix, resolution 1.37x1.71, 16 slices with 10mm gap). A purpose-built 
exercise apparatus was developed for operation with the magnetic resonance imaging 
(MRI) scanner (Figure 20). This apparatus permitted a controlled plantar flexion 
(between 0° to 30°) to isolate and exercise the soleus and gastrocnemius muscles with 
the patient lying supine, whilst using restraining straps to prevent the recruitment of the 
quadriceps. Subjects performed a validated exercise protocol which contained two 
periods of exercise, consisting of three minutes of rest, three minutes of plantar flexion 
at 0.5 Hz (sufficient time to deplete the PCr stores which would in turn stimulate the 
mitochondria for recovery analysis) and six and a half minutes of rest post exercise to 
measure recovery to equilibrium (Hollingsworth et al., 2008). The first period used a 
fixed load of 25% of the Maximum Voluntary Contraction (MVC, determined prior to 
spectroscopy) to accurately measure oxidative metabolism in recovery whilst attempting 
to maintain a stable pH as possible (Kemp and Radda, 1994). The second period, used a 
higher fixed load (35% of MVC) to produce greater anaerobic stimulus and allow 
evaluation of pH handling. TR = 5s was used with paired subtracted spectra to perform 
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1D ISIS selection in the anterior-posterior direction, so effectively there are 2 averages 
per final spectrum at time resolution 10s. The dimension of the 1D anterior-posterior 
ISIS selection was 48mm. The gradient strength used in the ISIS localisation was 3.09 
mT/m. The extent of spatial shift between Pi and γ-ATP (since α and β-ATP are not used 
in the calculations) is 7mm (The frequency difference induced across the selected 1D 
slab is 2556Hz and Pi and γ-ATP are 389Hz apart on the spectrum). Deviation from the 
prescribed slab is minimised by putting PCr on resonance. 
Quantification of the spectral peaks and calculation of pH was performed using the 
AMARES time domain fit routine in the jMRUI processing software (v 3.0) (Kemp et al., 
1997; Vanhamme et al., 1999). The prior knowledge model used assumed single 
Lorentzian resonances for Pi, PDE and PCr, with the α and γ moieties of ATP modelled as 
doublets of equal area with 17Hz separation, and the β-ATP moiety modelled as a triplet 
with 17Hz separation and area ratio 1:2:1 (Hamilton et al., 2003). Parameters of 
oxidative metabolism and pH handling were calculated. Exponential fits to the recovery 
data were made to estimate the half-times for recovery to equilibrium of PCr (τ1/2 PCr) 
and ADP (τ1/2 ADP) (Taylor et al., 1983). The relationship between ADP concentration and 
oxidation rate was used to estimate maximal oxidative ATP production (Qmax) as 
described in the equation: Qmax = V(1+Km / [ADP] end exercise) where Km is taken as 30 
µM (Kemp et al., 1993). Muscle pH was assessed using the chemical shift between 
phosphocreatine peak and the inorganic phosphate peak, 
pH = pKa + 10 log10 ((δ1-δ)/(δ-δ2)) 
where pKa = 6.75, δ is the chemical shift from PCr to Pi in ppm, δ1 = 3.27ppm, δ2 = 
5.63ppm (Moon and Richards, 1973). 
Proton efflux, E, was calculated for every time point after cessation of exercise, 
E = (+ m)d[PCr]/dt + dpH/dt 
where ν,m and β are cytosolic buffering capacity constants, which can be estimated 
based on previous work and which themselves have a dependency on pH (Kemp et al., 
1997). 
This allows the evaluation of the time point at which efflux reached its maximum. The pH 
at three key time points was examined: (i) baseline pH which can demonstrate resting 
metabolic imbalances, (ii) pH immediately post exercise which reflects the extent to 
which the anaerobic glycolytic pathway has been activated and (iii) the nadir pH after 
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exercise which indicates the maximum burden of acid clearance imposed by anaerobic 
metabolism and the resynthesis of phosphocreatine (Hoult et al., 1974). Time to pH 
recovery was calculated by measuring the time from the cessation of exercise until pH 
returned to within 0.01 units of its pre exercise value. If pH was higher or equal to its 
initial value at cessation of exercise, due to the pH raising effect of PCr hydrolysis, pH 
recovery time was taken to be zero. 
 
Figure 20 illustrates the apparatus used to permit exercise (plantar flexion) within the 
MR scanner (left) and the 0°-30° of plantar flexion involved (right)  
2.1.6 Assessing Quality of Life –AGHDA questionnaire  
The ‘Assessment of growth Hormone Deficiency in Adults’ (AGHDA) questionnaire is a 
self-administered instrument developed specifically to objectively evaluate the impaired 
quality of life (QoL) and fatigue experienced by adults with GHD (Holmes SJ, 1995). It has 
been validated in adults with GHD, besides forming an important criterion for 
qualification for GH therapy in adults in the United Kingdom (NICE, 2003). The measure 
is constructed of 25 items that evoke yes/no answers, acknowledging or denying certain 
problems. The total score is computed by quantifying a range of problems so that each 
‘yes’ is given a score of 1 and each ‘no’ is attributed a score of 0. Therefore, a higher 
numerical score depicts a poor QoL. It has been shown to have good reliability, 
reproducibility, internal consistency and construct validity (McKenna et al., 1999). The 25 
items may be clustered into five domains: tiredness (seven questions), memory and 
concentration (six questions), tenseness (three questions), social isolation (five 
questions), and self-confidence (four questions) (Koltowska-Haggstrom et al., 2006). For 
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each domain, the mean score per question was calculated (see Appendix A AGHDA-QoL 
questionnaire). 
2.1.7 Biochemical evaluation and assays 
Fasting bloods were obtained from all subjects. All biochemistry and quantitative 
hormone measurements were measured using standard methodologies in the medical 
biochemistry laboratory of Newcastle University Hospitals NHS Trust. The principles and 
performance assays are briefly described below: 
Serum IGF-1: 
Quantitative measurements of serum IGF-1 were undertaken using a solid-phase, 
enzyme-labelled chemiluminescent immunometric assay (Immulite 2000) with an intra-
assay coefficient of variation (CV) of 2.3-3.9% and inter-assay CV of 3.7-8.1%. 
Serum free thyroxine (fT4): 
The Roche Free T4 assay, a competitive immunoassay using electro-chemi-luminesce 
technology was used to measure fT4. It has an intra-assay coefficient of variation (CV) of 
1.6-2.5% and inter-assay CV of 3.0-3.8%. 
Serum insulin: 
The Mercodia Insulin kit, an enzyme linked immunosorbent assay (ELISA), was used for 
the quantitative measurement of serum Insulin. It has an intra-assay coefficient of 
variation (CV) of 2.8-3.2% and inter-assay CV of 3.0-3.9%. 
Serum glucose: 
Colorimetric detection was used based on the principle of glucose oxidase, in which H2O2 
reacts with various hydrogen donors to produce a colour change that is proportional to 
the glucose concentration. It has an intra-assay coefficient of variation (CV) of 0.9-1.8% 
and inter-assay CV of 1.0-1.8%. 
Glycated haemoglobin (HbA1c): 
The Tosoh Haemoglobin A1c method which utilises the principles of ion exchange high 
performance liquid chromatography (HPLC) was used. 
80 
 
Total cholesterol: 
The assay had an intra-assay coefficient of variation (CV) of 0.8-2.0% and inter-assay CV 
of 1.7-3.3%. 
High density lipoproteins (HDL): 
The assay had an intra-assay coefficient of variation (CV) of 0.1-2.5% and inter-assay CV 
of 3.9-5.7%. 
HOMA assessment: 
 All subjects had their homeostasis model of assessment (HOMA) index calculated 
(Matthews et al., 1985). The HOMA estimates steady state beta cell function and insulin 
sensitivity as percentages of a normal reference population. These measures correspond 
well, but are not necessarily equivalent, to non-steady state estimates of beta cell 
function and insulin sensitivity derived from stimulatory models such as the 
hyperinsulinaemic clamp and the oral glucose tolerance test. The HOMA index was 
calculated using the formula-(fasting glucose(mmol/L) x fasting insulin(mU/L) / 22.5) 
2.1.8 Anthropometric evaluation 
All subjects underwent anthropometric assessment with measurements of their standing 
height and weight using a calibrated vertical stadiometer and digital weight scale 
respectively. Waist circumference was measured using a non-elastic measuring tape. 
Body fat percentage was evaluated using a bio-impedance analysis scale (Bodystat 1500) 
which has a reported CV of 3% (Lukaski et al., 1985). 
2.1.9 Physical activity evaluation 
Self-reported levels of physical activity and inactivity were assessed with IPAQ 
(International Physical Activity Questionnaire), a validated questionnaire (Booth, 2002). 
The long format questionnaire, developed specifically for research purposes, assesses 
the physical activities undertaken by the respondent over the past 7 days (Craig et al., 
2003). Continuous scoring (MET/metabolic equivalent of task-minutes per week) was 
calculated to ensure matching of physical activity levels between subjects. MET is a scale 
of the energy cost of various physical activities in multiples of the resting metabolic rate 
(see Appendix B IPAQ physical activity questionnaire). 
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2.1.10 Outcome measures 
The primary outcome of this study was to compare recovery kinetics of phosphocreatine 
(τ1/2PCr), a direct marker of maximal mitochondrial oxidative function which is 
independent of work or power output, across the 3 groups (Binzoni et al., 1992). τ1/2PCr 
was compared with serum IGF-1 levels to evaluate the relationship between growth 
hormone status and the mitochondria. Comparisons between fatigue perception 
(assessed with Qol-AGHDA) and peripheral fatigue (assessed with 31P MRS) across the 3 
groups were undertaken to determine the aetiology of fatigue in GHD. 
2.1.11 Statistical analysis 
The study was designed to recruit a minimum group size of 19 subjects, with a 90% 
power to detect 10% impairment in τ1/2PCr. Sample size was estimated from pilot studies 
of healthy individuals at our centre who underwent repeat 31P MRS to determine 
repeatability. Using the Bland-Altman method, we expected to find a maximum of 9% 
variability in 1/2PCr from repeated measurements (Bland and Altman, 1986). Statistical 
analyses were undertaken using Minitab v16 software package. All data are expressed as 
mean ±SD unless described otherwise. The Kolmogorov-Smirnov test of normality was 
used to determine the distribution of data. Overall differences between the untreated 
GHD, treated GHD and control groups were tested with an ANOVA test (parametric) and 
Tukey’s family error rate was applied for post hoc pair-wise comparisons between the 3 
groups. Where data was non-parametric, the Kruskal-Wallis test was used. Differences 
between unpaired groups were tested with an unpaired t-test (parametric) or a Mann 
Whitney test (non-parametric). To test the association and relationship between 
variables, the chi square test and Pearson’s correlation coefficients were calculated 
respectively. Several bivariate regression models were independently created to identify 
predictors of mitochondrial function. A multiple linear regression was undertaken with 
continuous and categorical predictors to determine predictors of fatigue. All tests were 
two-sided and the level of significance was set at P<0.05. 
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2.2 Results 
2.2.1 Subject clinical characteristics  
Sixty five subjects were recruited between the ages of 16 and 50 years (See Table 4). The 
gender distribution was similar across the three groups with a male preponderance 
ranging from 59.2% to 65.2%. There was no difference in body mass indices (BMI) 
(p=0.06) or waist circumference (p=0.09) across the three groups. Controls had lower 
body fat percentage compared to both treated and untreated GHD adults (p=0.03). The 
proportion of subjects with multiple pituitary hormone deficiency and isolated growth 
hormone deficiency were similar in both the untreated and treated GHD groups 
(p=0.40). There was a preponderance of childhood onset GHD in both the untreated 
(n=18/22) and treated (n=15/23) GHD groups. The self-reported activity levels (MET 
min/week) amongst the 3 groups was similar (p=0.25). 
Untreated subjects with GHD had lower serum IGF-1 levels compared to both treated 
GHD and healthy controls (p<0.001) (Figure 21). In order to minimise the effects of other 
hormones on skeletal muscle function, stable hormone replacement in all patients was 
ensured (Table 4). There was also no difference between parameters of insulin 
sensitivity in the 3 groups. Treated GHD patients had elevated high density lipoprotein 
(HDL) compared to controls and untreated GHD adults (p=0.007). 
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Figure 21 shows lower IGF-1 levels in the untreated GHD group compared to the 
treated GHD group and the controls  
The boxplot depicts the sample minimum, lower quartile, median, upper quartile and 
sample maximum data.  
* refer to outliers.  
ʘ depicts the sample mean. 
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Table 4 Patient characteristics 
Mean ±SD 
 
OFF GH ON GH Controls P value 
Total No 22 23 20  
Age 27.85±9.34 29.76±10.07 31.05±7.93 0.537 
Sex ratio 
59.2% 
males 
65.2% males 60% males  
Aetiology of GHD: 
MPHD/ Isolated GHD 17/5 20/3 NA 0.396 
Childhood onset/ 
Adult onset 
18/4 15/8 NA 0.208 
Surgery 14 9 NA 0.475 
Radiotherapy 16 8 NA 0.475 
Chemotherapy 6 1 NA 0.475 
Anthropometry: 
BMI (kg/m2) 29.9±8.7 29.6±6.7 25.1±4.2 0.058 
Waist (cms) 94.8±21.9 99.5±16.9 86.84±10.8 0.085 
Body fat % 
31.2±13.4 
(A) 
30.1±9.9 
(A,B) 
22.5±9.1 
(B) 
0.031 
Activity level (MET 
min/week) 
1622† 2043† 2735† 0.246* 
Endocrine parameters: 
IGF-1 (nmol/L) 
14.0±11.1 
(B) 
38.1±19.9 
(A) 
30.7±9.5 
(A) 
<0.001 
Thyroxine fT4 
(pmol/L) 
18.2±3.7 19.0±3.9 16.3±2.1 0.085 
Testosterone (nmol/L) 20.6±9.5 15.9±7.9 20.7±5.5 0.250 
25OHD (nmol/L) 57.9±34.4 53.9±20.2 44.2±29.4 0.418 
Metabolic parameters: 
Fasting glucose 
(mmol/L) 
4.9±0.6 4.9±0.6 5.5±1.6 0.172 
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Fasting insulin 
(µU/ml) 
11.1±7.9 12.3±12.1 6.2±4.9 0.120 
HOMA index 2.5±1.9 2.7±2.8 1.4±1.3 0.198 
HbA1c (%) 5.6±0.8 5.5±0.4 5.2±0.4 0.254 
Total cholesterol 
(mmol/L) 
5.3±1.1 5.1±1.1 4.8±1.1 0.450 
HDL (mmol/L) 
1.2±0.3 
(A) 
1.5±0.4 
(A,B) 
1.4±0.3 
(B) 
0.007 
LDL (mmol/L) 3.3±1.1 2.9±1.2 2.7±0.8 0.292 
 
All data are expressed as mean ±SD unless expressed otherwise. † suggests median. The 
Kolmogorov-Smirnov method was used to test for normality (p>0.05 signifying 
parametric distribution). Overall differences (parametric data) between the untreated 
GHD, treated GHD and control groups was tested with an ANOVA test and Tukey’s family 
error rate was applied for post hoc pair-wise comparisons between the three groups 
(means that do not share a letter were significantly different). Where the data was non-
parametrically distributed the Kruskal-Wallis test was calculated (*) 
 
MPHD multiple pituitary hormone deficiency, MET metabolic equivalent-minutes, 
25OHD 25 Hydroxy vitamin D, HOMA homeostatic model assessment, HDL high density 
lipoprotein, LDL low density lipoprotein, testosterone levels were from males only 
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2.2.2  Parameters of mitochondrial oxidative phosphorylation 
There was no difference in τ 1/2PCr (p=0.54) nor τ 1/2ADP (p=0.42) between the 3 groups 
(Table 5) (Figure 22). Maximal oxidative mitochondrial function, Qmax, was computed 
which showed no difference between the 3 groups (p=0.73). Neither males (r=-0.08, 
p=0.64) nor females (r= -0.37, p=0.08) demonstrated any association between τ 1/2PCr 
and IGF-1 on bivariate analysis. 
 
 
Figure 22 Comparison of oxidative phosphorylation following exercise across the 3 
groups  
There was no difference in oxidative function between the 3 groups (ANOVA, p=0.54). 
The asterisks (*) refer to outliers. 
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2.2.3 Parameters of anaerobic glycolysis 
There was no difference in pH recovery times following cessation of exercise (p=0.38) 
amongst the 3 groups (Figure 23). There was no difference in the nadir pH of the skeletal 
muscle cells following exercise (p=0.68). There was also no difference in the maximum 
proton efflux rates following exercise (p=0.37). No difference between resting 
metabolites such as Pi (p=0.11), PCr (p=0.67) or pH (p=0.62) was detected across the 3 
groups (Table 5). There was no gender difference when resting Pi (P=0.14), PCr (p=0.96), 
end exercise pH (p=0.31), nadir pH (p=0.07) and pH recovery times (p=0.33) were 
examined. 
 
Figure 23 Comparison of pH recovery (proton excretion) following exercise across the 3 
groups  
There was no difference detected between the 3 groups (Kruskal-Wallis, p=0.38). The 
asterisks (*) refer to outliers. 
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Table 5 Comparison of bioenergetic parameters (31P MRS) 
 
 
All data are expressed as mean ±SD unless expressed otherwise. † suggests median. The 
Kolmogorov-Smirnov method was used to test for normality (p>0.05 signifying 
parametric distribution). Overall differences (parametric data) between the untreated 
GHD, treated GHD and control groups were tested with an ANOVA test. Where the data 
was non-parametrically distributed the Kruskal-Wallis test was used (*). 
The 25% MVC protocol was used to determine indices of recovery whereas the 35% MVC 
protocol was used to measure end of exercise parameters. 
  
Mean ±SD OFF GH Rx ON GH Rx Controls P value 
REST     
Pi (mM) 2.9±0.4 3.2±0.5 2.8±0.6 0.109 
PCr (mM) 31.8±2.9 32.4±2.8 32.4±1.5 0.668 
pH (U) 7.03±0.02 7.04±0.02 7.05±0.02 0.615 
END OF EXERCISE     
% PCr drop 23±0.09 22±0.08 21±0.07 0.823 
pH recovery time (sec) 
156.5±127.8 
115† 
108.3±113.3 
70† 
112.1±77.8 
110† 
0.297 
0.383* 
Nadir pH (U) 6.96±0.10 6.98±0.08 6.97±0.06 0.683 
Maximum efflux (mM/min) 2.46±1.30 2.34±1.20 2.98±2.01 0.365 
RECOVERY     
τ 1/2PCr (s) 37.51±26.40 31.19±12.60 34.47±13.75 0.535 
τ 1/2ADP (s) 22.81±9.13 26.30±12.53 26.69±8.70 0.421 
Qmax (mM/min) 18.2±10.9 20.4±8.6 18.5±11.6 0.730 
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2.2.4 Perception of fatigue and AGHDA scores  
Untreated GHD adults complained of significantly increased fatigue when compared to 
treated GHD adults and healthy controls (p= 0.031) (Figure 24). Untreated GHD adults 
also complained of significantly decreased quality of life when compared to treated GHD 
adults and healthy controls (p=0.001) (Figure 25). There was no significant difference in 
the remaining QoL domains amongst the 3 groups (Table 6). A higher numerical score 
depicts a poor QoL (discussed in Qol-AGHDA: A Disease specific questionnaire). 
 
Table 6 Comparison of AGHDA-QoL variables 
Mean ±SD OFF GH ON GH Controls P value 
Total AGHDA 7.5† (2.71) 5† (0.66) 1† (-3.51) 0.001* 
Fatigue 3.09±3.1 2.04±2.3 0.73±1.1 0.009 
Memory & Concentration 2.62±1.5 2.46±1.4 2.71±1.3 0.92 
Tenseness 2.18±1.2 1.50±0.9 1.33±0.6 0.24 
Social Isolation 2.28±1.3 2.16±0.9 2.00±1.4 0.95 
Self confidence 2.23±1.0 1.70±0.9 1.66±1.2 0.39 
 
All data are expressed as mean ±SD unless expressed otherwise. † suggests median. The 
Kolmogorov-Smirnov method was used to test for normality (p>0.05 signifying 
parametric distribution). Overall differences (parametric data) between the untreated 
GHD, treated GHD and control groups were tested with an ANOVA test. Where the data 
was non-parametrically distributed the Kruskal-Wallis test is also included (*). The Z 
values for each group are expressed within brackets.  
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Figure 24 shows a higher perception of fatigue in the untreated GHD group  
(ANOVA, p=0.009) 
 
 
Figure 25 shows impaired QoL in the untreated GHD group in comparison with the 
other groups 
(Kruskal-Wallis, p=0.001) 
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2.2.5 Pooled analyses and bivariate linear regression analysis to predict mitochondrial 
function (τ1/2PCr) 
Neither τ1/2PCr (r=-0.13, p=0.32) (Figure 26) nor τ1/2 ADP (r=-0.13, p=0.05) was associated 
with serum IGF-1 in our patients when pooled analyses were undertaken between 
indices of in vivo mitochondrial function and IGF-1. Several other bivariate linear 
regression models were developed in order to explore the possible relationship between 
mitochondrial function and factors influencing it. Using τ1/2PCr as the response, the 
predictors tested in individual bivariate models included age, 25-hydroxy vitamin D 
(25OHD), body fat %, testosterone, thyroxine, BMI, waist circumference, AGHDA-QoL 
scores, fatigue-AGHDA scores and IPAQ scores. Only serum 25OHD was a significant 
predictor of τ1/2
 PCr (r=-0.42, p=0.005). 
 
 
Figure 26 shows there is no correlation between serum IGF-1 and τ1/2PCr on bivariate 
analysis 
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2.2.6 Multiple regression analysis to predict factors contributing to fatigue perception 
A multiple regression was undertaken in order to examine the relationship between 
fatigue and the potential factors influencing it. Using fatigue scores from QoL-AGHDA as 
the response, the predictors entered in the model were age, τ1/2PCr, pH recovery time, 
maximum proton efflux rate, IGF-1, testosterone (in males), vitamin D, IPAQ scores, BMI 
and body fat %. The R2 for the overall model was 46.32% and there were no significant 
predictors of fatigue perception. 
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2.2.7 Effect of radiotherapy and chemotherapy on fatigue perception 
There was no significant difference in fatigue perception between those treated with 
radiotherapy (Figure 27; Table 7) or chemotherapy (Figure 28; Table 8). 
 
Figure 27 Effect of radiotherapy on fatigue in GHD 
 
Table 7 Effect of radiotherapy on fatigue perception 
 Patient numbers 
Median fatigue 
score 
P value 
OFF GH 
Radiotherapy 
16 1 1.00 
OFF GH 
No radiotherapy 
6 3.5  
ON GH 
Radiotherapy 
9 2 0.74 
ON Gh 
No radiotherapy 
14 1.5  
Comparisons were undertaken with the Mann-Whitney test 
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Figure 28 Effect of chemotherapy on fatigue in GHD 
 
Table 8 Effect of chemotherapy on fatigue perception 
 Patient numbers 
Median fatigue 
score 
P value 
OFF GH 
Chemotherapy 
6 2.5 1.00 
OFF GH 
No chemotherapy 
16 1.5  
ON GH 
Chemotherapy 
2 1 0.62 
ON Gh 
No Chemotherapy 
21 2  
Comparisons were undertaken with the Mann-Whitney test 
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2.2.8 Assessment of adequacy of other pituitary hormone replacement 
Since a significant proportion of the GHD patients had MPHD, it was important to ensure 
that the remaining pituitary hormones were being adequately replaced. There was no 
significant difference in free thyroxine levels between untreated (mean ±SD- 
18.2±3.7pmol/L) and treated GHD adults (mean ±SD: 19.0±3.9pmol/L) (p=0.48). There 
was also no significant difference in testosterone levels between untreated (mean ±SD: 
20.6±9.5nmol/L) and treated GHD adult males (mean ±SD- 15.9±7.9nmol/L) (p=0.23). 
There was also no difference in the hydrocortisone replacement regimen (mgs/m2/day) 
between the untreated GHD (mean ±SD: 8.27±1.67, range: 6.12-13.15) and treated GHD 
groups (mean ±SD: 8.21±1.39, range: 6.79-10.77) (p=0.93). 
 
 
Figure 29 Comparison of thyroxine levels in GHD patients 
There was no difference in fT4 levels between the untreated GHD and treated GHD 
adults (Mann Whitney, p=0.48) 
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Figure 30 Comparison of testosterone levels in GHD patients 
There was no difference in testosterone levels between the untreated GHD and 
treated GHD adult males (Mann Whitney, p=0.23) 
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2.3 Conclusions 
The data confirm that untreated GHD adults report enhanced fatigue when compared to 
treated GHD adults and healthy controls. These differences are not associated with 
differences in skeletal muscle oxidative capacity, nor anaerobic glycolysis as assessed by 
31P MRS: both features are seen in a range of conditions in which muscle fatigue is a 
clinical feature. This suggests a predominant central component in the pathophysiology 
of fatigue in GH deficiency. 
Phosphocreatine resynthesis rate after exercise (τ1/2PCr) is a sensitive, reliable and non-
invasive index of mitochondrial oxidative capacity in exercising skeletal muscle (Lanza et 
al., 2011). τ1/2PCr is delayed in both mitochondrial diseases and hypothyroidism 
confirming a significant peripheral basis of fatigue in these conditions (Kuhl et al., 1994; 
Pfeifer et al., 1999). It is important, however, to emphasise that 31P MRS does not 
measure muscle strength which has been extensively investigated in GHD subjects 
(Widdowson and Gibney, 2010). Rather 31P MRS provides insights into the metabolic 
processes occurring within the exercising skeletal muscle, specifically the aerobic 
oxidative (τ1/2PCr) and anaerobic glycolytic pathways. 
My data does not support an association between impaired IGF-1 and τ1/2PCr in patients 
with GHD. While previous data have demonstrated an association between IGF-1 and 
τ1/2PCr in healthy males (Makimura et al., 2011), the present study included both GHD 
adults and healthy volunteers, thereby examining mitochondrial function across a wider 
GH continuum. Furthermore although healthy controls had reduced body fat % 
compared to the GHD groups, they did not demonstrate any differences in oxidative 
function within the muscle compared to GHD adults. 
Peripheral muscle fatigue may also be caused by impairments in the anaerobic glycolytic 
pathway. This may occur either secondary to excessive lactic acid (Bangsbo et al., 1996) 
or inorganic phosphate (Dahlstedt et al., 2001) accumulation or due to delayed 
clearance of acid which is measured as pH recovery time. Delayed pH recovery can 
reflect impaired peripheral vascular supply (Cea et al., 2002). There was no difference in 
parameters of anaerobic metabolism between the 3 groups studied. 
Given the major significance of fatigue in the clinical setting, it is important to assess and 
measure this symptom in a relevant and reproducible manner. In the current study, 
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perception of fatigue (measured with the fatigue domain of the validated AGHDA-QoL 
score) was significantly higher in untreated GHD adults, confirming the findings of others 
(Table 3). However, there was a wide variation in perception of fatigue, particularly in 
the untreated GHD group. This could be due to the heterogeneity within the patient 
groups being studied. A significant proportion of patients in the GHD groups were 
survivors of cancer where some had also undergone therapy with radiotherapy and 
chemotherapy. Both cancer and treatment with radiotherapy and chemotherapy may 
independently cause fatigue (Forlenza et al., 2005). Besides there are challenges in 
quantifying fatigue in a clinical setting, especially where therapy remains unblinded. GHD 
adults also complain of reduced well-being, particularly due to social isolation, 
depressed mood and anxiety: features that are often observed in central fatigue (Lloyd, 
1998; Gilchrist et al., 2002).  
There are several possible mechanisms for central fatigue in growth hormone deficiency. 
Copinschi et al. identified abnormal sleep architecture in GHD adults (Copinschi et al., 
2010). They postulated that increased hypothalamic GH releasing hormone (GHRH) 
activity produced through the loss of negative feedback, could contribute to the daytime 
somnolence and fatigue. Many adults with GHD have associated corticotroph failure 
secondary to pituitary dysfunction. The principal central component of stress response is 
corticotrophin-releasing hormone (CRH) which not only regulates the hypothalamic-
pituitary-adrenal (HPA) axis but also modulates behavioural changes that occur during 
stress (Koob et al., 1993). Loss of circadian rhythm is well documented in subjects with 
corticotroph failure and exogenous replacement (Debono et al., 2009). Aberrations in 
the HPA axis may induce important biological and behavioural consequences leading to 
central fatigue in patients with GHD. Some biological models from chronic fatigue 
syndrome support this theory (Lloyd, 1998). In addition, CNS structures critical for 
cognitive functioning contain a high density of GH and IGF-1 receptors (Bondy and Lee, 
1993; Lai et al., 1993). Neuropsychological studies have demonstrated improvements in 
cognitive function in GHD adults with GH replacement (Deijen et al., 1998). Hence 
compromised central GH/IGF-1 signaling may contribute to fatigue in patients with GHD. 
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2.3.1 Study strengths 
The strengths of this study lie in the fact that unlike several other GHD studies, 
comparisons have been made with age and sex matched ‘treated’ GHD patients as well 
as healthy volunteers. Besides 31P MRS is a validated technique which measures skeletal 
muscle bioenergetics. This is also the first study to assess and compare dynamic skeletal 
muscle energetics in GHD adults.  
2.3.2 Study limitations 
This study has a number of limitations in terms of both the patient groups being studied 
and the tools used to study them. Firstly, untreated GHD patients, despite having 
impaired QoL, were not on GH replacement because of personal choice. Although this 
could introduce bias, it is interesting to note that there was still no difference in the 
metabolic functioning of the skeletal muscle between the 3 groups. Both untreated and 
treated GHD cohorts were unblinded and hence, I cannot eliminate a ‘nocebo’ effect in 
the untreated GHD group. However, if such were the case, it reinforces the powerful 
interaction between growth hormone and the patient's mind-brain interaction (Brody 
and Miller, 2011). 
Secondly, adults with GHD often had concomitant deficits of other pituitary hormones as 
isolated GHD in adulthood is relatively rare. Hence although attempts to minimise the 
impact of hormones other than GH through appropriate matching were undertaken, this 
process may have been imperfect. Exogenous hormone replacement rarely mimics the 
natural bioavailability and circadian rhythm of endogenous hormone secretion, 
especially glucocorticoids. However, the glucocorticoid replacement dosages were 
similar between the untreated and treated GHD group, thus minimising the likelihood of 
inappropriate glucocorticoid dosage causing the fatigue. The GH/IGF-1 axis also plays an 
important role in modulating the peripheral metabolism of glucocorticoids by inhibiting 
11β-hydroxy steroid dehydrogenase 1 (11β-HSD1) which functions in vivo as a reductase, 
catalysing the conversion of cortisone to cortisol. Enhanced activity of 11β-HSD1 in GHD 
may result in increased local and/or systemic cortisol production in patients on 
hydrocortisone replacement (Agha and Monson, 2007). To date, however, 11β-HSD1 and 
glucocorticoid action have not been shown to play a significant role in skeletal muscle 
function in GHD (Maiter et al., 2006). Hypogonadism has been reported to contribute to 
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cancer related fatigue but none of our patients were biochemically hypogonadal 
(Strasser et al., 2006). We also ensured all our patients were biochemically euthyroid 
(normal fT4 levels) since hypothyroidism is a well-known cause of fatigue (Louwerens et 
al., 2012). Some of my subjects were survivors of cancer and had undergone treatment 
with radiotherapy and chemotherapy which are independent causes of cancer related 
fatigue. However, neither radiotherapy nor chemotherapy was significantly associated 
with enhanced fatigue perception in my subject groups. 
Thirdly, while this cross-sectional study was designed to detect overt differences 
between the three groups, subtle short-term effects of GH action on mitochondrial 
function may not have been detected. Therefore there is a small possibility of a type II 
error (false negative). 
Fourthly, the measurement and comparison of fatigue perception amongst patient 
groups using self-reported outcomes has certain limitations. Differences in 
conceptualisation (understanding of which elements are included in a target construct), 
prioritisation (preference regarding the relative importance of certain components 
within the construct) and calibration (value of scaling of certain health states in relation 
to others) may often translate to wide inter-individual variations in outcome 
measurements. 
Finally, a sampling error could result in an inability to detect a difference between the 
groups because of the heterogeneous aetiology of the underlying GHD.  
2.3.3 Summary 
In summary, this data demonstrates that although untreated GHD adults experience 
fatigue when compared to both treated GHD adults and healthy volunteers, they do not 
demonstrate any corresponding perturbations in skeletal muscle metabolism. This data 
indicates that abnormal muscle energetics is not responsible for the fatigue of GHD 
adults. Taken together, this data suggests that fatigue in GHD adults may have a central 
component. 
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Chapter 3 Vitamin D and skeletal muscle energetics 
3.1 Introduction 
3.1.1 Background 
Recent randomised controlled trials by Ward et al. and Goswami et al. have refuted the 
notion that vitamin D might augment muscle strength (Ward et al., 2010; Goswami et al., 
2012). Furthermore, the inability to accurately identify vitamin D receptors (VDR) in 
skeletal muscle recently has raised questions about its role within skeletal muscle (Wang 
and DeLuca, 2011).On the other hand, fatigue and myopathy are well recognised in the 
context of vitamin D deficiency and muscle symptoms may arise independent of 
derangements of bone biochemistry (Glerup et al., 2000).  Physicians frequently 
encounter vitamin D deficient children, adolescents and adults presenting with 
musculoskeletal symptoms which resolve with calciferol therapy (Ziambaras and 
Dagogo-Jack, 1997; Pearce and Cheetham, 2010). However, the underlying mechanism 
for the reversible symptoms of fatigue and myopathy in vitamin D deficiency remains 
unclear. 
The assessment of muscle function involves measuring several parameters including 
endurance as well as strength. There are established approaches to studying these 
components but there are also novel tools that can focus on the functional relationship 
between vitamin D deficiency and skeletal muscle metabolism. One such approach is 
Phosphorus-31 MRS (31P MRS) which can be used to examine skeletal muscle energetics 
in vivo. 31P MRS can measure the metabolic work-cost relationship of the contracting 
skeletal tissue and thereby determine its oxidative capacity. 
3.1.2 Aims 
The aim of the study described in this chapter was to examine the effects of 
cholecalciferol therapy on skeletal mitochondrial oxidative function in vitamin D 
deficient subjects using 31P MRS. The hypothesis was that cholecalciferol therapy would 
be associated with improved skeletal muscle mitochondrial oxidative function in 
symptomatic vitamin D deficient individuals (<25nmol/L). 
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3.2 Methods 
3.2.1 Study subjects and general study protocol 
Twelve individuals with severe vitamin D deficiency (<15nmol/L) were studied. All 12 
subjects had their biochemistry assessed and underwent a standardised exercise 
protocol with an assessment of 31P MRS prior to being treated with cholecalciferol 
therapy as detailed below. Biochemistry and the exercise protocol with 31P MRS were 
then repeated following 10-12 weeks of calciferol therapy. 
15 age-matched healthy volunteers were recruited as controls through local 
advertisements. The 15 healthy controls for the Vitamin D study were sampled from the 
20 healthy controls used for the GH study. 15 patients were selected since only 15/20 
controls had their 25OHD measured. The study design is summarised in Figure 31. 
 
 
Figure 31 Vitamin D Longitudinal study 
 
Inclusion criteria: 
 For patients to enter the study, they were deemed to be both severely vitamin D 
deficient (<25nmol/L) and symptomatic. They all presented to primary care with fatigue 
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and/or muscle cramps between March and May 2012. The primary care team 
approached the patients who met these criteria and gave them patient information 
sheets. The patients subsequently contacted the researcher, Dr Akash Sinha and 
expressed an interest in participating in the study. 
Exclusion criteria: 
 Exclusion criteria included a history of thyroid, pituitary or inherited mitochondrial 
disease. Furthermore, those who were MR incompatible because of metallic implants 
were to be excluded as well. 
3.2.2 Approval for the study  
The study was approved by the Newcastle and North Tyneside 2 Research Ethics 
Committee (10/H0907/71-amendment 1) and written informed consent was obtained 
from all participants. The study was conducted according to the principles of the 
Declaration of Helsinki. 
3.2.3 Phosphorus-31 Magnetic Resonance Spectroscopy protocol 
MRS data were acquired using a 3T Achieva scanner (Philips, Best, NL) with a 14cm 
diameter Phosphorus surface coil for transmission/reception of signal and the in-built 
body coil for anatomical imaging (Boska, 1994). Imaging to localise to gastrocnemius and 
soleus muscles is performed by axial T1 turbo spin-echo imaging around the fattest part 
of the calf (TR = 671ms, TE = 10ms, 256x153 matrix, resolution 1.37x1.71, 16 slices with 
10mm gap). A purpose-built exercise apparatus was developed for operation with the 
imaging scanner. This apparatus permitted a controlled plantar flexion (between 0° to 
30°) to isolate and exercise the soleus and gastrocnemius muscles with the patient lying 
supine, whilst using restraining straps to prevent recruitment of the quadriceps. Subjects 
performed an exercise protocol consisting of three minutes of rest, three minutes of 
plantar flexion at 0.5 Hz and six and a half minutes of rest post exercise to measure 
recovery to equilibrium. A fixed load of 35% of Maximum Voluntary Contraction 
(determined prior to spectroscopy) was employed to accurately measure oxidative 
metabolism in recovery whilst maintaining a stable pH (Kemp and Radda, 1994). It is 
important to highlight that this differs from the 25% MVC employed in the GHD study 
including the healthy controls. 35% MVC in the vitamin D deficient patients was 
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deliberately selected since 25% MVC failed to adequately deplete their PCr reserves and 
hence skeletal muscle mitochondrial function (τ1/2PCr, τ1/2ADP) would not be accurately 
measured. Importantly, 35% MVC exercise in the vitamin D deficient group led to a 
similar % PCr depletion and nadir pH to the 25% MVC exercise in the healthy controls. 
Phosphorus spectra were collected at 10s intervals throughout the exercise using a fully 
adiabatic 1D-ISIS sequence to localise signal to gastrocnemius and soleus muscles. TR = 
5s was used with paired subtracted spectra to perform 1D ISIS selection in the anterior-
posterior direction, so effectively there are 2 averages per final spectrum at time 
resolution 10s. The dimension of the 1D anterior-posterior ISIS selection was 48mm. The 
gradient strength used in the ISIS localisation was 3.09 mT/m. The extent of spatial shift 
between Pi and γ-ATP (since α and β-ATP are not used in the calculations) is 7mm (The 
frequency difference induced across the selected 1D slab is 2556Hz and Pi and γ-ATP are 
389Hz apart on the spectrum). Deviation from the prescribed slab is minimised by 
putting PCr on resonance. 
Quantification of the spectral peaks and calculation of pH was performed using the 
AMARES time domain fit routine in the jMRUI processing software (v 3.0) (Kemp et al., 
1997; Vanhamme et al., 1999). The prior knowledge model used assumed single 
Lorentzian resonances for Pi, PDE and PCr, with the α and γ moieties of ATP modelled as 
doublets of equal area with 17Hz separation, and the β-ATP moiety modelled as a triplet 
with 17Hz separation and area ratio 1:2:1 (Hamilton et al., 2003). Parameters of 
oxidative metabolism and pH handling were calculated. Exponential fits to the recovery 
data were made to estimate the half-times for recovery to equilibrium of PCr (τ1/2 PCr) 
and ADP (τ1/2 ADP) (Taylor et al., 1983). The relationship between ADP concentration and 
oxidation rate was used to estimate maximal oxidative ATP production (Qmax) as 
described in the equation: Qmax = V(1+Km / [ADP] end exercise) where Km is taken as 30 
µM (Kemp et al., 1993). Muscle pH was assessed using the chemical shift between 
phosphocreatine peak and the inorganic phosphate peak, 
pH = pKa + 10 log10 ((δ1-δ)/(δ-δ2)) 
where pKa = 6.75, δ is the chemical shift from PCr to Pi in ppm, δ1 = 3.27ppm, δ2 = 
5.63ppm (Moon and Richards, 1973). 
Proton efflux, E, was calculated for every time point after cessation of exercise, 
E = (+ m)d[PCr]/dt + dpH/dt 
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where ν,m and β are cytosolic buffering capacity constants, which can be estimated 
based on previous work and which themselves have a dependency on pH (Kemp et al., 
1997). 
This allows the evaluation of the time point at which efflux reached its maximum. 
3.2.4 Vitamin D regimen 
All subjects were studied before and after treatment with Cholecalciferol 20,000IU on 
alternate days for 10-12 weeks for correction of their Vitamin D deficiency (Sinha et al., 
2012). 
3.2.5 Biochemistry 
Serum samples were obtained from participants at both visits. Serum concentrations of 
25OHD were measured using the DiaSorin 25Hydroxyvitamin D radio-immunoassay (RIA) 
(Cat # 68100E Stillwater, Minnesota USA). The DiaSorin RIA assay involves a two-step 
procedure. The first is a rapid extraction step using acetonitrile to isolate 25 Hydroxy 
vitamin D (25OHD) and other hydroxylated metabolites of vitamin D. Equilibrium RIA is 
then performed with 25ul (in duplicate) extracted sample, antibody to 25OHD and 
iodinated tracer to 25OHD. Phase separation is achieved by the addition of a second 
antibody and polyethylene glycol. Radioactive counts in the centrifuged pellet are then 
inversely proportional to the 25OHD concentration in the original sample. Serum 
samples used in this study were stored at -20ºC prior to analysis. Two quality controls 
are routinely used in the assay with mean values of 39 and 134 nmol/L and interassay 
coefficient of variations (CV’s) of 8.4% and 12.6% respectively. The intraassay CV for this 
method is < 8% with a functional sensitivity of 6nmol/L. 
3.2.6 Outcome measures  
The primary outcome of this study was to compare skeletal muscle mitochondrial 
function (τ1/2PCr, τ1/2ADP) in 12 symptomatic vitamin D deficient subjects before and 
after cholecalciferol therapy using 31P MRS. 
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3.2.7 Statistical analysis 
Sample size was estimated from pilot studies of healthy individuals at our centre who 
underwent repeat 31P MRS to determine repeatability. Using the Bland-Altman method, 
we expected to find a maximum of 9% variability in 1/2PCr from repeated 
measurements (Bland and Altman, 1986). In order to detect a 10% change in 1/2PCr at a 
significance p=0.05 with 90% power, an estimation of a minimum group of 10 subjects 
was made. Statistical analyses were undertaken using Minitab v16 software package. All 
data are expressed as mean ±SD. After ensuring parametric distribution with the 
Kolmogorov-Smirnov method (p>0.15), paired t-tests were undertaken to make 
comparisons pre and post cholecalciferol. A linear regression model was built to examine 
the relationship between 25OHD and 1/2PCr. Significance was set at P<0.05. 
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3.3 Results 
3.3.1 Subject clinical characteristics 
Participants presented to primary care with fatigue and myopathy. The mean age (±SD) 
of the subjects was 33.7±9.8years (range 18.1-50.4 years). One patient had a complex 
medical history including Hepatitis C, depression, epilepsy and anaemia and was on a 
thiamine, folic acid, vitamin B, levetiracetam and amitriptyline. The remaining 
participants had no other relevant past illness. 2 participants were Caucasian, 2 were 
Afro-Caribbean and 8 were of South-East Asian ethnicity. 5 females and 7 males 
participated. There was no change in diet, medication or exercise pattern between the 
two study visits. Symptoms of fatigue and myopathy were confirmed on the first visit 
with all patients reporting an improvement in symptoms at their second visit. The 15 
healthy controls were 31.3±7.0 years of age (range 22.3-45.9 years).  
3.3.2 Serum biochemistry 
All patients were severely vitamin D deficient at their first assessment (mean serum 
25OHD 8.83±4.28nmol/L). All were noted to have a significant improvement in 25OHD 
status (mean serum 25OHD 113.8±51.5nmol/L) following cholecalciferol therapy prior to 
the repeat MRS muscle study (p<0.001) (Figure 32). There was no significant difference 
in serum calcium, phosphate or alkaline phosphatase levels before and after 
cholecalciferol (Table 9). The mean serum 25OHD of the healthy controls was 
44.2±29.4nmol/L. 
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Figure 32 Serum 25OHD levels at presentation with vitamin D deficiency and then 
following calciferol therapy 
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3.3.3 Parameters of oxidative phosphorylation 
Post-exercise PCr and ADP recovery (1/2PCr, 1/2ADP), indices of mitochondrial oxidative 
function improved significantly following cholecalciferol therapy (p <0.001, p=0.003, 
Figure 33 and Figure 34 respectively) (Table 9) 1/2PCr improved from 34.44±8.18s 
(vitamin D deficient) to 27.84±9.54s (vitamin D optimal). The 1/2PCr of the healthy 
controls was 35.66±14.62s. The resting metabolites including Pi, PCr and pH did not 
differ significantly. There was also no difference in PCr depletion (%PCr drop) or 
differences in nadir pH and maximum proton efflux at the end of exercise (Table 9). 
Figure 35 shows a box plot of 1/2PCr comparisons between the vitamin D deficient, 
vitamin D optimal and the healthy controls. A pooled regression analysis which included 
vitamin D deficient, optimal and healthy controls showed lower serum 25OHD levels 
correlated with longer 1/2PCr (r=-0.41, p=0.009) (Figure 36). 
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Table 9 Biochemistry and 31P MRS measurements on skeletal muscle in vitamin D 
deficient subjects before and after calciferol therapy 
Mean ±SD 
Baseline 
(Vitamin D deficient) 
Follow-up 
(Vitamin D optimal) 
P 
value 
Healthy 
controls 
 
BIOCHEMISTRY 
Serum 25OHD 
(nmol/L) 
8.83±4.28 113.8±51.5 <0.001 44.2±29.4 
Serum 
calcium 
(mmol/L) 
2.29±0.1 2.35± 0.1 0.24 NA 
Serum 
phosphate 
(mmol/L) 
0.99±0.1 1.12±0.2 0.19 NA 
Alkaline 
phosphatase 
(U/L) 
86.7± 15.5 78.5± 9.5 0.16 NA 
REST 
Pi (mM) 2.63±0.48 2.78±0.47 0.38 2.94±0.59 
PCr (mM) 31.77±3.20 32.09±4.19 0.77 32.39±1.28 
Pi/PCr 0.08±0.02 0.09±0.02 0.38 0.09±0.02 
pH (U) 7.04±0.03 7.05±0.03 0.28 7.04±0.03 
END OF EXERCISE 
% PCr drop 0.25±0.14 0.24±0.10 0.81 0.21±0.08 
Nadir pH (U) 6.99±0.08 7.00±0.05 0.34 6.91±0.28 
Maximum 
proton efflux 
(mM/min) 
3.63±4.37 3.70±1.83 0.95 2.59±1.69 
RECOVERY 
1/2PCr (s) 34.44±8.18 27.84±9.54 <0.001 35.66±14.62 
1/2ADP (s) 26.84±6.58 21.93±6.81 0.003 27.49±9.12 
 
Data are expressed as mean± SD. Paired t-tests were undertaken for comparisons pre 
and post calciferol therapy. The healthy control data (n=15) was obtained from the GH 
study controls (n=20). Since only 15/20 of the healthy controls had their vitamin D 
analysed, only they could be selected. It is also important to highlight that the recovery 
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indices in the controls were calculated from 35% MVC exercise. Importantly, however, 
the % PCr depletion and nadir pH was similar across the 3 groups.  
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Figure 33 Comparison of τ1/2 PCr kinetics before and after calciferol therapy 
 
 
Figure 34 Comparison of τ1/2 ADP kinetics before and after calciferol therapy 
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Figure 35 Comparisons of mitochondrial function before and after calciferol therapy 
and with healthy controls.  
The boxplot above shows an improvement in mitochondrial function before and after 
calciferol therapy. The wide range of mitochondrial function in asymptomatic healthy 
controls as evident from the wide range of the box plot signifies the wide biological 
variability of this measure. It is important to note that vitamin D deficiency does not 
result in abnormal mitochondrial function but correction of vitamin D status leads to 
an enhancement in mitochondrial function. 
It is also important to highlight that the vitamin D deficient subjects were assessed 
using 35% MVC whereas the healthy controls were assessed using 25% MVC. 
Importantly, however, both groups demonstrated similar %PCr depletion and end-
exercise pH. 
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Figure 36 A regression model built by pooling data from serum 25OHD and τ1/2PCr of 
all the participants. 
 This model shows that lower vitamin D is associated with lower maximal 
mitochondrial oxidative phosphorylation. This model includes data from both pre and 
post vitamin D treatment subjects and healthy controls. (r=-0.41, r2 adj=14.67%, 
p=0.009) 
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3.4 Conclusions 
The maximal mitochondrial oxidative phosphorylation rate was enhanced (1/2PCr and 
1/2ADP recovery times were reduced) following cholecalciferol therapy in severely 
vitamin D deficient, symptomatic individuals. Correcting vitamin D deficiency was 
associated with an improvement in symptoms of myopathy and fatigue in all 
participants. There was no evidence of abnormal resting metabolic parameters often 
found in conditions with altered membrane permeability when compared with healthy 
controls (Kemp and Radda, 1994). 
The relationship between vitamin D and muscle has been a subject of much interest 
recently with 363 articles being published on this topic in PubMed from Jan 2011-Feb 
2013 (search terms: vitamin D +muscle). The present body of evidence suggests that 
treatment with vitamin D does not necessarily lead to an improvement in muscle 
strength in otherwise healthy vitamin D deficient adults (mean serum 25OHD 25nmol/L) 
(Gallagher, 2012). A recent meta-analysis concluded that vitamin D supplementation did 
not result in an improvement in muscle strength in vitamin D replete adults although 
there was evidence to suggest an increase in muscle strength in adults who had 25OHD 
≤25nmol/L pre-treatment (Stockton et al., 2011). A randomised controlled trial (RCT) 
investigated muscle strength and resting skeletal muscle energy metabolism in young 
(mean age 31.5yrs) vitamin D deficient Asian Indians (mean serum 25OHD 25nmol/L) 
and found improvements in muscle strength but no changes in resting skeletal muscle 
energy metabolism (Gupta et al., 2010). However, the authors did not acquire dynamic 
phosphorus data whilst exercising and hence did not compute oxidative phosphorylation 
capacity (1/2PCr and 1/2ADP). Besides the studied patient groups were neither 
symptomatic nor severely vitamin D deficient since they were apparently healthy 
volunteers. However, when the same group conducted a double-blinded, placebo-
controlled RCT to assess the effect of vitamin D and/or calcium on muscle strength in 
young, asymptomatic Asian Indian females (mean age 21.7yrs) with vitamin D deficiency 
(mean serum 25OHD 23.3nmol/L) they found no improvements in skeletal muscle 
strength (Goswami et al., 2012). This unexpected observation was surprising especially 
since the authors had used similar methods for the assessment of skeletal muscle 
strength and duration of supplementation, thus, minimising confounding variables. 
116 
 
Although the precise reasons for this discrepancy remain unclear, there could be several 
explanations. Firstly, as suggested by J.C. Gallagher in a recent editorial in the Journal of 
Clinical Endocrinology and Metabolism, improvements in 25OHD levels may not 
translate to improvements in 1,25OHD levels, the biologically active metabolite of 
vitamin D (Gallagher, 2012). 1,25OHD modulates calcium entry into the muscle (by its 
direct non-genomic action) and maybe important for muscle strength. However, 
Goswami et al. noted a similar increase in the serum 1,25OHD levels (7.1% in the double-
supplementation group and 9.2% in the cholecalciferol/placebo group) as did Bischoff et 
al. when they reported a significant reduction in the frequency of falls after 12 weeks of 
calcium and vitamin D supplementation in elderly women (8% increase in 1,25OHD 
levels) (Bischoff et al., 2003). Evidence for a possible direct action of 25OHD was also 
demonstrated by Birge et al. in 1975. They showed that administration of vitamin D to 
vitamin D deficient, phosphate depleted rats resulted in a significant increase in in vitro 
concentrations of phosphate metabolites in muscle cells followed by the stimulation of 
phosphate dependent metabolic processes including ATP synthesis in these cells. This 
effect was not reproduced by repletion of phosphates in the rats. The abolition of 1α 
hydroxylation following nephrectomy had no effect on 25OHD mediated phosphate 
uptake, thereby confirming a direct role of 25OHD in ATP synthesis (Birge and Haddad, 
1975). Secondly, gender specific differences may account for the discrepancy in findings. 
Whereas Gupta et al. recruited young males and females, Goswami et al. recruited only 
young postmenarchal females. Vitamin D levels have been shown to be positively 
associated with testosterone levels (Nimptsch et al., 2012) and therefore, vitamin D 
supplementation in adult males may lead to improvements in testosterone levels which 
subsequently may result in enhanced muscle strength. 
The broad evidence is generally in favour of a role of vitamin D in the development and 
function of skeletal muscle (discussed in subchapter Vitamin D and skeletal muscle 
function). The strongest evidence comes from studies that report distinct morphological 
changes in the muscle of vitamin D deficient subject, those that describe impairments in 
the muscle function of the VDRKO mouse and molecular in vitro studies that have 
mapped out the various intracellular responses of cultured muscles to vitamin D 
(Sorensen et al., 1979; Kalueff et al., 2004; Boland, 2011). This is also corroborated by 
clinical studies where clinicians have reported resolution of myopathy and myalgia in 
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vitamin D deficient adults with vitamin D therapy (Plotnikoff and Quigley, 2003; Reginato 
and Coquia, 2003; Mouyis et al., 2008; Badsha et al., 2009). 
In a broader context, the assessment of muscle function entails the measurement of 
strength as well as of efficiency. Exercise efficiency represents the chemical conversion 
of energy from nutrient to mechanical work and is a key factor in exercise performance. 
Using 31P MRS to study the metabolic work-cost relationship of the vitamin D deficient 
muscle, I have demonstrated an improvement in skeletal muscle metabolism or 
efficiency with calciferol therapy. 
Although my data did not show overt abnormalities of mitochondrial oxidative function 
in the vitamin D deficient subjects when compared to similar aged healthy controls, 
cholecalciferol therapy resulted in significant enhancement of mitochondrial maximal 
oxidative phosphorylation. It is also important to highlight that the vitamin D deficient 
subjects were assessed using 35% MVC whereas the healthy controls were assessed 
using 25% MVC. Importantly, however, both groups demonstrated similar %PCr 
depletion and end-exercise pH. The wide range of mitochondrial function in the healthy 
control data reflects the wide biological variability in mitochondrial function. 1/2PCr is a 
widely accepted measure of maximal mitochondrial capacity. It is a function that reflects 
a composite of mechanisms including mitochondrial number, oxidative enzyme content, 
mitochondrial components and vascular supply of substrates and oxygen (Kemp et al., 
1993). Perturbations in any or all of the above mechanisms may lead to suboptimal 
mitochondrial oxidative function. Lower 1/2PCr represents enhanced maximal 
mitochondrial oxidative phosphorylation. Long-term endurance training and ageing have 
been reported to positively and negatively modulate mitochondrial function respectively 
(McCully et al., 1989; Conley et al., 2000). A linear regression model confirmed the 
relationship between vitamin D and mitochondrial function. As vitamin D levels fall, 
mitochondrial recovery kinetics increase. 
The precise basis for the muscle symptoms observed in vitamin D deficiency has been 
unclear until now. The described study indicates that some of these symptoms maybe 
mediated by the mitochondria in the skeletal muscle. Mitochondria play an important 
role in the cellular processes via regulation of intracellular Ca2+ concentrations (Ca2+). 
Hormone responsive elements (HRE) are located at various sites within the mitochondria 
genome which in turn can upregulate cellular energy production through genomic and 
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non-genomic mechanisms (Psarra et al., 2006). Mitochondria in skeletal muscle fibers 
can take up cytoplasmic Ca2+released from the sarcoplasmic reticulum during twitch and 
tetanic responses (Rudolf et al., 2004). Such Ca2+ uptake may stimulate mitochondrial 
ATP production, although it may not be essential (Bruton et al., 2003). Experiments on 
vitamin D deficient chick muscles demonstrated alterations in oxidative phosphorylation 
and an inability of muscle mitochondria to retain Ca2+ (Mukherjee et al., 1981). An 
established link between cytosolic and mitochondrial Ca2+ concentrations, identification 
of transport mechanisms, and the proximity of mitochondria to Ca2+ release sites 
supports the notion that Ca2+ can be an important signaling molecule in the energy 
metabolism interplay of the cytosol with the mitochondria (Figure 37) (Glancy and 
Balaban, 2012). Vitamin D through stimulation of the vitamin D receptor (VDR) may play 
a significant role in Ca2+ uptake by the mitochondria which in turn are involved in the 
orchestration of cellular metabolic homeostasis such as oxidative phosphorylation, 
cytosolic calcium signaling and apoptosis. Further understanding of this molecular 
pathway may also help to improve our understanding of the putative role of vitamin D in 
several extraskeletal diseases. 
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Figure 37 Schematic diagram of the interaction of matrix Ca2+ with the processes 
involved in oxidative phosphorylation  
Enzyme abbreviations: PDH, pyruvate dehydrogenase; CS, citrate synthase; A, 
aconitase; ICD, isocitrate dehydrogenase; KDH, α-ketoglutarate dehydrogenase; SCS, 
succinyl- CoA synthetase; SDH, succinate dehydrogenase (also Complex II); F, 
fumarase; MDH, malate dehydrogenase; MCU, mitochondria calcium uniporter. The 
complexes of oxidative phosphorylation are labelled with Roman numerals (I−V). The 
DH on Complex 1 refers to the intrinsic and possibly associated NADH dehydrogenase 
activity. The red arrows from Ca2+ to the different interaction sites imply either a 
direct or indirect modulation of transport or enzymatic activity (Glancy and Balaban, 
2012). 
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3.4.1 Study Strengths 
Mitochondrial oxidative phosphorylation measurement using 31P MRS demonstrates low 
intra-individual variability with biological variability accounting for the vast majority of 
inter-individual variability (Layec et al., 2009). An advantage of the study design lies in its 
ability to control for confounding variables. Earlier pilot work in our unit demonstrating 
an intra-individual CV of 9% in healthy controls is pertinent when interpreting the study 
findings. It is also important to highlight the fact that an 8 week study of increased 
physical activity in 10 healthy controls at our centre did not alter mitochondrial function 
as measured by 1/2PCr (Trenell et al., 2008). Moreover, our test-retest reproducibility is 
consistent with another centre that has cross-validated 31P MRS by comparing oxidative 
capacity with high-resolution mitochondrial respirometry isolated from muscle biopsy 
tissue (Lanza et al., 2011). 
There are two major differences in my study compared to the recent experiments 
assessing the effects of vitamin D on muscle strength. All my subjects were symptomatic 
and presented to their General Practitioner with myalgia and myopathy. Secondly, to the 
best of my knowledge, no group has characterised skeletal muscle oxidative metabolism 
in vitamin D deficient adults using dynamic 31P MRS. 
3.4.2 Study Limitations 
There are limitations to this study: the number of subjects studied was relatively small; 
the study was not placebo-controlled; and neither patient nor investigators (myself) 
were blinded during treatment. Comprehensive fatigue questionnaires were deliberately 
not used because of their low specificity to vitamin D deficiency, their intrusive nature 
and issues of language translation e.g. the Fatigue impact score (FIS) is constructed of 
items that require a graded response such as ‘I engage in less sexual activity’ and ‘I worry 
about how I look to other people’. 
It also remains unknown whether vitamin D supplementation to asymptomatic 
individuals would result in enhancements in mitochondrial oxidative phosphorylation 
and there is much to learn about the precise relationship between vitamin D status and 
mitochondrial function. However, the presented data offers clear proof of principle that 
31P MRS is a valuable platform for future studies in this area. 
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3.4.3 Summary 
In conclusion, these data show that cholecalciferol therapy in symptomatic, vitamin D 
deficient individuals results in improved skeletal muscle mitochondrial oxidative function 
as measured by 31P MRS. 
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Chapter 4 Discussion 
4.1 Summary 
31P MRS has emerged as a powerful technique for measuring skeletal muscle metabolism 
non-invasively and dynamically. It provides novel insights into the phosphate dependent 
metabolic processes (such as ATP synthesis) occurring within the skeletal muscle. Apart 
from quantifying oxidative muscle metabolism, it can measure cytosolic pH and thereby 
provide useful information about anaerobic metabolism within skeletal tissue. In other 
words 31P MRS informs us of the metabolic work-cost relationship of the skeletal muscle 
for a given activity. Since skeletal muscles possess the distinctive ability to increase 
metabolic rate nearly 100-fold during the transition from resting basal state to near 
maximal contractile activity, it serves as an ideal candidate to interrogate. 31P MRS has 
improved our understanding in muscle pathology in various diseases. The fact that the 
skeletal muscle is the largest effector organ for several hormones explains why 
endocrine myopathies are commonly observed in several endocrine disorders. 
I have used 31P MRS to examine skeletal muscle metabolism in two diverse endocrine 
conditions, namely growth hormone deficiency and vitamin D deficiency using two 
separate designs. The first study investigated skeletal muscle metabolism in GHD adults 
in a cross-sectional study design. It determined that untreated GHD adults do not 
express an abnormal bioenergetic ‘footprint’ in their skeletal muscle metabolism when 
compared to age and sex matched GH replaced GHD adults and healthy controls despite 
an enhanced perception of fatigue and impaired QoL in the untreated GHD group. This 
may indirectly suggest that the fatigue perceived by GHD patients may have a central 
component. 
The second study investigated the effect of vitamin D therapy on skeletal muscle 
metabolism in vitamin D deficient adults using 31P MRS in a longitudinal design. The 
results showed that oxidative mitochondrial function was enhanced with calciferol 
therapy in vitamin D deficient, symptomatic patients. This suggests that the fatigue 
experienced by these patients could be due to suboptimal oxidative phosphorylation in 
the mitochondria. Hence, I have established a link between vitamin D and mitochondrial 
function in humans using 31P MRS. This work serves as a proof of concept study for 
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future work to further delineate the precise relationship between vitamin and muscle 
function. 
Finally, given that the two studies were designed differently, one must be careful not to 
interpret the positive results of the vitamin D study as confirming the lack of effect seen 
in the GHD study. 
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4.2 The future 
4.2.1 GH study 
There are two implications of my work. Firstly, I attempted to examine the relationship 
between GH and skeletal muscle metabolism. Secondly, in a wider clinical context, I 
attempted to understand the aetiology of fatigue in GHD. 
I have established that adults with GHD do not demonstrate any overt abnormalities in 
peripheral skeletal tissue metabolism. On the other hand they report increased fatigue 
compared to matched GH treated GHD adults and healthy controls, which therefore 
suggests a central determinant of fatigue. 
However, several outstanding questions remain unanswered. Are there any short term 
subtler effects of GH on skeletal muscle metabolism which my study design could not 
detect? Could the underlying cause of GHD (survivors of cancer) and its resultant 
treatment (radiotherapy, chemotherapy) play a larger role in the aetiology of fatigue 
rather than GH per se? If central fatigue is an important cause of fatigue, what is the 
precise pathway by which GH/IGF-1 acts on the central nervous system? With the recent 
identification of a potential cellular mechanism for cellular fatigue (serotonin spillover), 
what implication does it have for GHD patients? (Florence Cotel, 2013). Do other 
hormones such as cortisol modulate central fatigue in GHD adults? 
Future studies should be designed to address these unanswered questions. A trial of the 
effects of GH on peripheral muscle metabolism and cerebral metabolism in isolated GHD 
adults would help to answer many of the above questions. Apart from using 31P MRS to 
study skeletal muscle metabolism, the use of functional MRI would shed more light on 
neural metabolism. This technique is based on undertaking specific tasks of executive 
memory which activate the brain. This increases cerebral blood flow because neural 
activity is enhanced. The results would be correlated with AGHDA-QoL scores to map any 
changes in neural metabolism and patient-reported benefits. 
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4.2.2 Vitamin D study 
Using 31P MRS, I have measured the metabolic work-cost relationship of the vitamin D 
deficient skeletal muscle and provided novel insights into the relationship between 
vitamin D and muscle exercise efficiency. 
My study reports an enhancement in skeletal muscle mitochondrial oxidative function 
with vitamin D therapy in symptomatic vitamin D deficient individuals. This finding is 
corroborated by in vitro experiments on vitamin D deficient chick muscle demonstrating 
alterations in oxidative phosphorylation and an inability of muscle mitochondria to 
retain Ca2+ (Mukherjee et al., 1981). 
However, there are many unanswered questions. The precise mechanisms by which 
vitamin D modulates skeletal tissue mitochondrial function in human remains to be 
elucidated. Because of their central role in the regulation of energy transduction, 
mitochondria, the major site of oxidative processes within the cell, are considered likely 
subcellular targets for the action of steroid hormones. There is scope to clarify the 
molecular pathway by which vitamin D, a steroid hormone, affects the mitochondria. It 
also remains unclear whether this is modulated by 25OHD or its biologically active 
metabolite 1,25OHD. The debate continues regarding the true in vivo presence of VDR in 
skeletal tissue. It also remains uncertain whether there is any gender dimorphic effect of 
vitamin D on muscle strength. 
An essential objective of any future study would be to attempt to connect the non-
invasive measurements of skeletal muscle metabolism (using 31P MRS) with true physical 
characteristics of the skeletal tissue (using biopsies) to provide a clear understanding of 
the measurements capability and enable accurate interpretation. These findings would 
be mapped to muscle function tests. In essence one would attempt to translate 
improved metabolic responses in the tissue to improved functional outcomes. 
There is also considerable debate as to what constitutes optimum serum 25OHD levels. 
This partly stems from the absence of functional markers to corroborate serum 25OHD 
levels. 31P MRS, therefore, offers the possibility to investigate oxidative mitochondrial 
function in the skeletal muscle in a dose dependent manner. This could be investigated 
simultaneously with ex vivo analyses of mitochondrial quality, quantity, and function 
using muscle biopsy samples. This would provide evidence regarding the direct 
mechanistic role of vitamin D on muscle mitochondrial function. Simultaneous 
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measurements of 1,25OHD should also be undertaken to verify its precise role. However, 
its short circulating half-life (~4hrs) may limit its reproducibility. The study should be 
powered to examine for any gender dimorphic effect since testosterone may potentiate 
the action of vitamin D on muscle strength. Mitochondria are not only critical for 
supplying 95% of the energy used by the cell through oxidative phosphorylation but also 
for their role in induction of cell death through apoptosis. These functions are mediated 
by intramitochondrial Ca2+ concentrations. Hence further understanding of the link 
between vitamin D and intramitochondrial Ca2+ may help us understand the purported 
role of vitamin D in several extraskeletal diseases as well. 
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Appendix C Patient Information Sheet-GHD 
REC reference number: 10/H0907/71 
Committee; Newcastle and North Tyneside REC 1 
Protocol version 4.3, 25/11/10 
 
 
   Department of Endocrinology 
Royal Victoria Infirmary  
Newcastle upon Tyne  NE1 4LP 
 
 
A study using Magnetic Resonance Spectroscopy (MRS) to 
assess changes in skeletal muscle in patients with growth 
hormone deficiency (GHD) 
 
Patient Information Sheet 
 
Why have I been chosen? 
We are inviting you to take part in a research study because you have growth hormone 
deficiency (GHD). Before you accept or decline the invitation, it is important for you to 
understand why the research is being done and what it will involve. Please read the 
following information and feel free to discuss it with relatives, friends and your General 
Practitioner, if you wish. If there is anything that is not clear, or you have any further 
questions, please ask us (our contact details are at the end of this information sheet). 
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Take time to decide whether you would like to take part, or not. The study will not have 
any direct benefit to you, but will provide important information about the effects of 
growth hormone replacement therapy. 
 
Who is taking part in the study? 
We are asking patients with a diagnosis of growth hormone deficiency (GHD) to take 
part in this study. This includes patients with GHD who are on growth hormone 
replacement therapy as well as patients with GHD who are not on growth hormone 
therapy at the moment. Most patients will be asked to undergo one scan but some 
younger patients who have been on GH therapy until recently and who are thinking 
about whether to stay on GH may be asked to undergo a scan on 2 occasions.  
 
What is the purpose of the study? 
The aim of the study is to find out what happens to muscle when the levels of growth 
hormone are low. We will do this by taking a small sample of blood following an 
overnight fast (around 2 teaspoons in amount) and then by looking at the energy 
changes that take place within the muscle during a period of gentle foot exercise. The 
technique that is used to measure how the muscles are working is called Magnetic 
Resonance Spectroscopy (MRS). MRS allows doctors to obtain biochemical information 
about the tissues of the human body in a non-invasive way (without the need for a 
biopsy and without the need for X-rays). 
The MRS scan involves lying in a special Magnetic Resonance Imaging (MRI) Scanner and 
then flexing and extending your ankle whilst measurements are taken. The procedure is 
not painful and the movement required is like depressing a clutch pedal on the car. You 
will be required to do this for 15-20 minutes. 
 
What is a Magnetic Resonance Spectroscopy (MRS) scan? 
MRS is a special technique that uses magnets, radio waves and computers to produce 
detailed images (or scans) of the inside of your body. MRS does not use X-rays and 
doesn’t cause pain or discomfort. 
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The scanning session takes approximately two hours and you will be need to lie on your 
back on a moveable table, which slides inside the cylinder shaped scanner. The scanner 
is open ended and as we are only scanning your leg, you will not be completely enclosed 
at any time. 
 
A radiographer will operate the scanner from behind a window but will be able to hear 
you and see you during the scan. You will be given a call button to hold during the scan, 
which you can press to get the radiographer’s attention, should you need to. 
 
It can take several minutes for each image to be taken, and it is important to lie still and 
breath gently during the process. The machine is noisy and will make a loud knocking or 
buzzing sound throughout the scan. However, we will provide you with earplugs or 
headphones which will help block a lot of the sound out. 
 
When the scans are complete, the table will be removed from the scanner, whilst you 
are on the table and then you will be able to get off once safely out. There will be 
someone to help you off the table if required. 
 
What happens now? 
If you are happy to participate in the study, we will ask you to sign a consent form 
indicating your willingness to take part. We will also arrange a time for you to come for 
your scan. The scanning session will take approximately two hours. 
You will be able to eat and drink as usual and will not need to take any special 
precautions. 
 
Are there any side effects to taking part in the study? 
MRI scans are commonly performed and generally safe. However you need to be aware 
of the possible side-effects.  
Some people are slightly claustrophobic in the scanner, however with the scan of your 
leg you will not be completely enclosed. The radiowaves used in the MRI can also cause 
metal and tissues to heat up and move and so you will need to inform us if you have any 
of the following: 
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Surgical clips, 
A previous history of metal fragments in your eyes. 
Any pacemakers or heart defibrillators, 
Inner ear implant (a hearing aid), 
Medicine infusion pump (insulin pump),  
Neurostimulator, 
Aneurysm clip (a metal clip on an artery), 
Shunts (tubes) in the brain, 
Joint replacements/large metal implants, 
Stents (tubes) in the heart or arteries, 
Eye, penis or breast implants, 
An intrauterine contraceptive device or coil, 
Any allergies. 
 
You will also need to inform us if you have any body piercing, tattoos or transdermal 
patches, metal fragments anywhere in your body or gun/shrapnel wounds. 
 
If you are pregnant or possibly pregnant please let us know, as you will not be able to be 
included in the study. 
 
You may find that teeth fillings may tingle during the scan but they are safe. 
 
Please note that there will be someone to help you onto and off the table if needed. 
 
Since Magnetic Resonance Spectroscopy is primarily a research tool, we do not expect to 
detect any gross abnormalities. However, in the unlikely case that we detect any gross 
abnormalities, we shall discuss the findings with the relevant clinicians and contact you 
accordingly. 
 
Confidentiality 
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All data collected will be anonymised – you will not be able to be identified from the 
information we collect. The results of the study are likely to be published in a medical 
journal, but again, you will not be able to be identified from this information. 
 
Do I have to agree to take part in the study? 
You do not have to agree to take part in this study. If you do not wish to take part, your 
future care will not be affected in any way. You may also wish to change your mind and 
withdraw from the study at any time. Again this will not affect your care in any way. If 
you choose to withdraw from the study, we will not use any of the data already collected 
on you. 
 
 If you have any further questions or concerns, please do not hesitate to telephone Dr 
Tim Cheetham on 0191 282 9562 or Dr Steve Ball on 0191 282 9094 or you can write to 
them: 
 
Tim Cheetham (Department of Paediatric Endocrinology) or Dr Steve Ball (Department of 
Endocrinology), Royal Victoria Infirmary, Newcastle upon Tyne 
NE1 4LP. 
 
 
Thank you for reading this information sheet. 
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Appendix D Healthy control-GHD 
REC reference number: 10/H0907/71 
Committee; Newcastle and North Tyneside REC 2 
Protocol version 4.3, 25/11/10 
 
 
   Institute of Human Genetics 
International Centre for Life 
Central Parkway 
Newcastle upon Tyne  NE1 3BZ 
 
 
A study using Magnetic Resonance Spectroscopy (MRS) to 
assess changes in the skeletal muscle in patients with 
Growth hormone deficiency 
 
Volunteer Information Sheet 
 
Why have I been chosen? 
As a healthy person we are inviting you to take part in a research study. Before you 
accept or decline the invitation, it is important for you to understand why the research is 
being done and what it will involve. Please read the following information and discuss it 
with relatives, friends and your General Practitioner, if you wish. If there is anything that 
is not clear, or you have any further questions, please ask us (our contact details are at 
the end of this information sheet). Take time to decide whether you would like to take 
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part, or not. This study will have no direct benefit to you, but will provide important 
information for possible future therapeutic trials. 
 
Who is taking part in the study? 
We are asking healthy volunteers as well as patients with growth hormone deficiency 
(GHD) to take part in this study.  
 
What is the purpose of the study? 
The aim of the study is to find out what happens to muscle and the way that muscles 
work when growth hormone levels are low. To do this we will be studying people who 
make growth hormone normally (healthy volunteers like you) as well as people who are 
unable to make growth hormone normally. We plan to take a small sample of blood at 
the start of the study in the morning following an overnight fast (around 2 teaspoons in 
amount). We will then look at the energy changes that take place within the muscle 
during exercise. The technique that is used to measure how the muscle is working is 
called Magnetic Resonance Spectroscopy (MRS). MRS allows doctors to obtain 
biochemical information about the tissues of the human body in a non-invasive way 
(without the need for a biopsy and without the need for X-rays). The MRS scan involves 
lying in a special Magnetic Resonance Imaging (MRI) Scanner and then flexing and 
extending your ankle whilst measurements are taken. The procedure is not painful and 
the movement required is like depressing a clutch pedal on the car. You will be required 
to do this for 15-25 minutes. 
 
What is a Magnetic Resonance Imaging (MRI) scan? 
MRI is a special technique that uses powerful magnets, radio waves and computers to 
produce detailed images (or scans) of the inside of your body. MRI does not use X-rays 
and doesn’t cause pain or discomfort. 
 
The scanning session takes approximately two hours and you will be need to lie on your 
back on a moveable table, which slides inside the cylinder shaped scanner. The scanner 
is open ended and as we are only scanning your leg, you will not be completely enclosed 
at any time. 
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A radiographer will operate the scanner from behind a window but will be able to hear 
you and see you during the scan. You will be given a call button to hold during the scan, 
which you can press to get the radiographer’s attention, should you need to. 
 
It can take several minutes for each image to be taken, and it is important to lie still and 
breath gently during the process. The machine is noisy and will make a loud knocking or 
buzzing sound throughout the scan. However, we will provide you with earplugs or 
headphones which will help block a lot of the sound out. 
 
When the scans are complete, the table will be removed from the scanner, whilst you 
are on the table and then you will be able to get off once safely out. There will be 
someone to help you off the table if required. 
 
What happens now? 
If you are happy to participate in the study, we will ask you to sign a consent form 
indicating your willingness to take part. We will also arrange a time for you to come for 
your scan. The scanning session will take approximately two hours. 
You will be able to eat and drink as usual and will not need to take any special 
precautions. 
 
Are there any side effects to taking part in the study? 
MRI scans are commonly performed and generally safe. However you need to be aware 
of the possible side-effects.  
Some people are slightly claustrophobic in the scanner; however with the scan of your 
leg you will not be completely enclosed. The radiowaves used in the MRI can cause 
metal and tissues to heat up, you will therefore need to inform us if you have any of the 
following: 
 
Surgical clips, 
A previous history of metal fragments in your eyes. 
Any pacemakers or heart defibrillators, 
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Inner ear implant (a hearing aid), 
Medicine infusion pump (insulin pump),  
Neurostimulator, 
Aneurysm clip (a metal clip on an artery), 
Shunts (tubes) in the brain, 
Joint replacements/large metal implants, 
Stents (tubes) in the heart or arteries, 
Eye, penis or breast implants, 
An intrauterine contraceptive device or coil, 
Any allergies. 
 
You will also need to inform us if you have any body piercing, tattoos or transdermal 
patches, metal fragments anywhere in your body or gun/shrapnel wounds. 
 
If you are pregnant or possibly pregnant please let us know, as you will not be able to be 
included in the study. 
 
You may find that teeth fillings may tingle during the scan but are safe. 
 
Please note that there will be someone to help you onto and off the table if needed. 
 
Since Magnetic Resonance Spectroscopy is primarily a research tool, we do not expect to 
detect any gross abnormalities. However, in the unlikely case that we detect any gross 
abnormalities, we shall discuss the findings with the relevant clinicians and contact you 
accordingly. 
 
Confidentiality 
 
All data collected will be anonymised – you will not be able to be identified from the 
information we collect. The results of the study are likely to be published, but again, you 
will not be able to be identified from this information. 
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Do I have to agree to take part in the study? 
You do not have to agree to take part in this study. If you do not wish to take part, your 
future care will not be affected in any way. You may also wish to change your mind and 
withdraw from the study at any time. Again this will not affect your care in any way. If 
you choose to withdraw from the study, we will not use any of the data already collected 
on you. 
 
If you have any further questions or concerns, please do not hesitate to telephone Dr 
Tim Cheetham on 0191 282 9562 or Dr Steve Ball on 0191 282 9094 or you can write to 
them: 
 
 Tim Cheetham (Department of Paediatric Endocrinology) or Dr Steve Ball (Department 
of Endocrinology), Royal Victoria Infirmary, Newcastle upon Tyne 
NE1 4LP. 
 
Thank you for reading this information sheet. 
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Appendix E  Patient Information Sheet-Vitamin D 
REC reference number: 10/H0907/71 
Committee; Newcastle and North Tyneside REC 2 
Protocol version 4.4, 18/08/11 
 
 
   Institute of Human Genetics 
International Centre for Life 
Central Parkway 
Newcastle upon Tyne  NE1 3BZ 
 
 
A study using Magnetic Resonance Spectroscopy (MRS) to 
assess changes in the skeletal muscle in people with 
Vitamin D deficiency 
 
Volunteer Information Sheet 
 
Why have I been chosen? 
As a healthy person with vitamin D deficiency we are inviting you to take part in a 
research study. Before you accept or decline the invitation, it is important for you to 
understand why the research is being done and what it will involve. Please read the 
following information and discuss it with relatives, friends and your General Practitioner, 
if you wish. If there is anything that is not clear, or you have any further questions, 
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please ask us (our contact details are at the end of this information sheet). Take time to 
decide whether you would like to take part, or not. This study will have no direct benefit 
to you, but will provide important information for possible future therapeutic trials. 
 
Who is taking part in the study? 
We are asking healthy volunteers who have Vitamin D deficiency to take part in this 
study.  
 
What is the purpose of the study? 
The aim of the study is to find out what happens to muscle and the way that muscles 
work when Vitamin D levels are low. Vitamin D deficiency is widespread and is a public 
health concern, especially in certain high risk groups such as dark skinned people, the 
elderly and pregnant mothers. To do this we will be studying people who are Vitamin D 
deficient. We plan to take a small sample of blood at the start of the study. We will then 
look at the energy changes that take place within the muscle during exercise. The 
technique that is used to measure how the muscle is working is called Magnetic 
Resonance Spectroscopy (MRS). MRS allows doctors to obtain biochemical information 
about the tissues of the human body in a non-invasive way (without the need for a 
biopsy and without the need for X-rays). The MRS scan involves lying in a special 
Magnetic Resonance Imaging (MRI) Scanner and then flexing and extending your ankle 
whilst measurements are taken. The procedure is not painful and the movement 
required is like depressing a clutch pedal on the car. You will be required to do this for 
15-25 minutes. 
We shall then invite you for a repeat MRS scan and a repeat blood test 8-12 weeks later 
when your vitamin D deficiency has been corrected (as per the local guidelines). 
 
 
What is a Magnetic Resonance Imaging (MRI) scan? 
MRI is a special technique that uses powerful magnets, radio waves and computers to 
produce detailed images (or scans) of the inside of your body. MRI does not use X-rays 
and doesn’t cause pain or discomfort. 
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The scanning session takes approximately two hours and you will be need to lie on your 
back on a moveable table, which slides inside the cylinder shaped scanner. The scanner 
is open ended and as we are only scanning your leg, you will not be completely enclosed 
at any time. 
 
A radiographer will operate the scanner from behind a window but will be able to hear 
you and see you during the scan. You will be given a call button to hold during the scan, 
which you can press to get the radiographer’s attention, should you need to. 
 
It can take several minutes for each image to be taken, and it is important to lie still and 
breath gently during the process. The machine is noisy and will make a loud knocking or 
buzzing sound throughout the scan. However, we will provide you with earplugs or 
headphones which will help block a lot of the sound out. 
 
When the scans are complete, the table will be removed from the scanner, whilst you 
are on the table and then you will be able to get off once safely out. There will be 
someone to help you off the table if required. 
 
What happens now? 
If you are happy to participate in the study, we will ask you to sign a consent form 
indicating your willingness to take part. We will also arrange a time for you to come for 
your scan. The scanning session will take approximately two hours. 
You will be able to eat and drink as usual and will not need to take any special 
precautions. 
 
Are there any side effects to taking part in the study? 
MRI scans are commonly performed and generally safe. However you need to be aware 
of the possible side-effects.  
Some people are slightly claustrophobic in the scanner; however with the scan of your 
leg you will not be completely enclosed. The radiowaves used in the MRI can cause 
metal and tissues to heat up, you will therefore need to inform us if you have any of the 
following; 
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Surgical clips, 
A previous history of metal fragments in your eyes. 
Any pacemakers or heart defibrillators, 
Inner ear implant (a hearing aid), 
Medicine infusion pump (insulin pump),  
Neurostimulator, 
Aneurysm clip (a metal clip on an artery), 
Shunts (tubes) in the brain, 
Joint replacements/large metal implants, 
Stents (tubes) in the heart or arteries, 
Eye, penis or breast implants, 
An intrauterine contraceptive device or coil, 
Any allergies. 
 
You will also need to inform us if you have any body piercing, tattoos or transdermal 
patches, metal fragments anywhere in your body or gun/shrapnel wounds. 
 
If you are pregnant or possibly pregnant please let us know, as you will not be able to be 
included in the study. 
 
You may find that teeth fillings may tingle during the scan but are safe. 
 
Please note that there will be someone to help you onto and off the table if needed. 
 
Since Magnetic Resonance Spectroscopy is primarily a research tool, we do not expect to 
detect any gross abnormalities. However, in the unlikely case that we detect any gross 
abnormalities, we shall discuss the findings with the relevant clinicians and contact you 
accordingly. 
 
Confidentiality 
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All data collected will be anonymised – you will not be able to be identified from the 
information we collect. The results of the study are likely to be published, but again, you 
will not be able to be identified from this information. 
 
Do I have to agree to take part in the study? 
You do not have to agree to take part in this study. If you do not wish to take part, your 
future care will not be affected in any way. You may also wish to change your mind and 
withdraw from the study at any time. Again this will not affect your care in any way. If 
you choose to withdraw from the study, we will not use any of the data already collected 
on you. 
 
 
If you have any further questions or concerns, please do not hesitate to telephone Dr 
Tim Cheetham on 0191 282 9562 or Dr Steve Ball on 0191 282 9094 or you can write to 
them: 
 
 Tim Cheetham (Department of Paediatric Endocrinology) or Dr Steve Ball (Department 
of Endocrinology), Royal Victoria Infirmary, Newcastle upon Tyne 
NE1 4LP. 
 
Thank you for reading this information sheet. 
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Appendix F Consent form 
Patient Identification Number for this trial: 
 
CONSENT FORM 
 
 
Title of Project: MRS assessment of skeletal muscle function in GHD 
 
 
 
 
Name of Researchers: Dr A Sinha, Dr S Ball and Dr T Cheetham 
 
 
Please initial box 
 
1. I confirm that I have read and understand the information sheet 
dated 25/11/10 (version 4.3) regarding the above study and have had the 
opportunity to ask questions. 
 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
 
 
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from the University of Newcastle or from regulatory 
authorities where it is relevant to my taking part in research.  I give permission for 
these individuals to have access to my records. 
 
 
4. I agree to take part in the above study.     
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Name of Patient Date Signature   
 
 
   
 
Name of Person taking consent Date Signature 
(If different from researcher) 
 
 
  
 
 
Researcher Date Signature 
 
 
 
 
[1 for patient; 1 for researcher; 1 to be kept with hospital notes] 
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Appendix H Treated GHD patient details 
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Appendix I Publication-Improving the vitamin D status of vitamin 
D deficient adults is associated with improved mitochondrial 
oxidative function in skeletal muscle   
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Appendix J Publication-Prevention and treatment of vitamin D 
deficiency  
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